WorldWideScience

Sample records for alprostadil

  1. Alprostadil Urogenital

    Science.gov (United States)

    Alprostadil injection and suppositories are used to treat certain types of erectile dysfunction (impotence; inability to get or keep an erection) in men. Alprostadil injection is also sometimes used in combination with ...

  2. Does alprostadil cream hit the spot?

    Science.gov (United States)

    2015-02-01

    Alprostadil, a prostaglandin, has been marketed for many years as a urethral stick and an intracavernous injection for the treatment of erectile dysfunction.(1) It is now available in the form of a cream (Vitaros-Takeda). Adverts for the product declare: "Sex with no pills, pellets or needles. Spot on." In this article, we consider the evidence for alprostadil cream, and its place in the management of erectile dysfunction.

  3. Unstable angina following intracavernous injection of alprostadil: a case study

    OpenAIRE

    Delongchamps, Nicolas Barry; Legrand, Guillaume; Zerbib, Marc; Peyromaure, Michael

    2009-01-01

    Intracavernous injection of alprostadil is the gold standard treatment for erectile dysfunction following radical prostatectomy. After surgery, low doses of alprostadil can be delivered for the sole purpose of penile rehabilitation. The only reported systemic side effects of such injections are arterial hypotension and headache. In the current report, a case of unstable angina immediately following an intracavernous injection of alprostadil is described.

  4. A comparison of colour duplex ultrasonography after transurethral alprostadil and intracavernous alprostadil in the assessment of erectile dysfunction.

    Science.gov (United States)

    Ahn, H S; Lee, S W; Yoon, S J; Hann, H J; Hong, J M

    2004-01-01

    This study aimed to investigate whether transurethral alprostadil could be used for the diagnosis of erectile dysfunction using colour duplex ultrasound. The ultrasonography results were compared after transurethral and intracavernous alprostadil administration in 20 patients with erectile dysfunction. There were no significant differences in the mean peak systolic velocities (PSVs) between the two routes of administration, but the mean end diastolic velocities (EDVs) showed significant differences, with patients treated with transurethral alprostadil having higher EDVs. Linear regression analysis of the PSVs reached following the two routes of administration showed a moderate relationship, but linear regression analysis of the EDVs showed no relationship. We concluded that transurethral alprostadil was an inappropriate vasoactive drug to use with colour duplex ultrasonography for the evaluation of patients with erectile dysfunction because it required a longer scan time and it was less effective and less reliable than intracavernous alprostadil at stimulating complete corporeal smooth muscle relaxation.

  5. [Alprostadil Reference Standard (Control 001) of National Institute of Health Sciences].

    Science.gov (United States)

    Maekawa, K; Iwata, M; Koide, T; Saito, H; Tanimoto, T; Okada, S

    2001-01-01

    The raw material of Alprostadil was examined for the preparation of "Alprostadil Reference Standard (Control 001)". Analytical data obtained were: IR spectrum, same as that of the Alprostadil Reference Standard (Control 923); thin-layer chromatography, no impurities were detected until 20 micrograms; high-performance liquid chromatography (HPLC), total amount of impurities estimated to be less than 0.2%. Based on the above results, the raw material was authorized as the Japanese Pharmacopoeia Alprostadil Reference Standard (Control 001).

  6. Intraurethral alprostadil for erectile dysfunction: a review of the literature.

    Science.gov (United States)

    Costa, Pierre; Potempa, Axel-Juerg

    2012-12-03

    The global burden of erectile dysfunction (ED) is increasing. It is estimated that 8-19% of men in Europe have ED and that by 2025 the prevalence of ED worldwide will reach 322 million. The gold standard therapy for ED is an oral phosphodiesterase type 5 (PDE5) inhibitor, but they are not suitable for everyone; approximately 25% of patients do not respond to this therapy and it is contraindicated in others, e.g. those with vascular disease. When PDE5 inhibitors are not suitable, available options include intraurethral and intracavernosal alprostadil - a synthetic vasodilator chemically identical to the naturally occurring prostaglandin E(1) indicated for the treatment of ED. Intraurethral alprostadil is delivered by the Medicated System for Erection (MUSE).- a single-use pellet containing alprostadil suspended in polyethylene glycol administered using an applicator. It is recommended that intraurethral alprostadil be initiated at a dose of 500 μg, as it has a higher efficacy than the 250 μg dose, with minimal differences with regard to adverse events. Data from key clinical studies of intraurethral alprostadil show that it has a fast onset of effect and a good safety profile, with no occurrences of priapism, fibrosis (as seen with intracavernosal injection) or the typical systemic effects observed with oral ED pharmacological treatments. Intraurethral alprostadil has been associated with high patient preference, acceptance rates and quality of life versus intracavernosal injection due to its ease of administration. Evidence has shown that combination treatment with sildenafil may be a possible efficient alternative when single oral or local treatment has failed. Intraurethral alprostadil can be administered in all patients irrespective of ED origin and should be the first option in patients with ED for whom therapy with PDE5 inhibitors has failed or is contraindicated.

  7. Clitoral hemodynamic changes after a topical application of alprostadil.

    Science.gov (United States)

    Becher, E F; Bechara, A; Casabe, A

    2001-01-01

    We performed duplex ultrasonography of the clitoris to assess the local hemodynamic changes after a topical application of alprostadil. Color duplex ultrasonography was used to evaluate 18 women before and after the application of 1 g of 0.2% alprostadil gel. The peak systolic velocity and end diastolic velocity showed a statistically significant difference after the application. All women showed labial and clitoral engorgement, 72% reported a pleasant sensation of warmth, and no systemic side effects were found. These findings are similar to the values reported after sexual stimulation, indicating that topical vasoactive drugs might help in the differential diagnosis of the vascular component of female sexual dysfunction.

  8. Therapeutic Effect of Alprostadil in Diabetic Nephropathy: Possible Roles of Angiopoietin-2 and IL-18

    Directory of Open Access Journals (Sweden)

    Changqing Luo

    2014-08-01

    Full Text Available Background/Aims: To investigate the role of angiopoietin-2 (Ang-2 and IL-18 in the pathogenesis of diabetic nephropathy (DN and the molecular mechanisms through which alprostadil protects renal function. Methods: DN was induced by streptozotocin and intraperitoneal injection of alprostadil was given to diabetic mice. After 2, 4 and 8 weeks of alprostadil treatment, the mRNA and protein expression of kidney Ang-2 and IL-18 were detected by reverse transcription PCR, Western blot and immunohistochemistry analyses. Mouse glomerular endothelial cells (GEnCs were cultured in high glucose and treated with alprostadil. After transfection with an Ang-2-pcDNA and Ang-2-siRNA, both Ang-2 and IL-18 expression were measured by Western blot analyses. Results: Alprostadil treatment caused a significant decrease in the renal damage parameters. Both Ang-2 and IL-18 were significantly increased in DN mice and in GEnCs cultured in high glucose; however, their expression was greatly reduced by alprostadil treatment. Ang-2 could also increase IL-18 expression in cultured endothelial cells under high glucose, and this response was partially blocked by Ang-2 siRNA. Conclusions: Ang-2 and IL-18 may be associated with the development and progression of DN in mice. Alprostadil treatment can protect renal function by reducing proteinuria. These effects are mediated, at least in part, through down-regulation of Ang-2 and IL-18 expression.

  9. Effectiveness of combined alprostadil and pancreatic kininogenas in treating gerontal diabetic peripheral neuropathy

    Institute of Scientific and Technical Information of China (English)

    张玉

    2013-01-01

    Objective To observe the clinical effectiveness of alprostadil combined with pancreatic kininogenas in the treatment of gerontal diabetic peripheral neuropathy.Methods Totally 90 gerontal patients with diabetic peripheral neuropathy were randomly divided into three

  10. Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction.

    Science.gov (United States)

    Yeager, J; Beihn, R M

    2005-01-01

    Retention and migration of a specially designed alprostadil transdermal cream was assessed after single-dose administration to the glans meatus of the penis. Seven men were enrolled in this two-way crossover study. Three subjects self-administered the radio-labeled alprostadil transdermal cream (approximately 100 mg of cream containing 300 microg alprostadil) by inserting the tip of the dispenser into the meatus. In three others, the dose was administered by dispensing the cream dropwise into the metal opening without touching the penis (the preferred and directed method). Retention and migration of the cream mass was measured in the penis with a gamma scintillation camera. The alprostadil transdermal cream was retained in the fossa navicularis at or near 99% in five of six subjects regardless of the method of dosing, thus indicating that the cream formulation performed as designed. A mild, transient burning sensation in the penis was the most common adverse event.

  11. Topical alprostadil cream for the treatment of erectile dysfunction.

    Science.gov (United States)

    Becher, Edgardo

    2004-03-01

    Erectile dysfunction (ED) has serious negative consequences on both sexual experience and emotional well being and affects a broad range of age groups. The prevalence of ED is associated with increasing age and has been reported to be as high as 70%. Although the disorder is common and underdiagnosed, its treatment can significantly improve patients' quality of life. Systemic treatment with oral phosphodiesterase type-5 (PDE-5) inhibitors is the current standard of care for patients with ED. Some patients, however, have absolute contraindications for PDE-5 inhibitors. In addition, these agents can be associated with adverse effects. Furthermore, because PDE-5 inhibitors are not as effective in patients who have undergone radical prostatectomy or who have severe vascular disease, a substantial unmet medical need exists among patients who have ED as a result of these conditions. Consequently, PDE-5 inhibitor therapy is associated with a high rate of discontinuation, as are intracavernosal or transurethral therapies, which are inconvenient and invasive. Several studies, including four double-blind, placebo-controlled, Phase II trials, show that alprostadil topical cream is efficacious and well-tolerated in ED in patients with mild-to-severe symptoms, in those undergoing treatment for cardiovascular diseases and diabetes and in otherwise healthy ED patients. Thus, alprostadil topical cream is a potential first-choice alternative for ED in patients who do not respond or who cannot tolerate or do not accept PDE-5 inhibitor therapy.

  12. Sildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled study.

    Science.gov (United States)

    Mancini, M; Raina, R; Agarwal, A; Nerva, F; Colpi, G M

    2004-02-01

    We compared the effectiveness of sildenafil citrate and alprostadil in improving arterial penile inflow (peak systolic velocity (PSV)) and penile rigidity in 55 patients with erectile dysfunction caused by atherosclerosis. A total of 35 patients with pure vasculogenic impotency were randomly assigned to alprostadil (Av group; n=11), sildenafil (Sv group; n=12), or placebo (P group; n=12), and 20 patients with nonvasculogenic impotency were randomly assigned to alprostadil (A group; n=10) or Sildenafil (S group; n=10): Av and A used alprostadil injection (capable of giving a full erection) once a week for 1 month, Sv and S took daily oral sildenafil (25 mg) for 1 month, and P took daily oral placebo for one month. The PSV was measured with Duplex sonography and penile rigidity was assessed using the IIEF-15 questionnaire, both of which were administered before and after treatment. Although both treatments improved penile rigidity, they increased PSV only in the Av and Sv groups. Our results suggest that alprostadil and oral therapy should be the starting therapy in men with vasculogenic impotency, whereas alprostadil should be avoided as the first-line approach in men with nonvasculogenic impotency.

  13. PGE1 analog alprostadil induces VEGF and eNOS expression in endothelial cells.

    Science.gov (United States)

    Haider, Dominik G; Bucek, Robert A; Giurgea, Aura G; Maurer, Gerald; Glogar, Helmut; Minar, Erich; Wolzt, Michael; Mehrabi, Mohammad R; Baghestanian, Mehrdad

    2005-11-01

    Endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor 1-alpha (HIF-1alpha) are important regulators of endothelial function, which plays a role in the pathophysiology of heart failure (HF). PGE1 analog treatment in patients with HF elicits beneficial hemodynamic effects, but the precise mechanisms have not been investigated. We have investigated the effects of the PGE1 analog alprostadil on eNOS, VEGF, and HIF-1alpha expression in human umbilical vein endothelial cells (HUVEC) using RT-PCR and immunoblotting under normoxic and hypoxic conditions. In addition, we studied protein expression by immunohistochemical staining in explanted hearts from patients with end-stage HF, treated or untreated with systemic alprostadil. Alprostadil causes an upregulation of eNOS and VEGF protein and mRNA expression in HUVEC and decreases HIF-1alpha. Hypoxia potently increased eNOS, VEGF, and HIF-1alpha synthesis. The alprostadil-induced upregulation of eNOS and VEGF was prevented by inhibition of MAPKs with PD-98056 or U-0126. Consistently, the expression of eNOS and VEGF was increased, and HIF-1alpha was reduced in failing hearts treated with alprostadil. The potent effects of alprostadil on endothelial VEGF and eNOS synthesis may be useful for patients with HF where endothelial dysfunction is involved in the disease process.

  14. Topical alprostadil (PGE1) for the treatment of female sexual arousal disorder: in-clinic evaluation of safety and efficacy.

    Science.gov (United States)

    Heiman, Julia R; Gittelman, Marc; Costabile, Raymond; Guay, Andre; Friedman, Alice; Heard-Davison, Amy; Peterson, Craig; Dietrich, John; Stephens, Darby

    2006-03-01

    This multi-center, randomized, placebo-controlled, crossover design study evaluated the effects of a topical alprostadil solution for the treatment of female sexual arousal disorder (FSAD). A total of 79 naturally or surgically post menopausal women with FSAD were treated with either 100 or 400 micrograms of alprostadil solution and placebo, delivered on separate clinic visits in random order. Study drug was applied to the external genitalia and was followed by 30 minutes of visual sexual stimulation. Study evaluations included investigator assessments of genital vasocongestion and patient assessments of physical and emotional sexual arousal, and sexual satisfaction. Genital vasocongestion in response to PGE1 was significantly greater than placebo (p alprostadil. Topical alprostadil was well tolerated with no reports of significant systemic side effects. The most common adverse event was mild, transient genital burning typically alprostadil should be further researched as a potentially appropriate on-demand therapeutic choice for women experiencing FSAD.

  15. Expression of VEGF and neural repair after alprostadil treatment in a rat model of sciatic nerve crush injury

    Directory of Open Access Journals (Sweden)

    Tang Jinrong

    2009-01-01

    Full Text Available Background: Vasoactive drug alprostadil improves microcirculation and can be effective in treating disorders of peripheral nerves. Vascular endothelial growth factor (VEGF has been shown to have protective action in cerebral ischemia, disorders of spinal cord, and also peripheral nerves. However, the mechanism of action of VEGF in peripheral nerve injuries is uncertain. Objectives: To study the effect of application of alprostadil on the pathological and functional repair of crush nerve injuries and also the expression of VEGF. Materials and Methods: Rat sciatic nerves were crushed by pincers to establish the model of crush injury. All of the 400 sprague dawley (SD rats were randomly divided into: Control; saline; saline + VEGF-antibody; alprostadil; and alprostadil + VEGF antibody groups. The SPSS 11.5 software was used for statistical analysis. The expression of VEGF in dorsal root ganglia (DRGs, following crush injury to sciatic nerves, was studied by reverse transcribed-polymerase chain reaction (RT-PCR, immunohistochemistry, electromicroscope, and electrophysiology. The effects of alprostadil on expression of VEGF, repair of neural pathology, and recovery of neural function were also evaluated. Results: We found that VEGF messenger ribonucleic acid (mRNA was significantly increased in alprostadil and alprostadil + VEGF-antibody groups, compared to the saline and saline + VEGF antibody groups. The number of VEGF-positive neurons was significantly increased in the alprostadil group, compared to the saline, saline + VEGF antibody, and alprostadil + VEGF antibody groups. Besides, addition of this drug also caused less pathological changes in DRGs, better improvement of nerve conduction velocities of sciatic nerves, and more increase of toe spaces of right hind limbs of rats. Conclusions: The vasoactive agent alprostadil may reduce the pathological lesion of peripheral nerves and improve the rehabilitation of the neural function, which may

  16. Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers.

    Science.gov (United States)

    McCluskey, Susan V; Kirkham, Kylian; Munson, Jessica M

    2017-01-01

    The stability of alprostadil diluted in 0.9% sodium chloride stored in polyvinyl chloride (VIAFLEX) containers at refrigerated temperature, protected from light, is reported. Five solutions of alprostadil 11 mcg/mL were prepared in 250 mL 0.9% sodium chloride polyvinyl chloride (PL146) containers. The final concentration of alcohol was 2%. Samples were stored under refrigeration (2°C to 8°C) with protection from light. Two containers were submitted for potency testing and analyzed in duplicate with the stability-indicating high-performance liquid chromatography assay at specific time points over 14 days. Three containers were submitted for pH and visual testing at specific time points over 14 days. Stability was defined as retention of 90% to 110% of initial alprostadil concentration, with maintenance of the original clear, colorless, and visually particulate-free solution. Study results reported retention of 90% to 110% initial alprostadil concentration at all time points through day 10. One sample exceeded 110% potency at day 14. pH values did not change appreciably over the 14 days. There were no color changes or particle formation detected in the solutions over the study period. This study concluded that during refrigerated, light-protected storage in polyvinyl chloride (VIAFLEX) containers, a commercial alcohol-containing alprostadil formulation diluted to 11 mcg/mL with 0.9% sodium chloride 250 mL was stable for 10 days.

  17. [Sildenafil and alprostadil in the combined drug therapy of erectile dysfunction].

    Science.gov (United States)

    Mazo, E B; Dmitriev, D G; Gamidov, S I; Ovchinnikov, R I

    2002-01-01

    Forty-four patients with erectile dysfunction (ED) aged 21-72 years aged 21-72 years (mean age 61 years) were examined and treated with sildenafil and alprostadil monotherapy or combined therapy. ED was psychogenic in 9(20.5%), arterial in 12(27.2%), vein occlusive in 9(20.5%) and neurogenic in 14(31.8%) patients. Monotherapy was most effective in psychogenic ED (alprostadil--100%, sildenafil--88.9%), least effective in vein occlusive ED (alprostadil--33.3%, sildenafil--22.2%). Alprostadil was more effective in arterial and neurogenic ED (83.3 vs 66.7 and 78.6 vs 57.1%, respectively). Combination of the two drugs produced much high response: 100, 85.7 and 55.5% in arterial, neurogenic and vein occlusive ED, respectively. Thus, combined treatment with sildenafil and alprostadil is a method of choice in the treatment of ED in failure of monotherapy with these drugs or in vein occlusive ED. In the combined treatment dose of the drugs, number of side effects and cost of therapy are lower.

  18. Topical alprostadil in the treatment of Female Sexual Arousal Disorder: a pilot study.

    Science.gov (United States)

    Islam, A; Mitchel, J; Rosen, R; Phillips, N; Ayers, C; Ferguson, D; Yeager, J

    2001-01-01

    This study evaluated the efficacy and safety of three doses of topical alprostadil USP (prostaglandin E1) cream in 8 patients with Female Sexual Arousal Disorder (FSAD). Each patient was administered a single intravaginal dose of placebo followed by escalating intravaginal doses of the active drug at 2-week intervals. Alprostadil's effectiveness in enhancing subjective and physiological arousal during visual sexual stimulation was supported by patient ratings and physician assessments of vaginal erythema and transudate volume. Photoplethysmography measurement of vaginal pulse amplitude was not able to demonstrate treatment sensitivity in the present study. Adverse events included mild cases of vaginal itching and burning. The data support further investigation of the use of alprostadil for FSAD.

  19. Combined use of hydration and alprostadil for preventing contrast-induced nephropathy following percutaneous coronary intervention in elderly patients.

    Science.gov (United States)

    Xu, Rong-He; Ma, Gui-Zhou; Cai, Zhi-Xiong; Chen, Ping; Zhu, Zhi-Dan; Wang, Wen-Liang

    2013-10-01

    Contrast-induced nephropathy (CIN) is a complex syndrome of acute kidney injury that follows exposure to intravascular contrast media. Although a series of preventive measures have been developed, CIN remains a major challenge encountered in elderly patients by interventional cardiologists. No data are currently available concerning the potential effects of the combined use of hydration and alprostadil in the prevention of CIN following percutaneous coronary intervention (PCI) in elderly patients. Therefore, the aim of the present study was to investigate the ability of a combination of hydration and alprostadil to prevent CIN following PCI in elderly patients. From June 1, 2010 to January 31, 2012, 85 elderly patients undergoing PCI were included in the present study. The included patients were randomly allocated into three groups: the control (22 cases), hydration (28 cases) and hydration + alprostadil (35 cases) group. Serum creatinine (SCr) levels were measured prior to PCI and then daily for 3 days following PCI. Creatinine clearance (Ccr) was also calculated. Following investigation of the incidence of CIN, a significant decline in Ccr was observed in the control group but not in the hydration + alprostadil group after PCI. The reduction in the level of Ccr from baseline in the hydration + alprostadil group was the smallest among the three groups. Moreover, the highest incidence of CIN was in the control group (6 cases, 27.27%), followed by the hydration group (3 cases, 10.71%) and the hydration + alprostadil group (1 case, 2.86%). Therefore, the combined use of hydration and alprostadil significantly reduces the incidence of CIN in elderly patients undergoing PCI. Hydration and alprostadil are suggested to act synergistically to protect renal function. In conclusion, the combined use of hydration and alprostadil is more effective in the prevention of CIN in elderly patients undergoing PCI compared with hydration alone.

  20. Specific enhancement of vascular endothelial growth factor (VEGF) production in ischemic region by alprostadil--potential therapeutic application in pharmaceutical regenerative medicine.

    Science.gov (United States)

    Inoue, Hajime; Aihara, Masaki; Tomioka, Miyuki; Watabe, Yu-ichi

    2013-01-01

    Alprostadil (lipo-PGE1) is a drug delivery system preparation. This preparation is applied to treat refractory skin ulcers and arteriosclerosis obliterans. We investigated the effects of alprostadil by using the earflap ischemic model. The following results were obtained: 1) Treatment with alprostadil significantly increased the VEGF contents in an ischemic ear; 2) Treatment with alprostadil resulted in strongly expressed VEGF levels only in the ischemic region; 3) Image analysis revealed a significant increase in the number of vessel bypasses and paths after flap creation with alprostadil administration compared to the vehicle-treated ears. The results suggest that it may be possible to apply alprostadil as one device for regenerative medical technology.

  1. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review

    Directory of Open Access Journals (Sweden)

    Anaissie J

    2016-08-01

    Full Text Available James Anaissie, Wayne JG Hellstrom Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA Abstract: Erectile dysfunction (ED is a common and debilitating disorder seen in over 50% of men older than 70 years. Oral phosphodiesterase type 5 (PDE5 inhibitors are the mainstay of treatment for ED, but cannot be used by a significant subset of patients due to systemic side effects and drug–drug interactions. Second-line therapy may include intracavernosal therapies, but are associated with poor compliance due to their invasive nature. Alprostadil has a mechanism of action different from that of PDE5 inhibitors. Clinical trials have shown topical alprostadil cream to be effective, increasing the erectile function (EF score of the International Index of EF by up to 13 points from baseline. It has also proven to be safe and well tolerated, with mild-to-moderate and transient treatment-related adverse events that are generally localized to the application site. Topical alprostadil cream is a safe and effective second-line therapy for ED, indicated for those who cannot tolerate, or are not satisfied with, oral PDE5 inhibitor therapy. Keywords: erectile dysfunction, topical cream, second-line treatment, alprostadil

  2. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men

    NARCIS (Netherlands)

    Heaton, JPW; Lording, D; Liu, SN; Litonjua, AD; Guangwei, L; Kim, SC; Kim, JJ; Zhi-Zhou, S; Israr, D; Niazi, D; Rajatanavin, R; Suyono, S; Benard, F; Casey, R; Brock, G; Belanger, A

    2001-01-01

    The efficacy and safety of intracavernosal alprostadil was evaluated for the treatment of erectile dysfunction in men with type I or type II diabetes mellitus. This was an open-label, flexible dose-escalating study involving 336 men (77% of whom were Asian/Oriental) enrolled by 15 centres in Austral

  3. How effective are alprostadil and hydrocortisone on reperfusion injury in kidney after distant organ ischemia?

    Directory of Open Access Journals (Sweden)

    Ali Ebrahimi

    2013-01-01

    Full Text Available Background: After reestablishment of blood flow to ischemic limb recirculation of free radicals may cause ischemia-reperfusion injury in many organs. This study designed to investigate effects of hydrocortisone and alprostadil distant injury to kidneys by both measuring biochemical markers of oxidative stress and histopathologic examination in an experimental rat model of hind limb ischemia-reperfusion. Materials and Methods: This study conducted in Isfahan University of Medical Sciences during 2011-2012. Ischemia was established by infra renal aortic clamping for 60 min in 32 male Wistar rats. Animals were divided into those receiving alprostadil (group ischemia-reperfusion plus alprostadil (IR/A, n = 8, those receiving hydrocortisone (group ischemia-reperfusion plus hydrocortisone (IR/H, n = 8, control group (group ischemia-reperfusion (IR, n = 8, and sham group (n = 8. After 120 min of reperfusion both kidneys were removed. Levels of superoxide dismutase (SOD, malondialdehyde (MDA, and glutathione (GSH as indirect markers of oxidative injury was measured. Finally all data in different groups were compared using the analysis of variance (ANOVA test by Statistical Package for Social Sciences (SPSS version 16. Results: Administration of alprostadil or hydrocortisone does not improve the biochemical parameters of oxidative injury including MDA and SOD. However, statistically significant difference was seen in GSH level among sham and IR groups. Mean (΁ standard deviation (SD concentration of GSH in IR, IR/A, IR/H, and sham groups were 1028.77 (72.65, 924.82 (70.66, 1000.28 (108.77, and 846.69 (163.52, respectively (P = 0.015. Histopathological study of specimens did not show any significant changes between groups. Conclusion: Alprostadil and hydrocortisone do not improve the kidney GSH, SOD, and MDA level and kidney releases its GSH reserve during ischemia-reperfusion event, and another point is that, 3 h of ischemia-reperfusion does not develop

  4. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men.

    Science.gov (United States)

    Heaton, J P; Lording, D; Liu, S N; Litonjua, A D; Guangwei, L; Kim, S C; Kim, J J; Zhi-Zhou, S; Israr, D; Niazi, D; Rajatanavin, R; Suyono, S; Benard, F; Casey, R; Brock, G; Belanger, A

    2001-12-01

    The efficacy and safety of intracavernosal alprostadil was evaluated for the treatment of erectile dysfunction in men with type I or type II diabetes mellitus. This was an open-label, flexible dose-escalating study involving 336 men (77% of whom were Asian/Oriental) enrolled by 15 centres in Australia, Canada and seven countries in Asia. The effective alprostadil dose, ie the dose producing penile rigidity adequate for intercourse and lasting up to 60 min, was established by titration at the clinic prior to entry into the 6 month self-treatment home phase. All men were fully trained in the self-injection technique before entry into the home phase. Efficacy and safety were assessed using patient and partner diaries and by interview at clinic visits during the titration phase and after 1, 3 and 6 months of treatment. An effective home dose was established by titration for 94% of the 336 men (median dose 20 microg, range 2.5-60 microg). Of 278 (83%) men who entered the home phase, 277 men (247 with type II diabetes and 30 with type I diabetes) had evaluable data for alprostadil dosage and clinical response. During the home phase, a satisfactory erectile response was achieved after 99% of injections, and the median alprostadil dose remained unchanged. The initial home dose and clinical response were similar in type I and type II diabetic men. Treatment was generally well tolerated with a low incidence of penile pain (24%) In conclusion, intracavernosal alprostadil was effective and well tolerated in type I and type II diabetic men with erectile dysfunction of mixed aetiology.

  5. Renoprotective effect of alprostadil in combination with statins in patients with mild to moderate renal failure undergoing coronary angiography

    Institute of Scientific and Technical Information of China (English)

    LIU Wei-jing; ZHANG Bu-chun; GUO Rong; WEI Yi-dong; LI Wei-ming; XU Ya-wei

    2013-01-01

    Background The role of alprostadil and statins in contrast-induced acute kidney injury (CI-AKI) is controversial.The purpose of this study was to explore the efficacy of combined therapy with alprostadil and statins in protecting renal function and preventing contrast-induced nephropathy (CIN) in patients undergoing coronary angiography.Methods A total of 156 consecutive patients with mild to moderate renal failure who underwent coronary angiography were enrolled in our study,and randomly categorized into two groups.In the statins group,80 patients were treated with statins before and after coronary angiography.in the alprostadil plus statins group,76 patients were treated with statins and alprostadil before and after coronary angiography.Serum creatinine (SCr),serum cystatin (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) were detected after administration of contrast media,and adverse events were evaluated within six months.Results In both groups,the SCr,CysC and NGAL significantly increased after coronary angiography and peaked at 48,24 and 6 hours,respectively.SCr,CysC and NGAL were significantly lower in the alprostadil plus statins group than in the statins group (P<0.05).The incidence of CIN in the alprostadil plus statins group was slightly lower than in the statins group.The incidence of adverse events within six months in the alprostadil plus statins group was significantly lower than in the statins group (P=0.034).Conclusions Intravenous alprostadil in combination with oral statins is superior to statins alone for protecting renal function in patients with mild to moderate renal dysfunction who undergo coronary angiography,and can reduce the incidence of adverse events seen within six months.

  6. Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats.

    Science.gov (United States)

    Hsieh, Cheng-Chu; Hsieh, Shu-Chen; Chiu, Jen-Hwey; Wu, Ying-Ling

    2014-01-01

    Ischemia-reperfusion (I/R) injury has a complex pathophysiology resulting from a number of contributing factors. Therefore, it is difficult to achieve effective treatment or protection by individually targeting the mediators or mechanisms. Our aim was to analyze the individual and combined effects of N-acetylcysteine (NAC) and the prostaglandin E1 (PGE1) analog alprostadil on hepatic I/R injury in rats. Thirty male Sprague-Dawley rats were randomly divided into five groups (six rats per group) as follows: Control group, I/R group, I/R + NAC group, I/R + alprostadil group, and I/R + NAC + alprostadil group. The rats received injections of NAC (150 mg/kg) and/or alprostadil (0.05 μg/kg) over a period of 30 min prior to ischemia. These rats were then subjected to 60 min of hepatic ischemia followed by a 60-min reperfusion period. Hepatic superoxide dismutase (SOD), catalase, and glutathione levels were significantly decreased as a result of I/R injury, but they were increased in groups treated with NAC. Hepatic malondialdehyde (MDA), myeloperoxidase (MPO), and nitric oxide (NO) activities were significantly increased after I/R injury, but they were decreased in the groups with NAC treatment. Alprostadil decreased NO production, but had no effect on MDA and MPO. Histological results showed that both NAC and alprostadil were effective in improving liver tissue morphology during I/R injury. Although NAC and alprostadil did not have a synergistic effect, our findings suggest that treatment with either NAC or alprostadil has benefits for ameliorating hepatic I/R injury.

  7. Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience.

    Science.gov (United States)

    Cuzin, Béatrice

    2016-08-01

    Erectile dysfunction (ED) is a very common disorder with a deep impact on quality of life on both patients and partners. Several options are available for treating ED: oral pharmacotherapy with phosphodiesterase 5 (PDE5) inhibitors currently represents the first-line option for many patients with ED. Alprostadil, a prostaglandin, has been marketed for many years as a urethral stick and an intracavernous injection for the treatment of ED. It is now available in the form of a cream (Vitaros/Virirec), a noninvasive treatment which combines an active drug (alprostadil, a synthetic prostaglandin E1) with a skin enhancer improving its local absorption directly at the site of action. Alprostadil has a favourable pharmacodynamic profile and is poorly absorbed in systemic circulation, which makes it suitable in a lot of circumstances and results in a reduced risk of adverse effects (AEs). Systemic AEs are reported in only 3% of the treated population. Clinical efficacy has been demonstrated in both phase II and III trials, showing a global efficacy up to 83% with the 300 μg dose in patients with severe ED, significantly better than placebo. Its fast onset of action and lack of interactions with other drugs makes alprostadil cream a possible first-line therapeutic option for some patients with ED: individuals who are reluctant to take systemic treatments or have AEs, patients who do not respond, cannot tolerate, or do not accept PDE5 inhibitor therapy, and patients treated with nitrates. Therefore, this new treatment for ED can be offered to patients and could help address the needs unmet by other treatments.

  8. A Controlled Study of Alprostadil Liposomal Preparation in the Treatment of Blue Toe Syndrome.

    Science.gov (United States)

    Xi, Hai-Lin; Li, Rui; Tian, Zhi-Long; Feng, Su; Jia, Gao-Lei

    2015-05-01

    The aim of this study is to examine the efficacy of alprostadil liposomal preparation in the treatment of blue toe syndrome. As many as 32 patients with blue toe syndrome were randomized into the test group and a control group. Patients out of the test group were treated with alprostadil liposomal preparation, while those out of the control group received placebo administration. Inter-group comparisons were conducted for the post-therapeutic changes of microcirculation and improvements of clinical symptoms. In the test group, there were eight subjects with marked response (50.0 %), six subjects with partial response (37.5 %), and two subjects with no response (12.5 %), with the overall response rate of 87.5 %. In the control group, there were three cases (18.8 %), one case (6.4 %), and 12 cases (75 %), respectively, with the overall response rate of 25.0 %. The inter-group difference of response was statistically significant (Χ (2) = 12.987, P = 0.002 0.05). The post-therapeutic points of nail-fold microcirculation in the test group decreased significantly (P 0.05). The post-therapeutic waveform changes of photoelectric plethysmography were significant for the test group in comparison to the control. The safety and efficacy of alprostadil liposomal preparation have been demonstrated in the treatment of blue toe syndrome.

  9. Effect of alprostadil combined with conventional therapy on serum markers in patients with acute cerebral infarction

    Institute of Scientific and Technical Information of China (English)

    Li-Lan Chen; Guo-Qiang Chen; Tao Yang; Mu-Qing Long

    2016-01-01

    Objective:To study the effect of alprostadil combined with conventional therapy on serum markers in patients with acute cerebral infarction.Methods:Patients with acute cerebral infarction treated in our hospital from May 2012 to August 2014 were enrolled and randomly divided into two groups. Observation group received alprostadil combined with conventional therapy and control group received conventional treatment. Then serum markers of both groups were compared.Results:(1) contents of serum nerve function related molecules: serum NSE and S100βcontents of observation group showed a decreasing trend, and BDNF and NGF contents showed an increasing trend; (2) contents of atherosclerosis related enzymes: serum GGT, iNOS and MPO contents of observation group showed a decreasing trend, and PON1 and PON2 contents showed an increasing trend; (3) platelet activation related molecules: serum PPARγ, CD62p, YKL-40, sCD40L and Fibulin-5 contents of observation group all showed a decreasing trend.Conclusions:Alprostadil combined with conventional treatment is helpful to alleviate neuronal damage and inhibit the processes of atherosclerosis and platelet activation;it’s an ideal method for treating acute cerebral infarction.

  10. A synthetic prostaglandin E1 analog, alprostadil alfadex, relaxes sphincter of Oddi in humans.

    Science.gov (United States)

    Koshitani, Tatsuya; Kodama, Tadashi; Sato, Hideki; Takaaki, Junpei; Imamura, Yoichi; Kato, Keimei; Wakabayashi, Naoki; Tokita, Kazuhiko; Mitsufuji, Shoji

    2002-01-01

    It is well established that prostaglandins (PGs) exert potent pharmacological actions on vascular and nonvascular smooth muscle, although their effects on the sphincter of Oddi (SO) remain to be elucidated. The aim of this study was to investigate the effect of PGE1 on motility of the human SO. Twenty patients appearing for routine endoscopic retrograde cholangiopancreatography (ERCP) examination were studied. Each patient was randomly allocated to receive an intravenous infusion of normal saline (six patients), or alprostadil alfadex, a synthetic PGE1 analog, at a dose of either 0.05 or 0.1 microg/kg/min (seven patients for each condition). Endoscopic biliary manometry was done with a recording of basal SO pressure, amplitude of SO phasic contractions, and phasic contractile frequency before and 5 min after intravenous infusions, using a 4-French microtransducer catheter. There was no significant change in SO motor variables following application of normal saline. Alprostadil alfadex significantly decreased basal SO pressure at a dose of 0.05 microg/kg/min, and significantly decreased all parameters at a dose of 0.1 microg/kg/min. A synthetic PGE1 analog, alprostadil alfadex, effectively inhibits motility of the human SO. This drug may be of clinical application as a SO-relaxing agent.

  11. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review.

    Science.gov (United States)

    Anaissie, James; Hellstrom, Wayne Jg

    2016-01-01

    Erectile dysfunction (ED) is a common and debilitating disorder seen in over 50% of men older than 70 years. Oral phosphodiesterase type 5 (PDE5) inhibitors are the mainstay of treatment for ED, but cannot be used by a significant subset of patients due to systemic side effects and drug-drug interactions. Second-line therapy may include intracavernosal therapies, but are associated with poor compliance due to their invasive nature. Alprostadil has a mechanism of action different from that of PDE5 inhibitors. Clinical trials have shown topical alprostadil cream to be effective, increasing the erectile function (EF) score of the International Index of EF by up to 13 points from baseline. It has also proven to be safe and well tolerated, with mild-to-moderate and transient treatment-related adverse events that are generally localized to the application site. Topical alprostadil cream is a safe and effective second-line therapy for ED, indicated for those who cannot tolerate, or are not satisfied with, oral PDE5 inhibitor therapy.

  12. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].

    Science.gov (United States)

    Potempal, Axel-Jürg; Potempa, Dirk M; Görlich, Hans Diether; Stolpmann, Rainer M

    2007-01-01

    In a multicenter clinical monitoring study (observation of use investigation according to 67.6 of the German Drug Law), which was conducted between 2003 and 2005 in 105 urological practices in 314 patients with organic erectile dysfunction (ED), efficacy, safety, convenience and acceptance of intraurethral administered alprostadil (CAS 745-65-3; MUSE - Medicated Urethral System for Erection) was studied. 306 patients could statistically be evaluated. The patients were 61.3 +/- 9.2 years old (median+/- SD) (181 patients between 60 and 80 y). The time of ED was from 2 to 120 months with a mean duration of 21.5 +/- 22 months (median+/-SD. Genesis of the ED was in 55 % of the patients a local damage, which followed in 42.8 % a prostate cancer surgery. 46 % of the patients had vascular, 28 % metabolic diseases including diabetes and 11% neural damages. In 51.3% of the patients drugs, which were known to induce ED, were suspected to have caused or partially caused the impairment. The degree of the disturbance was in 93 % of the cases moderate to severe. Alprostadil (MUSE) was applicated three times in doses of 250, 500 or 1000 microg. The dosage of 1000 microg was used for the third application by 65 % of the patients. Very good and good efficacy increased from 45.8% of the patients after the first through 63.7 % after the second to 69.3 % after the third application. In patients after surgery because of prostate cancer very good and good efficacy improved in comparison to the first application about 20% and concerned 53.9 % of the patients after the third application. Sexual intercourse was possible by 67% of the patients after the first, 83 % after the second and 87 % after the third use. Tolerability of alprostadil (MUSE) was very good and good in 90% of the patients. 81.1% intended to continue the treatment. The handling of alprostadil (MUSE) was assessed very good and good by 75%, the acceptance was very good and good in 96% of the patients. In a retrospective

  13. Effect of alprostadil on hemorheology, immune function, MDA, SOD and ROS in patients with diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    Li-Li Xia; Yu-Bin Tang; Kan Shao

    2016-01-01

    Objective: To investigate the effect of alprostadil on hemorheology, oxidative stress and immune function in patients with diabetic nephropathy. Methods:A total of 90 cases of diabetic nephropathy patients were divided into control group (45 cases) and observation group (45 cases). The control group was treated by conventional therapy, and the observation group was received extra alprostadil. The levels of hemorheology, oxidative stress and immune function indexes were measured and compared. Results:The levels of blood glucose, blood lipid and UAER had a significant improvement in both groups, and the level of UAER in the observation group decreased more significantly than that in the control group after treatment;the levels of hemorheology indexes (high, middle and low shear of blood viscosity, plasma viscosity, deformation index and erythrocyte aggregation index) had a significant improvement after treatment, and the levels of low shear of blood viscosity and erythrocyte aggregation index in the observation group decreased more significantly than that in the control group after treatment. The levels of oxidative stress indexes (MDA, ROS and SOD) had a significant improvement in both groups, and the levels of MDA, ROS and SOD decreased more significantly after treatment. The levels of CD4+, CD4+/CD8+ in the observation group increased significantly after treatment, while the level of CD8+ had no significant improvement. The levels of CD4+, CD8+,CD4+/CD8+in the control group had no significant differences, while the levels of CD4+, CD4+/CD8+in the observation group were significantly higher than that in the control group. Conclusions:Alprostadil treatment can obviously improve renal function, hemorheology, oxidative stress and immune function in patients with diabetic nephropathy.

  14. Effect of alprostadil combined with butylphthalide on the serum inflammatory factors and coagulable function in patients with acute ischemic stroke

    Institute of Scientific and Technical Information of China (English)

    Wen-Zhuo Dai; Yue-Nan Kong

    2016-01-01

    Objective:To observe the effect of alprostadil combined with butylphthalide on the serum inflammatory factors, coagulable function in patients of acute ischemic stroke.Methods: A total of 84 cases of patients with acute ischemic stroke were randomly divided into observation group (44 cases) and control group (40 cases). The observation group was given alprostadil combined and butylphthalide based on conventional treatment, and the control group was given alprostadil based on conventional treatment. Treatment was developed for 14 d to observe the changes of serum inflammatory factors (IL-6, IL-8, CRP, TNF-α) and coagulation correlated parameters (PT, FIB, DDI, TXB2, PAI-1) between the two groups.Results: After treatment, IL-6, IL-8, CRP, TNF-α of the two groups decreased obviously compared with before, PT increased and FIB, DDI, TXB2, PAI-1 decreased obviously compared with before. All indexes of the observation group were improved more significantly than that of the control group, with statistical difference.Conclusion:Alprostadil combined with butylphthalide can help to inhibit inflammatory reaction and improve high coagulation state in treatment of acute ischemic stroke.

  15. Effects of alprostadil on blood rheology and nucleoside metabolism in patients affected with lower limb chronic ischaemia.

    Science.gov (United States)

    Acciavatti, A; Laghi Pasini, F; Capecchi, P L; Messa, G L; Lazzerini, P E; De Giorgi, L; Acampa, M; Di Perri, T

    2001-01-01

    The acute (0.57 microg/kg i.v. in 2 hours) and long-term (0.57 microg/kg i.v. in 2 hours for 5 days over 4 weeks) effects of the PGE1 analogue alprostadil were studied in patients affected with intermittent claudication. Whole Blood Viscosity (WBV), Whole Blood Filterability (WBF), haematocrit (Htc) and fibrinogen plasma concentration, were studied together with P50, 2,3-diphosphoglycerate, and adenosine plasma levels. Moreover, in the long-term study, pain-free (PFWD) and maximal walking distance (MWD) were measured. Single alprostadil infusion induced an improvement in WBV, WBF, and oxygen transport, and an increase in adenosine plasma levels. Long-term alprostadil administration produced a decrease in WBV only, without significant changes in WBF, Htc, fibrinogen, P50, 2,3-diphosphoglycerate, also inducing a significant prolongation of PFWD and MWD. The possibility is suggested that pulse rises in adenosine plasma levels play a role in the effects of chronic alprostadil administration, maybe in a way similar to that observed in the phenomenon of ischaemic preconditioning,

  16. Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia–reperfusion injury in rats

    Science.gov (United States)

    Erer, Dilek; Özer, Abdullah; Demirtaş, Hüseyin; Gönül, İpek Işık; Kara, Halil; Arpacı, Hande; Çomu, Faruk Metin; Oktar, Gürsel Levent; Arslan, Mustafa; Küçük, Ayşegül

    2016-01-01

    Objectives To evaluate the effects of alprostadil (prostaglandin [PGE1] analog) and iloprost (prostacyclin [PGI2] analog) on renal, lung, and skeletal muscle tissues after ischemia reperfusion (I/R) injury in an experimental rat model. Materials and methods Wistar albino rats underwent 2 hours of ischemia via infrarenal aorta clamping with subsequent 2 hours of reperfusion. Alprostadil and iloprost were given starting simultaneously with the reperfusion period. Effects of agents on renal, lung, and skeletal muscle (gastrocnemius) tissue specimens were examined. Results Renal medullary congestion, cytoplasmic swelling, and mean tubular dilatation scores were significantly lower in the alprostadil-treated group than those found in the I/R-only group (Palprostadil- and iloprost-treated groups (P=0.017 and P=0.001; PAlprostadil and iloprost significantly reduce lung tissue I/R injury. Alprostadil has more prominent protective effects against renal I/R injury, while iloprost is superior in terms of protecting the skeletal muscle tissue against I/R injury. PMID:27601882

  17. Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia–reperfusion injury in rats

    Directory of Open Access Journals (Sweden)

    Erer D

    2016-08-01

    Full Text Available Dilek Erer,1,* Abdullah Özer,1,* Hüseyin Demirtaş,1 İpek Işık Gönül,2 Halil Kara,3 Hande Arpacı,4 Faruk Metin Çomu,5 Gürsel Levent Oktar,1 Mustafa Arslan,6 Ayşegül Küçük7 1Department of Cardiovascular Surgery, 2Department of Pathology, Gazi University Medical Faculty, 3Department of Pharmacology, Yıldırım Beyazıt University Medical Faculty, 4Department of Oral and Maxillofacial Surgery, Ankara University Faculty of Dentistry, Besevler, Ankara, 5Department of Physiology, Kırıkkale University Medical Faculty, Kırıkkale, 6Department of Anesthesiology and Reanimation, Gazi University Medical Faculty, Ankara, 7Department of Physiology, Dumlupınar University Medical Faculty, Kütahya, Turkey *These authors contributed equally to this work Objectives: To evaluate the effects of alprostadil (prostaglandin [PGE1] analog and iloprost (prostacyclin [PGI2] analog on renal, lung, and skeletal muscle tissues after ischemia reperfusion (I/R injury in an experimental rat model.Materials and methods: Wistar albino rats underwent 2 hours of ischemia via infrarenal aorta clamping with subsequent 2 hours of reperfusion. Alprostadil and iloprost were given starting simultaneously with the reperfusion period. Effects of agents on renal, lung, and skeletal muscle (gastrocnemius tissue specimens were examined.Results: Renal medullary congestion, cytoplasmic swelling, and mean tubular dilatation scores were significantly lower in the alprostadil-treated group than those found in the I/R-only group (P<0.0001, P=0.015, and P<0.01, respectively. Polymorphonuclear leukocyte infiltration, pulmonary partial destruction, consolidation, alveolar edema, and hemorrhage scores were significantly lower in alprostadil- and iloprost-treated groups (P=0.017 and P=0.001; P<0.01 and P<0.0001. Polymorphonuclear leukocyte infiltration scores in skeletal muscle tissue were significantly lower in the iloprost-treated group than the scores found in the nontreated I

  18. Peripheral Female Genital Arousal as Assessed by Thermography Following Topical Genital Application of Alprostadil vs Placebo Arousal Gel: A Proof-of-Principle Study Without Visual Sexual Stimulation

    Directory of Open Access Journals (Sweden)

    Sue W. Goldstein, BA, CCRC, IF

    2016-09-01

    Conclusion: Topical alprostadil administered to healthy premenopausal women induced statistically significant, sustained increases in genital temperatures of the vestibule, clitoris, and vulva within 20 minutes compared with OTC lubricant.

  19. Effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats

    Institute of Scientific and Technical Information of China (English)

    Wei-Yan Cai; You-Yi Gu; Ai-Min Li; Huan-Qin Cui; Yi Yao

    2014-01-01

    Objective:To observe effect of alprostadil combined with Diammonium glycyrrhizinate on renal interstitial fibrosis in SD rats. Methods:A total of 75 SD rats were randomly divided into A, B, C, D, E groups with 15 in each group. Rats in group A served as the control group received just only but tissue separation without modeling operation, while model of unilateral ureteral obstruction (UUO) was established in B, C, D, E groups. Rats in A, B group were given saline lavage placebo treatment, while rats in C, D, E groups were given diammonium glycyrrhizinate and alprostadil injection. Five rats were sacrificed 1, 2, 3 weeks after modeling, serum creatinine level of femoral venous blood was determined. Transforming growth factor-β1 (TGF-β1) and concentration of connective tissue growth factor (CTGF) were also detected by using ELISA. Line renal interstitial tissue was taken after HE staining, renal interstitial TGF - β1 and CTGF expression were detected by using immunohistochemical method. Results:Serum creatinine levels of B, C, D, E group at different time points in were significantly higher than that of group A (P0.05);while serum and kidney tissue TGF-β1, concentration of CREA, expression of rats in B, C, D, E groups showed a gradual increasing trend over time. TGF-β1 and CREF of Group B in serum and kidney tissues at each time point were significantly higher than that of the other groups (P<0.05). TGF-β1 and CREF of Group E in serum and kidney tissues at each time point were significantly lower than that of B, C, D group at all time points in serum and kidney tissues (P<0.05). Conclusions:Alprostadil combined with diammonium glycyrrhizinate can significantly lower the expression of TGF-β1 and CTGF in serum and tissues of SD rat with renal interstitial fibrosis, thus inhibit rat renal interstitial fibrosis process. It has synergy protective effect.

  20. Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats

    OpenAIRE

    Hsieh, Cheng-Chu; Hsieh, Shu-Chen; Chiu, Jen-Hwey; Wu, Ying-Ling

    2014-01-01

    Ischemia–reperfusion (I/R) injury has a complex pathophysiology resulting from a number of contributing factors. Therefore, it is difficult to achieve effective treatment or protection by individually targeting the mediators or mechanisms. Our aim was to analyze the individual and combined effects of N-acetylcysteine (NAC) and the prostaglandin E1 (PGE1) analog alprostadil on hepatic I/R injury in rats. Thirty male Sprague-Dawley rats were randomly divided into five groups (six rats per group...

  1. Effect of alprostadil combined with fosinopril therapy on renal function and oxidative stress in patients with diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    Wei Wang; Zhi-Yuan Lu; Zhen Ren; Guo-Zhao Zhang

    2016-01-01

    Objective:To analyze the effect of alprostadil combined with fosinopril therapy on renal function and oxidative stress in patients with diabetic nephropathy.Methods: A total of 80 cases of patients with diabetic nephropathy were included in this study and randomly divided into observation group and control group (n=40), control group received fosinopril therapy alone and observation group received alprostadil combined with fosinopril therapy. Differences in serum renal function indexes, renal damage indexes of ultrasound contrast, oxidative stress indexes, etc were compared between two groups.Results:Serum BUN, Scr and 24 h urine protein values of observation group were lower than those of control group; the left kidney and right kidney AUC and TTP values were lower than those of control group while DPI value was higher than that of control group; serum 8-OHdG and MDA values were lower than those of control group while SOD and T-AOC values were higher than those of control group. Conclusion:Alprostadil combined with fosinopril therapy can reduce renal cortex damage in patients with diabetic nephropathy, and plays a positive role in optimizing renal function and reducing systemic oxidative stress.

  2. Effect of alprostadil on early proinflammatory cytokines and its therapeutic effect in patients with severe acute pancreatitis

    Directory of Open Access Journals (Sweden)

    Min-li LI

    2017-04-01

    Full Text Available Objective  To investigate the effects of alprostadil on expression of proinflammatory cytokines in patients with severe acute pancreatitis (SAP and evaluate the clinical efficacy. Methods  Seventy-three SAP patients were collected from January 2014 to May 2016, and then were randomly divided into control group (n=37 and experimental group (n=36. On the basis of routine treatment, the experimental group patient was given alprostadil at a dose of 15µg/d. The expression of C-reactive protein (CRP, white blood cell (WBC count, amylase, alanine aminotransferase (ALT, aspartate aminotransferase (AST, creatinine, serum proinflammatory cytokine tumor necrosis factor alpha (TNF-α, interleukin -1 beta (IL-1β, interleukin -6 (IL-6 were detected in serum on the 1st, 3rd and 7th day. Results  The biochemical indexes and expression of proinflammatory cytokines were significantly increased in the two groups on the 1st day, and decreased gradually, with a significant difference between the time points (P0.05. These indexes were decreased significantly with the passage of time and there were significant differences between the two groups at the 3rd and 7th day (P<0.05. Conclusion  Alprostadil can effectively reduce the severity of early inflammatory reaction in SAP patients, and has important significance for improving the prognosis. DOI: 10.11855/j.issn.0577-7402.2017.02.09

  3. 前列地尔注射液致血压下降%Hypotension induced by alprostadil injection

    Institute of Scientific and Technical Information of China (English)

    甘泉; 侯惠如; 赵诺

    2011-01-01

    1例80岁老年男性,因糖尿病大血管病变和糖尿病周围神经病变,为改善微循环和营养周围神经,给予前列地尔注射液10μg和甲钴胺注射液500μg,qd,先后入100mL0.9%氯化钠注射液静脉滴注.使用约4d后患者血压下降,降压药物剂量减半后血压仍较前明显偏低,收缩压最大下降30mmHg.考虑为前列地尔引起的不良反应.出院后停用前列地尔,血压逐渐恢复至原有水平.%A 80-year old male patient with long course of diabetes was treated with alprostadil and mecobalamine for diabetic neuropathies and improving microcirculation. Four days later, his blood pressure dropped out and was lower than before after reducing a half of the dosage of hypotensive drug. The maximum amplitude of systolic blood pressure decreasing was 30 mm Hg.It is considered as hypotension induced by alprostadil injection. After stopped using alprostadil, his blood pressure increased to the level before gradually.

  4. Determination of alprostadil in rat plasma by ultra performance liquid chromatography-electrospray ionization-tandem mass spectrometry after intravenous administration.

    Science.gov (United States)

    Lin, Xia; Zhang, Yu; Cui, Yue; Wang, Lin; Wang, Jing; Tang, Xing

    2009-05-01

    A rapid, highly selective ultra performance liquid chromatography-electrospray ionisation-tandem mass spectrometry method (UPLC-ESI-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of alprostadil in rat plasma. After a simple sample preparation procedure involving a one-step liquid-liquid extraction, alprostadil and the internal standard, diphenhydramine, were chromatographed on an ACQUITY UPLC BEH C(18) column with gradient elution using a mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.25 mL min(-1). The detection was performed on a triple quadrupole tandem mass spectrometer in multiple reaction monitoring (MRM) mode via an electrospray ionization (ESI) source. The calibration curve was linear (r(2)=0.99) over the concentration range 0.4-250.0 ng mL(-1), with a lower limit of quantification of 0.4 ng mL(-1) for alprostadil. The inter- and intra-day precision (%R.S.D.) was less than 8.5% and 2.4%, respectively, and the accuracy (RE%) was between 9.3% and 1.0% (n=6). Alprostadil in rat plasma was stable when stored at room temperature for 0.5h and at -20 degrees C for two weeks. The method was very rapid, simple and reliable, and was employed for the first time for the pharmacokinetic studies of alprostadil in rats after a single intravenous administration of 50 microg kg(-1).

  5. Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction.

    Science.gov (United States)

    Harding, L M; Adeniyi, A; Everson, R; Barker, S; Ralph, D J; Baranowski, A P

    2002-12-01

    Patients identified from hospital records as using alprostadil injections for erectile dysfunction were invited to take part in this open crossover study. On alternate weeks eight patients were given intracavernosal needle injections and transdermal needle-free injection of alprostadil in a randomized order. Efficacy of injection and associated pain were assessed and compared for the two methods. Pain produced during injection was significantly greater with the needle-free system than with the needle-tipped injection whilst efficacy was significantly less. Bruising was reported in all except one patient following needle-free injection only. Patient ratings of the needle-free injector were significantly lower than ratings for needle-tipped alprostadil delivery and when asked to express a preference, every patient chose the needle-tipped injection over the needle-free device.

  6. 前列地尔注射液致静脉炎10例%10 Cases of Phlebitis Caused by Alprostadil Injection

    Institute of Scientific and Technical Information of China (English)

    潘珂佳

    2015-01-01

    Objective To explore the causes of alprostadil injection caused by adverse drug reactions of phlebitis. Methods According to the analysis of the causes of literature retrieval of alprostadil injection used in our hospital. Results Patients with adverse drug reaction occurred phlebitis infusion of alprostadil injection after the reported visible adverse reactions of alprostadil forefront, but clinicians awareness rate is not high, that clinicians did not alprostadil injection adverse drug reactions to give enough attention. Conclusion To improve the drug adverse reaction alprostadil injection attention, the safe use of drugs, to ensure patients.%目的:探讨前列地尔注射液引起药物不良反应静脉炎的原因。方法根据我院患者使用前列地尔注射液情况检索文献分析原因。结果患者情况符合输注前列地尔注射液后出现静脉炎的药物不良反应,文献报道可见前列地尔注射液不良反应情况,但临床医师知晓率并不高,说明临床医师并未对前列地尔注射液的药物不良反应给予足够重视。结论提高前列地尔注射液药物不良反应关注度,安全使用药品,保证患者疗效。

  7. Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians

    Institute of Scientific and Technical Information of China (English)

    WimpieI.Pangkahila

    2000-01-01

    Aim: To evaluate the efficacy and safety of transurethral application of alprostadil (MUSE.) for the treatment of erectile dysfunction in Indonesians. Methods: Twenty erectile dysfunction patients aged between 32 - 74 years old were recruited in this study. The inclusion criteria were as follows: 1 ) adult males 18 years or older with a subjective complaint or erectile dysfunction, 2) to provide written informed consent, 3) to agree not to use other forms of treatment for erectile dysfunction, 4) fulfill the screening laboratory values. Part 1, eligible patients were titrated in the clinic starting with a dose of 250 μg and proceed in a stepwise manner to 500μg and 1000μg on separate clinic visits until they identified a dose that produced a satisfactory response. The interval between each in-clinic titration was 2-3 days. Each in-clinic titration dose was evaluated at 15 min intervals over a one hour period for erection assessment, blood pressure and pulse. Part 2, patients used MUSE at home for three months at the dose identified during the inclinic titration. Monthly interim visits were required for patient follow-up and drug distribution. At the end of the study, patients had another laboratory (except testosterone, only assayed in screening procedure) and physical examination. Results: The etiology of erectile dysfunction was psychological in 5 patients and organic in 15 patients. The 65% of the patients achieved the erection scale of 4 or 5 either in the clinic or at home, 10% achieved the scale of 4 at home, but not in the clinic, and 25 % only achieved the scale of 2 or 3 with the highest dose of 1000μg either in the clinic or at home. No significant differences were found in biochemical examination before and after the study. The 60 % of the patients who achieved erection scale 4 or 5 continued to use MUSE until the end of the study, while 40 % of them complained of pain at the time of MUSE application, during erection and/or during intercourse. They

  8. Alprostadil promotes the early recovery of transplanted renal function%前列地尔促进移植肾功能的早期恢复

    Institute of Scientific and Technical Information of China (English)

    王振璞; 曲青山; 苗书斋

    2013-01-01

    BACKGROUND:Studies have found that alprostadil can inhibit platelet aggregation, relax vascular smooth muscle, diastole peripheral blood vessels and thereby improving peripheral circulation. OBJECTIVE:To further verify whether alprostadil can promote the early recovery of renal function of renal transplantation recipients. METHODS:Total y 125 patients in the alprostadil group received intravenous infusion of 20μg alprostadil daily, and then compared with the 115 patients in the unused alprostadil group in the same time. The urine volume, serum creatinine and the creatinine clearance were compared between two groups;blood flow resistance-indexes, as wel as the incidences of delay recovery of renal function and acute rejection were detected under color doppler ultrasound. RESULTS AND CONCLUSION:The urine volume and creatinine clearance in the alprostadil group were significantly higher than those in the unused alprostadil group;while the serum creatinine and the blood flow resistance-indexes were lower than the unused alprostadil group. The incidence of delay recovery of renal function in the alprostadil group was 7.2%which was significantly lower than that in the unused alprostadil group (P<0.01);there was no significant difference in the incidence of acute rejection between two groups. The findings suggest that the administration of alprostadil in renal transplantation recipients during the early stage of kidney transplantation can accelerate the recovery of the renal function and can promote the early rehabilitation after renal transplantation.%背景:研究发现前列地尔具有抑制血小板凝集、松弛血管平滑肌、舒张外周小血管进而改善末梢循环的作用。目的:进一步验证前列地尔能否促进肾移植后移植肾功能早期恢复。方法:对125例加用前列地尔组患者肾移植后2周内每天静脉滴注前列地尔20μg,与同期内115例未用前列地尔组进行对比,比较两组患者肾移植后7d尿

  9. Research about the influence of alprostadil for the renal blood flow parameters and fibrosis indexes of patients with diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    Li Ling; Guo-Juan Lao; Li-Bo Chen; Diao-Zhu Lin

    2016-01-01

    Objective:To observe the curative effects of alprostadil on diabetes nephropathy and its influences on the renal blood flow parameters and fibrosis indexes of patients.Methods:Eighty cases of patients with diabetic nephropathy who were treated in our hospital from May 2013 to September 2014 were randomly selected as the research objects and were divided into the control group and the observation group. Each group had 40 cases. Patients of the control group were treated by routine therapy, while patients of the observation group were treated with alprostadil on the basis of routine therapy. The fasting blood glucose, renal function-related indexes, serum creatinine, blood urea nitrogen, urinary albumin excretion rate and fibrosis markers, matrix metalloproteinase-9 (MMP-9), hyaluronic acid (HA), laminin (LN),Ⅲ procollagen (PCⅢ) and typeⅣ collagen (ⅣC) of the two groups before and after treatments were respectively tested, and the peak systolic velocity (PSV), end diastolic velocity (EDV), resistance index (RI) and pulsatility index (PI) of renal artery segment were tested by color doppler ultrasound.Results:After 14 and 28 d of treatments, the blood urea nitrogen, urinary albumin excretion rate of the observation group were all significantly lower than those of the control group; the PSV and EDV were all significantly faster than those of the control group; RI and PI were all observably lower than those of the control group and the serum levels of MMP-9, HA, LN, PCⅢ, andⅣC were also prominently lower than those of the control group. Conclusions:Alprostadil can effectively slow the development of fibrosis and protect the renal function of patients with diabetic nephropathy by improving renal blood supply for them.

  10. Effect of alprostadil combined with Shenkang injection on urine protein, renal function and serum inflammatory in patients with chronic nephritis

    Institute of Scientific and Technical Information of China (English)

    Chen Wang; Zhi-Feng Gu; Shuo Wang; Liang-Lan Shen; Fen Zhang

    2016-01-01

    Objective:To study the effect of alprostadil combined with Shenkang injection on urine protein, renal function and serum inflammatory in patients with chronic nephritis.Methods:A total of 96 patients with chronic nephritis in our hospital from May 2013 to May 2016 were enrolled in this study. The subjects were divided into control group (n=48) and treatment group (n=48) randomly. Patients in control group were treated with Shenkang injection, the treatment group were treated with alprostadil combined with Shenkang injection. The two groups were treated for 12 days. The levels of 24 h Upro, Uβ2-MG, SCr, BUN, UAER, hs-CRP, TNF-α, IL-6, IL-8 and IL-18 of the two groups before and after treatment were compared. Results:There were no significantly differences of the levels of 24 h Upro, Uβ2-MG, SCr, BUN, UAER, hs-CRP, TNF-α, IL-6, IL-8 and IL-18 of the two groups before treatment (P>0.05). The levels of 24 h Upro, Uβ2-MG, SCr, BUN and UAER of the two groups after treatment were significantly lower than before treatment (P<0.05), and that of experiment were significantly lower than control group (P<0.05). The levels of hs-CRP, TNF-α, IL-6, IL-8 and IL-18 of the two groups after treatment were significantly lower than before treatment (P<0.05), and that of experiment were significantly lower than control group (P<0.05).Conclusions: Alprostadil combined with Shenkang injection can significantly reduce urine protein and serum inflammatory, protect renal function of patients with chronic nephritis, and it is worthy clinical application.

  11. Metabolism of eicosanoids and their action on renal function during ischaemia and reperfusion: the effect of alprostadil.

    Science.gov (United States)

    Dołegowska, B; Pikuła, E; Safranow, K; Olszewska, M; Jakubowska, K; Chlubek, D; Gutowski, P

    2006-12-01

    Eicosanoids, active metabolites of arachidonic acid (AA), play an important role in the regulation of renal haemodynamics and glomerular filtration. Our study verified the hypothesis on the positive action of exogenously administered PGE(1) on renal function during an operation with temporary ischaemia of the lower half of the body. Also the effect of alprostadil (prostaglandin E(1) analogue) administered during the operation of an abdominal aorta aneurysm on the postoperative systemic metabolism of AA and the glomerular filtration rate (GFR) was investigated. The study included 42 patients with a diagnosed abdominal aorta aneurysm who have been qualified for the operation of implantation of the aortic prosthesis. The patients were randomly assigned to two groups: the study group (I) receiving alprostadil and the control group (II) without alprostadil. The levels of hydroxyeicosatetraenoic acids (15-HETE, 12-HETE, 5-HETE) were determined by RP-HPLC and the level of thromboxane B(2) (TxB(2)) was determined by ELISA in the plasma of the blood drawn from vena cava superior immediately before aortic clamping (A) and 5 min after aortic declamping (B). The administration of PGE(1) affects the metabolism of 15-HETE in a manner dependent on the baseline value of GFR but does not significantly change the postoperative renal function. The metabolism of 15-HETE is affected by the baseline value of GFR1 and a longer period of ischaemia is correlated with lower concentrations of 5-HETE during reperfusion. The results of our studies indicate that TxB(2) influences the postoperative function of kidneys.

  12. Is It Worth Continuing Sexual Rehabilitation after Radical Prostatectomy with Intracavernous Injection of Alprostadil for More than 1 Year?

    Directory of Open Access Journals (Sweden)

    René Yiou, MD, PhD, PUPH

    2015-03-01

    Conclusion: The response to IAI remained stable after 2 years of treatment, and no significant improvement of spontaneous erections during intercourse attempts was found between M12 and M24. Patients should be informed of the limited effect of IAI on natural erections after 1 year. Yiou R, Bütow Z, Parisot J, Binhas M, Lingombet O, Augustin D, de la Taille A, and Audureau E. Is it worth continuing sexual rehabilitation after radical prostatectomy with intracavernous injection of alprostadil for more than 1 year? Sex Med 2015;3:42–48.

  13. Clinical Analysis the Pharmacologic Action of Alprostadil%前列地尔的药理作用临床分析

    Institute of Scientific and Technical Information of China (English)

    赵娟

    2016-01-01

    Alprostadil the common drugs in treatment of chronic disease, there has speciifc function of elderly patient clinical therapy, which is continuously extending the clinial appplication range, has higher value of clinical application. At present, the clinical application study increase gradually about the pharmacologic action of alprostadil. This article analysis the research progress, pharmacologic, application status of alprostadil, aim at provide some reference in alprostadil clinical application.%前列地尔是治疗较多慢性疾病的常用药,其在老年疾病的临床治疗中有特殊的作用,临床应用范围也不断扩大,有较高的临床应用价值。当前,关于前列地尔药理作用及临床应用研究逐渐增多,本文对前列地尔应用现状、药理作用及研究进展进行分析,以期为前列地尔临床应用提供借鉴。

  14. 注射用前列地尔的处方与工艺研究%Study on formulation and Preparation of Alprostadil for Injection

    Institute of Scientific and Technical Information of China (English)

    吉宁; 顾平荣

    2013-01-01

    Objective:To study the reasonal formulation and preparation technique of Alprostadil for Injection.Methods:The formu-lation of Alprostadil for Injection was optimized by choice of suitable vehicle,the preparation technique was study. Results:Dextran as ve-hicle, Alprostadil for Injection with good shape and quality can be made through 18 hours lyophilization.Conclusion:Both the formulation and preparation technique of Alprostadil for Injection were feasible.%目的:确定注射用前列地尔的制备处方及工艺。方法:选择适宜赋形剂,对冻干工艺进行筛选。结果:以右旋糖酐为赋形剂,经过18小时的冻干过程,制得成型性好,质量可靠的注射用前列地尔。结论:注射用前列地尔处方工艺可行。

  15. Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial.

    Science.gov (United States)

    Padma-Nathan, Harin; Brown, Candace; Fendl, Jane; Salem, Shawki; Yeager, James; Harningr, Ronald

    2003-01-01

    We evaluated the efficacy and safety of three doses of a novel alprostadil cream in a randomized, double-blind, placebo-controlled study in 94 women presenting with female sexual arousal disorder of at least 6 month s duration. We sent the subjects home with 10 premeasured doses of 500 g, 1000 g, or 1500 g alprostadil or a placebo cream to be applied to the vulvar area prior to vaginal intercourse over a period of 6 weeks. The primary efficacy parameter, the arousal success rate (as measured by diary responses to the Female Sexual Encounter Profile [FSEP]), was highest in the alprostadil 1000 g group and lowest in the 500 g group, but the responses were not different from that of the placebo cream, at the p = 0.05 level, for any of the three alprostadil doses. However, the change from baseline for Item 6 of the Female Sexual Function Index (FSFI; Rosen et al., 2000; satisfaction with arousal during sexual activity) suggested an important dose-related trend (p = 0.173; 1500 g versus placebo). The mean percent responder rate (responder = > 50% arousal success rate with > 3 sexual attempts) suggested a dose-response effect (p = 0.157; 1500 g versus placebo). Adverse events were generally mild or moderate in intensity and mainly involved localized reactions in the genital area.

  16. Special safety study on Alprostadil Emulsion%前列地尔乳剂的特殊安全性实验研究

    Institute of Scientific and Technical Information of China (English)

    李萍; 刘宏大; 王宏英; 薛雁; 薛百忠; 潘月军

    2011-01-01

    目的:评价前列地尔乳剂的安全性.方法:采兔血配制成2%的红细胞混悬液,进行溶血试验;兔耳缘静脉分别注射前列地尔乳剂和生理盐水,观察药物对血管的刺激性;豚鼠腹腔注射前列地尔乳剂,观察过敏反应.结果:前列地尔乳剂对兔红细胞未出现溶血和凝聚作用;家兔耳缘静脉未见明显刺激作用;豚鼠仅出现轻微搔鼻或颤抖反应,未引起死亡.结论:前列地尔乳剂无溶血作用,元血管刺激性,无过敏反应,安全性符合要求.%Objective: To evaluate the safty of Alprostadil Emulsion. Methods: Preparated rabbit blood into 2% erythrocyte suspension for hemolytic test. In order to observe the stimulation vessel, Alprostadil Emulsion and 0.9% Sodium chloride injection were injected into ear vein of rabbit respectively. The allergic response on guinea pig in vitro were performed.Results: It was showed that the Alprostadil Emulsion had no hemolysis and agglomeration effects on the red blood cell of rabbit while no significant stimulation on ear vein. Guinea pig only appeared minor response, such as slight scratching nose or shivering response, did not cause death. Conclusion: It is proved that the Alprostadil Emulsion has no hemolyzation, stimulation on blood vessel and allergic reactions. The safety of Alprostadil Emulsion is fit for the requirements.

  17. [Determination of apomorphine, sildenafil and alprostadil in medicines for erectile dysfunction by high performance liquid chromatography-mass spectrometry].

    Science.gov (United States)

    Xu, Yuanjin; Xu, Guiping

    2005-11-01

    A high performance liquid chromatography-mass spectrometry (LC-MS) analytical method for illicit drugs, apomorphine, sildenafil and alprostadil, in medicines for erectile dysfunction has been developed. The samples were extracted with methanol using ultrasound-assisted extraction. The chromatographic separation was performed on a Zorbax Eclipse XDB-C18 column using acetonitrile-0.5% formic acid aqueous solution as mobile phase. The three compounds were identified by retention time and m/z and quantified by peak area. The results demonstrated that the linear ranges were 50.0 - 5 000.0 microg/L, 10.0 - 1 000.0 microg/L, 40.0 - 4 000.0 microg/L, with detection limits of 20.0, 4.0, 10.0 microg/L for apomorphine, sildenafil and alprostadil, respectively. The average recoveries and the relative standard deviations were 89% - 95% and 9.5% - 11%. The method is simple, rapid, accurate and suitable for the simultaneous determination of these drugs in medicines for erectile dysfunction.

  18. Six Cases of Anaphylactic Shock Induced by Alprostadil Injection%前列地尔注射液致过敏性休克6例

    Institute of Scientific and Technical Information of China (English)

    刘茵; 杨云; 应朦朦; 苗春平; 颜耀东

    2015-01-01

    Objective:To analyze the feature of anaphylactic shock induced by alprostadil injection. Methods: Totally 1624 pa-tients treated with alprostadil injection in our hospital from January to March 2014 were undergone adverse drug reaction monitoring. Six cases of anaphylactic shock induced by alprostadil injection were statistically analyzed. Results:6 cases of anaphylactic shock induced by alprostadil injection occurred in the department of intervention and most of thd reaction happened in arterial injection. Two lot num-ber of drugs were in high frequency. Patients showed a sharp fall in blood pressure, chest discomfor, palpitation, shortness of breath, paleness, sweating and other symptoms. After anti allergy, blood pressure, oxygen the rapy and other treatment measures vital signs gradully stabilized. Conclusion:Anaphylactic shock induced by alprostadil injection is in correlation with the administration mode of artery injection. The change of the patient' s condition and vital signs should be closely observed when we inject the patient with alpros-tadil injection. We must prevent the occurrence of serious adverse reactions.%目的:分析前列地尔注射液致过敏性休克的特点. 方法:对2014年1~3月我院使用前列地尔注射液的1 624例患者进行药品不良反应监测,对其中发生过敏性休克的6例患者病例资料进行统计分析. 结果:6例过敏性休克均发生在介入科,多发生在动脉插管时给药,两个批号药品发生率高. 患者均出现血压急剧下降、胸闷、心慌、气喘、而色苍白、大汗淋漓等症状,经过抗过敏、升压、给氧等一系列治疗措施,生命体征逐步稳定. 结论: 前列地尔注射液致过敏性休克与动脉注射的给药方式有相关性,因此用药时应严密观察患者病情及生命体征变化,防止发生严重不良反应.

  19. Combined therapeutic effect of alprostadil and mecobalamin on 128 patients with diabetic peripheral neuropathy%前列地尔联合甲钴胺治疗糖尿病周围神经病变128例

    Institute of Scientific and Technical Information of China (English)

    王志宏; 陈海燕; 郭瑞清

    2009-01-01

    Objective To observe the clinical effect of combined treatment of alprostadil and mecobalamin on diabetic peripheral neuropathy (DPN). Methods One hundred and twenty eight patients of DPN were divided into four groups: the alprostadil combined mecobalamine treated group, the alprostadil treated group, the meeobalamine treated group and the underline treated group, randomly. The therapeutic effect and nerve conduction velocity were compared between the four groups prior treatment and post-treatment. Results The alprostadil combined mecobalamine treated group gain an advantage than the alprostadil treated group or the mecobalamine treated group at clinical effectiveness and nerve conduction velocity(P<0.05). Conclusions Alprostadil combined meeobalamine treated can improve DPN more effective than alprostadil treated or mecobalamine treated only.%目的 观察前列地尔联合甲钴胺治疗糖尿病周围神经病变的效果.方法 128例糖尿病神经病变患者,随机分为前列地尔联合甲钴胺治疗组、单用前列地尔治疗组、单用甲钴胺治疗组及基础治疗组,比较四组患者治疗前后肌电图改变及临床疗效.结果 前列地尔联合甲钴胺治疗组在临床疗效及神经传导速度方面明显优于单用前列地尔组或单用甲钴胺治疗组(P<0.05).结论 前列地尔联合甲钴胺治疗比单用前列地尔或甲钴胺治疗可更有效改善糖尿病周围神经病变.

  20. Rapid improvement of distal vasculitis in PAN related to hepatitis B with alprostadil infusion: a case report.

    Science.gov (United States)

    Lim, Mie-Jin; Kwon, Seong Ryul; Lee, Seunghee; Park, Won

    2006-08-01

    Polyarteritis nodosa (PAN) related to hepatitis B is an uncommon vasculitis that is sometimes associated with the rapid progression of distal ischemia. A few recent reports have proposed the use of antiviral therapy. However, there is not yet a consensus for the standard treatment of this disease entity and none of these treatments have been focused on fast symptomatic improvement. We describe here a 39-year-old female patient with PAN related to hepatitis B infection who completely recovered from the acutely progressing ischemic manifestations of her distal extremities with the use of alprostadil infusion (prostaglandin E1). The reactivation of her hepatitis B infection after glucocorticoid and cyclophosphamide therapy was successfully managed by the antiviral lamuvudine therapy. Most importantly, the vasodilator together with the conventional therapy may be desirable in the early stages of the disease before irreversible ischemic tissue damage can occur.

  1. Alprostadil and Octreotide Treat Hepatorenal Syndrome%前列地尔联合奥曲肽治疗肝肾综合征

    Institute of Scientific and Technical Information of China (English)

    于凤芹

    2016-01-01

    目的:探讨前列地尔联合奥曲肽治疗肝肾综合征疗效。方法对2008年1月至2013年10月42例肝肾综合征患者随机分为治疗组和对照组,两组均同时采用基础治疗加前列地尔10µg/d。治疗组在对照组的基础上加用奥曲肽0.1 mg ih q8h/d,观察患者的临床症状、腹水减少情况以及肾功能指标。结果治疗组总有效率(71.43%)、腹水减少及肾功能好转均明显优于对照组(38.10%)(P<0.05)。结论前列地尔联合奥曲肽治疗肝肾综合征疗效明显优于前列地尔。%Objective To observe the effect of octretide combined alprostadil on hepatorenal syndrome. Methods 42 patients of hepatorenal syndrome were randomized into the treat and control groups. In addition, to routine management, the patients in the treat group were given octretide 0.1 mg ih q8h/d, while the control group was only given alprostadil 10 µg/d during the period of the treatment. Patient’s clinical symptoms, abdomen and renal function were observed. Result After treatment, the total effective rate, ascites reduce and renal function were significant between the two gyoups. Conclusion The octretide combined with alprostadil in the treatment of hepatorenal syndrome was efficacy, better effect than single alprostadil.

  2. Determination of the molecular complexation constant between alprostadil and alpha-cyclodextrin by conductometry: implications for a freeze-dried formulation.

    Science.gov (United States)

    Sheehy, Philip M; Ramstad, Tore

    2005-10-04

    The binding constant between alprostadil (PGE1) and alpha-cyclodextrin (alpha-CD) was determined at four temperatures using conductance measurements. Alpha-cyclodextrin is an excipient material in Caverject dual chamber syringe (DCS) that was added to enhance stability. The binding constant was used to calculate the amount of PGE1 free upon reconstitution and injection, since only the free drug is clinically active. The conductivity measurement is based on a decrease in specific conductance as alprostadil is titrated with alpha-CD. The change in conductivity was plotted versus free ligand concentration (alpha-CD) to generate a binding curve. As the value of the binding constant proved to be dependent on substrate concentration, it is really a pseudo binding constant. A value of 742+/-60 M(-1) was obtained for a 0.5 mM solution of alprostadil at 27 degrees C and a value of 550+/-52 M(-1) at 37 degrees C. These results compare favorably to values previously obtained by NMR and capillary electrophoresis. Calculation of the fraction PGE1 free upon reconstitution and injection show it to approach the desired outcome of one. Hence, the amount of drug delivered by Caverject DCS is nominally equivalent to that delivered by Caverject S. Po., a predecessor product that contains no alpha-cyclodextrin.

  3. Alprostadil in the Application of Hepatorenal Syndrome (HRS)%前列地尔在肝肾综合征中的应用

    Institute of Scientific and Technical Information of China (English)

    梅勇

    2013-01-01

    Objective Observation alprostadil (Alprostail Injection) treatment of hepatorenal syndrome (HRS) curative effect. Method Of 69 patients with HRS cases randomly divided into two groups, control group and an example, alprostadil group of 38 cases. Control group did conventional treatment, alprostadil in addition to routine therapy group outside, all use ha medicine group biological engineering co., LTD. Is the production of alprostadil (Alprostail Injection) 10μg intravenous drop until the kidney function returned to normal or renal no improvement or deterioration. Result Control group 16 cases of effective or powerfully, the effective rate was 51.61%. Alprostadil group of 23 cases effective or powerfully, the effective rate was 60.53%. Obviously, the clinical curative effect of alprostadil group than in control group. Conclusion In the dispel incentive, active therapy liver disease, and its complications, such as infection control measures of comprehensive treatment, under the precondition of combined application of alprostadil treatment HRS, to improve renal blood flow reduction and filtration rate is reduced, reversal functional renal insufficiency, has a more positive therapeutic action.%  目的观察前列地尔(Alprostail Injection)治疗肝肾综合征(HRS)的疗效。方法对69例HRS病例随机分为两组,对照组31例,前列地尔组38例。对照组行常规治疗,前列地尔组除常规治疗外,均采用哈药集团生物工程有限公司生产的前列地尔(Alprostail Injection)10μg静脉点滴,直至肾功能恢复正常或肾功能无改善或恶化。结果对照组16例有效或显效,有效率51.61%。前列地尔组23例有效或显效,有效率60.53%。显然,其临床疗效前列地尔组优于对照组。结论在祛除诱因,积极治疗肝病及其并发症,控制感染等综合治疗措施的前提下,合并应用前列地尔治疗HRS,对于改善肾脏血流量的减少和滤过率降低,

  4. Clinical efficacy and safety of Vitaros©/Virirec© (Alprostadil cream) for the treatment of erectile dysfunction.

    Science.gov (United States)

    Moncada, Ignacio; Cuzin, Béatrice

    2015-01-01

    Erectile dysfunction (ED) is a very common disorder with a deep impact on patients and their partners. Several options are now available for treating ED; oral pharmacotherapy with phosphodiesterase-5 (PDE5) inhibitors currently represents the first-line option for many ED patients. Vitaros©/Virirec© is new topical, non-invasive treatment for ED that offers the combination of an active drug (alprostadil, a synthetic PGE1) with a skin enhancer that improves its local absorption directly at the site of action. Vitaros©/Virirec© has a favorable pharmacodynamic profile and is poorly absorbed in systemic circulation. This makes it suitable in any circumstances and results in a reduced risk of adverse events (AEs), being systemic AEs reported in only 3% of the treated population. Its clinical efficacy has been demonstrated in both phase II and III trials, showing a global efficacy up to 83% with the 300 μg dose in patients with severe ED significantly better than placebo. Its fast onset of action together with its favorable toxicity profile and lack of interactions with other drugs makes Vitaros©/Virirec© a first-line therapeutic option for patients with ED, particularly for individuals who are reluctant to take systemic treatments or with AEs. It may also have an important role in patients not responding to PDE5 inhibitors, particularly those with ED after radical prostatectomy.

  5. 前列地尔对脑梗塞的治疗价值分析%Analysis of the Value of Alprostadil in the Treatment of Cerebral Infarction

    Institute of Scientific and Technical Information of China (English)

    张力月

    2015-01-01

    Objective To investigate the value of alprostadil in the treatment of cerebral infarction. Methods 72 patients were randomly assigned into control group and observation group. The control group was Xuesetong treatment, observation group alprostadil treatment. Results The effective rate of the observation group was 86.11%, higher than that of the control group of 63.89%, The neurological function defect score in the observation group was (9.27±1.36), which was lower than that in the control group (15.34± 2.18), and the difference was statistically significant (P<0.05). Conclusion The effect of alprostadil in patients with cerebral infarction was signiifcantly high clinical value.%目的:探讨前列地尔在脑梗塞治疗中的应用价值。方法选取患者72例,按随机数字表法分为对照组与观察组。对照组采用血塞通治疗,观察组采用前列地尔治疗。结果观察组治疗有效率为86.11%,高于对照组的63.89%;观察组治疗后神经功能缺损评分为(9.27±1.36)分,低于对照组的(15.34±2.18)分,对比差异有统计学意义(P<0.05)。结论前列地尔在脑梗塞患者治疗中的效果较好。

  6. 前列地尔注射液治疗糖尿病足疗效观察%Observation of curative effect of alprostadil injection on diabetic foot

    Institute of Scientific and Technical Information of China (English)

    周燕萍; 廖勇

    2011-01-01

    Objective It is to observe the efficiency and security of alprostadil on diabetic foot ( DF ). Methods 64 cases of DF patients were randomly divided into 2 groups and both were given normal combined treatment. 33 cases of treatment group were treated with alprostadil, while 31 cases of control group were treated with Compound Salvia injection at the same time. The curative effects hetween the two groups were compared. Results The total efficient rate was 88 % in treatment group and 52 % in control group. There was statistically significant difference in the rats( P < 0. 05 ). No ohvious adverse effect was found in hoth groups. Conclusion Alprostadil has good effect on diabetic foot, it is worthy of expanding usage in clinical prescription.%目的 观察前列地尔治疗糖尿病足的有效性和安全性.方法 将64例糖尿病足患者随机分为2组,均给予常规综合治疗,治疗组33例同时给予前列地尔注射液治疗,对照组给予接受复方丹参注射液治疗,比较2组患者治疗效果.结果 治疗组总有效率(88%)明显高于对照组(52%)(P<0.05),且均未发生明显不良反应.结论 前列地尔注射液治疗糖尿病足效果良好,值得推广应用.

  7. 前列地尔联合丹红注射液治疗早期糖尿病肾病疗效观察%Effect of Alprostadil injection combined with Danhong injection on early diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    刘青员; 朱静和; 李冬玲; 蒋凤

    2016-01-01

    目的:观察前列地尔联合丹红注射液治疗早期糖尿病肾病的临床效果。方法将67例早期糖尿病肾病患者随机分为3组,常规组22例行常规治疗,前列地尔组21例为前列地尔注射液加常规治疗,联合组24例为前列地尔与丹红注射液加常规治疗。疗程2周,并监测尿微量白蛋白、β2微球蛋白、血尿素氮、肌酐。结果前列地尔组及联合治疗组尿微量白蛋白、β2微球蛋白在治疗后明显下降,与常规治疗组比较差异有统计学意义(P<0.01);联合组与前列地尔组比较,差异有统计学意义(P<0.01)。结论前列地尔联用丹红注射液可明显降低早期糖尿病肾病患者的尿白蛋白,防止病情进展。%ObjectiveTo observe the effects 0f alprostadil injection combined with danhong injection on diabetic nephropathy in the early stage.Methods67 case with early diabetes nephrosis patient were randomly divided into the conventional group(n=22)with conventional treatment,the alprostadil injection group with alprostadil injection (n=21),the union group alprostadil injection and danhong injection(n=24). The treatment course two weeks,and monitors the β2 microballoons protein,the urine micro albumin,blood creatinine,urea nitrogen.ResultsFor the alprostadil injection group and the union treatment groupβ2 microballoons protein,the urine micro albumin droped obviously after treatment compared with conventional group(P<0.01). And there was significant difference between alprostadil injection group and union group(P<0.01).ConclusionAlprostadil injection combined danhong injection can obviously reduce the urine albumin in patients with early diabetic nephropathy and prevent the progress of condition.

  8. Daily application of alprostadil topical cream (Vitaros) does not impact vaginal pH, flora, or histology in female cynomolgus monkeys.

    Science.gov (United States)

    Meier-Davis, Susan R; Debar, Salma; Siddoway, Jacob; Rabe, Mark

    2015-01-01

    Topical alprostadil cream (Vitaros) is approved in Canada and Europe for the treatment of erectile dysfunction. To determine the effects on the female urogenital tract with repeated administration of the entire dose (300 μg alprostadil containing 2.5% dodecyl-2-n,n-dimethylaminopropionate hydrochloride), the vaginal pH, flora, and histology were assessed as a model for 100% transference from male to the female during unprotected sexual intercourse. Female cynomolgus monkeys were administered the entire dose of Vitaros for 14 days with a 7-day recovery. Relative to vehicle and placebo cream, the vaginal pH and microflora were determined at baseline and weekly, thereafter. Vaginal biopsies were evaluated at the end of dosing and recovery. All animals were clinically normal for the study duration, and the vaginal pH was consistent between dose groups and the dosing period. Vaginal microflora and histopathology findings of mild inflammation were generally similar across treatment groups. In conclusion, repeated vaginal exposure to Vitaros did not alter the pH, microflora, or histology after 14 daily doses, supporting the safety of Vitaros transference to the female partner.

  9. The effect of alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention in diabetic patients

    Science.gov (United States)

    Ye, Ziliang; Lu, Haili; Guo, Wenqin; Dai, Weiran; Li, Hongqing; Yang, Huafeng; Li, Lang

    2016-01-01

    Abstract Background: At present, there are a lot of research about the effect of Alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention (PCI) in diabetic patients, but the clinical efficacy is not consistent, so we conduct this study and therefore determine the dominant strategy for the treatment of PCI in diabetic patients based on the best evidence currently. Methods: An electronic database search was conducted in MEDLINE, Embase, Cochrane library, CBM, CNKI, VIP, and WanFang to retrieve randomized controlled trial (RCT) comparing Alprostadil versus hydration on preventing CIN for PCI in diabetic patients. Reference lists of relevant articles were also screened manually to retrieve additional ones. Two investigators independently assessed the eligibility of retrieved articles using predefined inclusion and exclusion criteria. All characteristics as well as outcome variables including incidence of CIN, blood urea nitrogen (BUN), cystatin C (CysC), glomerular filtration rate (GFR), serum creatinine (Scr), serum beta 2-microspheres (β2-MG) presented in each included study were extracted. Heterogeneity was thought to be significant when I2 > 50%. All of the meta-analytic procedures were performed by using Review Manager software, version 5.3. Results: Finally, data from 8 articles including 969 patients were included into this meta-analysis, among them, 487 patients in the experience group, and 482 patients in the control group. Meta analysis showed that the incidence of CIN in the experimental group was significantly lower than that in the control group (OR = 0.28,95%CI[0.18,0.42]). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group (OR = 0.46,95%CI[0.24,0.85]). The BUN of 24 hours, 48 hours, and 72 hours in the experimental group were significantly lower than that of control group (MD = –0.77, 95%CI [−1.22, –0.32]; MD = –1

  10. 100例前列地尔不良反应分析%Analysis of 100 Cases of Adverse Drug Reactions Induced by Alprostadil

    Institute of Scientific and Technical Information of China (English)

    沈颖; 吴泊

    2015-01-01

    Objective To provide references for clinical prevention and treatment by analyzing the clinical features and related factors of adverse drug reactions due to alprostadil. Methods The incidences of ADRs caused by alprostadil reported in the hospital from 2010 to 2014 were analyzed in terms of gender, age, primary disease, specification and dosage, the method of administration, clinical manifestation, relevance evaluation, treatment and prognosis. Results Totally, 100 cases of ADR caused by alprostadil were reported. In 100 patients, 56 cases were male, average age was (65.5+1.7) years old, while 44 cases was female, average age was (52.5 + 26.5) years old. Mainly primary disease were fracture (20 cases), nephropathy (19 cases), varicose vein (13 cases). Alprostadil doses were 10 μg·d-1 (2 cases) and 20 μg·d-1 (27 cases). 96 patients were treated with intravenous infusion, 4 cases with intravenous injection. Medication time was 2 d (2.9 + 2.8) d. Clinical manifestations of adverse reactions were mainly cardiac vascular system damage, accounting for 62.4%. In all 100 cases of ADR, 2 cases were "must", 47 cases "very likely", 51 cases "possible". Treatment methods of adverse reaction were withdrawal, external application, oxygen inhalation, intravenous injection of glucocorticoid. Among the outcomes, 17 cases were cured, 83 cases improved. Conclusion Adverse reactions of alprostadil have occurred from time to time, clinical attention should be paid to the proper preservation and use of alprostadil and alprostadil adverse reactions monitoring.%目的:分析前列地尔不良反应的临床特点和相关因素,为临床预防及治疗提供参考。方法检索我院2010至2014年收到的前列地尔不良反应报告(ADR),分析患者的性别、年龄、原患疾病、前列地尔规格及用药剂量、给药方式、临床表现、关联性评价、处置方法和预后。结果共收集到前列地尔不良反应100例。100例患者中男性56

  11. The Effect of Ligustrazine and Alprostadil on the Early Diabetic Nephropathy%前列地尔联合川芎嗪治疗早期糖尿病肾病的疗效观察

    Institute of Scientific and Technical Information of China (English)

    康英英; 李波; 李明; 霍莹莹; 李芸兰

    2012-01-01

    Objective: Ligustrazine and Alprostadil treatment of the early diabetic nephropathy. Methods: 120 patients with early type 2 diabetes of hospitalization were collected and randomly divided into 3 groups: Ligustrazine group (40 cases), Alprostadil group(40 cases), combined therapeutic group (40 cases). All cases were observed for 2 weeks. The changes of serum creatinine (Cr), blood urea nitrogen (BUN), 24 hour urinary albumin before and after the treatment were compared. Results: After treatment for 2 weeks, the treatment of combined therapeutic group in decreasing 24 h urinary albumin was better than Ligustrazine group and Alprostadil group,the differences were significant (P<0.05). The differences between Ligustrazine group and Alprostadil group were significant (P<0.05). Conclusion: The treatment of Alprostadil combined with Irbesartan in early diabetic nephropathy is an effective way. Intravenous ligustrazine and alprostadil can delay the progression of diabetic nephropathy. It would be valuable to widespread popularization.%目的:观察前列地尔(凯时)联合川芎嗪注射液(川青)治疗糖尿病肾病的临床疗效,探讨其降低尿蛋白,减轻肾损害的机制.方法:收集早期2型糖尿病患者120例,随机分成川芎嗪组(40例)、前列地尔组(40例)和联合治疗组(40例).全部病例进行临床观察2周,分别比较三组血肌酐(Cr)、尿素氮(BUN)、24 h尿蛋白定量治疗前后的变化.结果:治疗2周后,联合治疗组降低24 h尿蛋白定量的作用优于川芎嗪组和前列地尔组差异有统计学意义(P<0.05).前列地尔组和川芎嗪组比较,差异有统计学意义(P<0.05).结论:静脉应用前列地尔联合川芎嗪注射液能够降低糖尿病肾病患者尿蛋白,延缓糖尿病肾病的进展,值得临床推广.

  12. Analysis of alprostadil in the treatment of patients with diabetic nephropathy%前列地尔治疗糖尿病肾病病例分析

    Institute of Scientific and Technical Information of China (English)

    赵明; 朱坤明

    2015-01-01

    Objective:To investigate the effect of alprostadil in the treatment of diabetic nephropathy.Methods:84 patients with diabetic kidney disease were selected.They were divided into the alprostadil treatment group(group A) with 43 cases,and the control group(group B) with 41 cases.All of the patients in the two groups were given symptomatic treatment,including diabetic diet,controlling blood glucose,stable blood pressure,hypolipidemic,anticoagulant,improve microcirculation etc.Results:Group A:There 31 cases were increased in urinary protein quantitative during 24 h,and 9 cases were stable,3 cases were decreased;and 8 cases with stable EGFR,35 cases were reduced,in which there were 2 cases had renal failure.Group B:There 38 cases were increased in urinary protein quantitative during 24 h,and 5 cases were stable;and 4 cases with stable EGFR,37 cases were reduced,in which there were 5 cases had renal failure.Conclusion:Standardized use of alprostadil can alleviate the development of diabetic kidney disease effectively.%目的:探讨前列地尔治疗对糖尿病肾病的治疗效果。方法:收治糖尿病肾脏病患者84例,将其分为前列地尔治疗组(A组)43例,对照组(B组)41例,两组均给予糖尿病饮食、控制血糖、稳定血压、降血脂、抗凝、改善微循环等对症基础治疗。结果:A组:24 h尿蛋白定量增加31例,稳定9例,减少3例;eGFR稳定8例,下降35例,其中发生肾衰竭2例。B 组:24 h 尿蛋白定量增加38例,稳定3例;eGFR 稳定4例,下降37例,其中5例发生肾衰竭。结论:前列地尔的规范化使用可有效缓解糖尿病肾病的发展。

  13. 前列地尔序贯治疗糖尿病肾病的临床研究%Clinical study on sequential therapy of alprostadil in treatment of diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    孙永艳; 杨叶虹

    2014-01-01

    目的:探讨前列地尔序贯治疗糖尿病肾病的临床疗效和安全性。方法选取2009年7月—2014年7月朝阳市第二医院内分泌科收治的2型糖尿病且初次诊断为糖尿病肾病临床前期患者116例,随机分为对照组(38例),前列地尔组(39例)和前列地尔序贯组(39例)。对照组给予常规治疗方案,前列地尔组在对照组基础上第1、2周加用前列地尔注射液,静脉滴注,2 mL/次,1次/d,第3、4周继续常规治疗。前列地尔序贯组第1、2周治疗方法同前列地尔组,第3、4周采用常规治疗联合口服贝前列素钠片,1片/次,3次/d。3组患者均连续治疗4周。比较3组治疗前后总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)尿素氮(BUN)、肌酐(Cr)、24 h尿微量白蛋白(24 h UMA)、总蛋白、24 h尿6-酮前列素F1α(6-keto-PGF1α)、血栓素B2和肾动脉血管阻力指数的变化情况。结果治疗后,3组TC、TG、LDL-C、24 h UMA、尿总蛋白、Cr、BUN、血栓素B2、肾动脉阻力指数均显著降低,HDL-C、24 h尿6-keto-PGF1α显著升高,同组治疗前后差异有统计意义(P<0.05)。且治疗后,前列地尔组、前列地尔序贯组这些指标改善程度优于对照组,而前列地尔序贯组优于前列地尔组,差异有统计学意义(P<0.05)。结论前列地尔序贯治疗糖尿病肾病具有较好的临床疗效,可明显改善患者血脂水平和肾功能,同时还可升高24 h尿6-keto-PGF1α,降低血栓素B2和肾动脉阻力指数,值得临床推广应用。%Objective To investigate the curative effect and safety of sequential therapy of alprostadil in treatment of diabetic nephropathy. Methods Patients suffered from diabetic nephropathy from July 2009 to July 2014 in the Second Hospital of Chaoyang City (116 cases) were collected and randomly divided into control

  14. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED.

    Science.gov (United States)

    Padma-Nathan, H; Steidle, C; Salem, S; Tayse, N; Yeager, J; Harning, R

    2003-02-01

    In two multicenter, placebo controlled, phase 2 studies, patients with mild-to-moderate (n=161, Study 1) or severe (n=142, Study 2) erectile dysfunction (ED) were randomized to receive placebo, 0.05, 0.1, or 0.2 mg (Study 1) or placebo, 0.1, 0.2, or 0.3 mg (Study 2) of topically applied alprostadil (containing a proprietary skin permeation enhancer). The primary efficacy end point in both studies was the change in erectile function (EF) score from baseline to final visit. The changes from baseline for EF scores were -0.8+/-1.1, 1.8+/-1.1, 0.7+/-1.2, and 3.7+/-1.2 (Palprostadil was well tolerated with the most common adverse event being urogenital pain. These results suggest this topical alprostadil formulation may be a potentially useful agent for the treatment of ED.

  15. 前列地尔联合复合辅酶治疗急性肾损伤的疗效探讨%The Protective Effects of Alprostadil Combined with Coenzyme Complex in Treatment of Acute Kidney Injury

    Institute of Scientific and Technical Information of China (English)

    焦闻文; 谭轶湘; 唐光荣; 邓建龙; 项金华

    2015-01-01

    Objective To investigate the protective effects of alprostadil combined with coenzyme complex in treatment of acute kidney injury (AKI).Methods Using a retrospective analysis of clinical data of acute kidney injury patients who received blood purification. According to the therapy, there were 3 groups, control group with 14 cases: besides blood purification ,patients received supportive and symptomatic therapy as well as etiological treatment as the base; alprostadil group with 16 cases, adding alprostadil in the treatment; combination-therapy group with 12 cases ,adding alprostadil combined with coenzyme complex in the treatment. The value of renal function detected before and 1 week,2weeks after treatment start were recorded, and on the 28th day the rate of patients who didn’t need hemodialysis and had renal function recovered fully were also reco rded.Results After 1week treatment, urea nitrogen and creatinine of combination-therapy group decreased most obviously,compared with control group, the difference was statistically significant (P<0.05). After 2 weeks treatment,combination-therapy group decreased fast, alprostadil group next, comparisons between groups out of 3, the differences were statistically significant(P<0.05).28 days from dialysis rate: alprostadil group and combination-therapy group were higher than control group,the difference was statistically significant(P<0.05). 28 days of renal function recovery rate: combination-therapy group was higher than control group and alprostadil group,the difference was statistical ly significant(P<0.05).Conclusion On the basis of blood purification, alprostadil is effective in the treatment of AKI, combined with coenzyme complex ,the effect is better.%目的:探讨前列地尔联合复合辅酶治疗急性肾损伤的疗效。方法运用回顾性研究分析进行血液净化的急性肾损伤患者临床资料,按治疗方案不同分为3组,对照组14例,支持对症及病因治疗,前列地尔组16例,

  16. 前列地尔对突发性耳聋听力恢复的效果分析%The effect analysis of Alprostadil on recruitment of hearing of patients with sudden deafness

    Institute of Scientific and Technical Information of China (English)

    梁晓东

    2003-01-01

    @@ BACKGROUND: Sudden deafness means sudden unknownneural deafness, which exact cause has not been found. And theroutine treatment adopts low molecular dextran and power mixtureand usually has a long course of treatment. Alprostadil useslipo-microball as carrier and does not easily lose activity and has theproper of distributing to injured blood vessehs, so brings into fullplay in dilating blood vessels and inhibiting gathering of bloodplatelet, which is used for curing sudden deafness.

  17. 前列地尔联合地塞米松治疗突发性聋疗效观察%Observation of alprostadil combined with dexamethasone in treatment of sudden deafness

    Institute of Scientific and Technical Information of China (English)

    胡成全

    2014-01-01

    To observe the curative effect of alprostadil combined with dexamethasone in the treatment of sudden deafness . Methods:Control group:normal saline 100ml+alprostadil 10 μg, QD ×14, intravenous infusion; treatment group: the addition of dexamethasone injection therapy based on the control group treatment .Results:The clinical effective rate was 80.39%, 58.33% in the control group , the difference was statistically significant by statistical analysis .Conclusion:Alprostadil combined with dexamethasone in treating sudden deafness should be worthy of promotion .%目的:观察前列地尔联合地塞米松治疗突聋的疗效。方法:对照组:生理盐水100ml+前列地尔10μg,1日1次,静脉滴注14天;治疗组:在对照组治疗的基础上加入地塞米松注射液治疗。结果:治疗组临床有效率为80.39%,对照组为58.33%,其差异经统计学分析有统计学意义。结论:前列地尔联合地塞米松治疗突发性聋疗效确切,值得推广。

  18. 前列地尔药理学研究进展及在呼吸系统疾病中的应用%Pharmacological research advance of alprostadil and its application in respiratory system diseases

    Institute of Scientific and Technical Information of China (English)

    刘春云; 刘永平; 龚享文

    2012-01-01

    Alprostadil (prostaglandin E1, PGE1) has many pharmacological actions, such as vasodila-tion, anti - inflammatory, anti - platelet aggregation, protection of vascular endothelial cells, prevention of athe -rosclerosis, and so on. As the development of its formulations lipid carrier (Lipo-PGE1) , alprostadil has been used more widely in clinic. Pharmacological mechanism of alprostadil and its application status in pulmonary hypertension, bronchial asthma, bronchiolitis and chronic pulmonary heart disease are reviewed in this paper.%前列地尔即前列腺素E1 (PGE1),具有扩血管、抗炎、抗血小板聚集、保护血管内皮细胞、防止动脉粥样硬化等作用.其制剂PGE1脂质载体(Lipo-PGE1)的开发,使其在临床上应用更广泛.本文概述前列地尔的药理学作用机制及其在肺动脉高压、支气管哮喘、毛细支气管炎及慢性肺心病等呼吸系统疾病中的应用现状.

  19. 凯时联合舒血宁治疗突发性耳聋的疗效观察%Synergic Effect of Alprostadil Injection and Shuxuening in Treating Sudden Deafness

    Institute of Scientific and Technical Information of China (English)

    李洪跃Δ; 徐先发

    2013-01-01

      目的探讨凯时联合舒血宁治疗突发性聋的疗效。方法对95例(98耳)突发性耳聋患者随机抽样分组,分为甲组(舒血宁组)、乙组(凯时组)、丙组(凯时+舒血宁组),分别给予舒血宁、凯时、凯时联合舒血宁静滴。结果甲、乙、丙组总有效率分别为58.82%、58.06%、87.88%,甲、丙组间及乙、丙组间疗效均差异有统计学意义(均P<0.05),甲、乙组间疗效差异无统计学意义(P>0.05)。纯音电测听听力图中盆型、上升型、平坦型听力图预后较好,下降型及全聋型预后较差。结论凯时及舒血宁治疗突发性聋有效,凯时联合舒血宁治疗突发性聋效果更好,有显著的协同效应。%Objective To explore synergic effect of alprostadil injection and shuxuening in treating sudden deafness.Method ninty-five patients (ninty-eight eares) with deafness were divided into group A,B and C at random;patients of group A were treated with shuxuening injection by vein,patients of group B were treated with alprostadil injection by vein,patients of group C were treated with alprostadil injection and shuxuening by vein.Result The effective rate of group A is 58.82%,the effective rate of group B is 58.06%,the effective rate of group C is 87.88%,the treating effect was significantly different in group A and C(P<0.05),it was significantly different in group B and C,but also there is no significant difference between group A and B.Conclusion It is effective for alprostadil injection and shuxuening in treating sudden deafness,and it has significantly synergic effect in treating sudden deafness with alprostadil injection and shuxuening.

  20. 移植肾功能延迟恢复患者早期应用前列地尔临床观察%Effect of alprostadil on recovery of renal transplant recipients with delayed graft function

    Institute of Scientific and Technical Information of China (English)

    汪帮琦; 朱云松; 聂海波; 赵永斌; 童亮; 胡卫列

    2012-01-01

    Objective To assess the effect of alprostadil on accelerating early recovery of renal transplant patients with delayed graft function.Methods A randomized control clinical trial was designed in renal recipients with delayed graft function(DGF)who were administered with 50μg alprostadil each day after the operation.The effects of alprostadil were compared with the control group which included 14 recipients with DGF to determine the influences of alprostadil on urine,serum creatinine(SCr).Under Doppler ultrasound,the renal blood flow resistance-indexes(RI)were measured.The rates of acute renal graft rejection(AR)were also calculated in both groups,and the 1year patient/graft survival rates were compared between the two groups.Results Urine was significantly higher in alprostadil-treated group than in control group(P < 0.05).On the contrary,SCr and RI were significantly lower in alprostadil-treated group than in control group(P < 0.05).No significant differences were found between the two groups in AR rate(6.25% vs 7.14%)and the 1-year patient/graft survival rates(P > 0.05).Conclusion The application of alprostadil in renal recipients with DGF had beneficial effects on accelerating recovery of renal graft function.%目的 评估前列地尔在肾移植术后移植肾功能延迟恢复(DGF)患者早期应用对促进移植肾功能恢复的效果.方法 回顾性分析肾移植术后发生移植肾功能延迟恢复应用前列地尔患者16例,与同期未使用前列地尔的DGF患者14例进行比较,比较两组间术后尿量、血肌酐(SCr)、移植肾血流阻力指数、急性排斥反应的发生率及1年人/肾生存率.结果 应用前列地尔的患者术后尿量明显大于对照组(P <0.05);SCr浓度、移植肾血流阻力指数均明显低于对照组(均P <0.05);两组急性排斥反应发生率差异无统计学意义(P>0.05).结论 肾移植受者术后DGF患者早期应用前列地尔有利于促进移植肾功能的恢复.

  1. Effect of Alprostadil Injection on Contrast-induced Nephropathy in Patients with Heart Failure after Coronary Intervention%前列地尔注射液对心功能不全患者冠脉介入术后对比剂肾病的影响

    Institute of Scientific and Technical Information of China (English)

    徐蓉; 夏进东; 金川连; 沈旭峰; 毛建强

    2012-01-01

    [Objective]To explore the effect of alprostadil injection on contrast-induced nephropathy(CIN) in patients with heart failure after coronary intervention. [Methods]Totally 60 patients with heart failure undergoing coronary intervention were randomly divided into control group and alprostadil group with 30 patients in each group. Control group routinely underwent coronary intervention. Alprostadil group was given the intravenous injection of 10μg alprostadil before coronary intervention on surgery day, as followed by l0μg alprostadil per day to 1 week after surgery. Serum creatinine(SCr) was measured and glomerular filtration rate(GFR) was evaluated before, and 24 and 48h after coronary intervention in two groups. [Results]Compared with before coronary intervention and control group, alprostadil had a trend in inhibiting the increasing of SCr and the decreasing of GFR caused by usage of contrast, but the difference between two groups had no significance. The incidence of CIN in alprostadil group was significantly lower than that in control group( P <0. 05). [Conclusion] Alprostadil can obviously reduce the incidence of CIN, and be used to prevent CIN in patients with heart failure undergoing coronary intervention.%[目的] 探讨前列地尔注射液对心功能不全患者冠脉介入术后对比剂肾病(CIN)的影响.[方法] 60例心功能不全行冠脉介入术患者,随机分为对照组与前列地尔组,每组30例,对照组常规进行冠脉介入术,前列地尔组于手术日术前给予前列地尔10 μg静脉注射,随后10 μg/日静脉注射,至术后1周.检测两组患者术前、术后24h与48h血清肌酐(SCr)水平并估测肾小球滤过率(GFR).[结果] 与术前及与对照组比较,前列地尔有抑制应用对比剂后SCr升高与GFR降低的趋势,但是差异无显著性;前列地尔组CIN的发生率显著低于对照组(P<0.05).[结论] 前列地尔能显著减少CIN的发生,可用于心功能不全行冠脉介入术患者CIN的预防.

  2. 瑞舒伐他汀联合前列地尔治疗糖尿病肾病的临床研究%Clinical study of Rosuvastatin combined with Alprostadil Injection in the treatment of diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    鞠富霞

    2015-01-01

    目的:观察瑞舒伐他汀联合前列地尔治疗糖尿病肾病的临床疗效。方法90例糖尿病肾病患者随机分为两组。前列地尔组45例,给予前列地尔注射液20μg,静脉滴注,每天1次;联合用药组45例,给予瑞舒伐他汀与前列地尔注射液,瑞舒伐他汀10 mg,口服,每天1次,前列地尔注射液用法同前组。两组疗程均为24周,观察两组治疗前后的尿蛋白排泄率、24 h 尿蛋白、血肌酐、血脂等指标。结果治疗后,两组尿蛋白排泄率与24 h 尿蛋白均降低(P ﹤0.01)。联合用药组尿蛋白排泄率、24 h 尿蛋白降低幅度大于前列地尔组(P ﹤0.01),两组血肌酐与空腹血糖均下降,差异无显著意义(P ﹥0.05)。两组血脂和血压降低均有所改善(P ﹤0.01),联合用药组血脂改变程度优于前列地尔组(P ﹤0.01)。结论瑞舒伐他汀联合前列地尔治疗糖尿病肾病,对肾脏保护有协同作用。%Objective To observe the clinical efficacy of Rosuvastatin combined with Alprostadil Injection in the treat-ment of diabetic nephropathy. Methods Ninety patients were randomly divided into two groups:45 patients of alprostadil group were treated with Alprostadil Injection 20 μg,qd;45 patients in combination therapy group were treated with Rosuvas-tatin 10 mg,po,qd and Alprostadil Injection 20 μg,qd. All patients in each group received the correlative therapy for 24 weeks. The urinary albumin excretion rate(UAER),serum creatinine(Scr),blood lipid were observed and recorded before and after the treatment. Results After the treatment,UAER,24 h urine protein decreased in two groups(P ﹤ 0. 01). But the UAER,24 h urine protein decreased in combination therapy group which was better than those in alprostadil group(P ﹤0. 01). The Scr and fasting blood glucose decreased in two groups with no significant difference among them(P ﹥ 0. 05). The blood lipid was improved in two groups(P ﹤ 0

  3. 前列地尔对大鼠体内羟苯磺酸钙的药动学影响%Effect of alprostadil on pharmacokinetics of calcium dobesilate in rats

    Institute of Scientific and Technical Information of China (English)

    王岩; 陈秋晨; 张廷剑; 孟繁浩

    2013-01-01

    Objective To evaluate the effect of alprostadil on calcium dobesilate pharmacokinetic in rats. Methods 24 rats were divided into alprostadil group and control group by weight. Two groups were given calcium dobesilate of 87. 8 mg · kg-1 by po administration, espectively. The alprostadil group was given alprostadil of 11. 7 μg · kg-1 by intraperitoneal injection. The concentrations of calcium dobesilate were determined by HPLC. Pharmacokinetic parameters were calculated by using DAS 2. 0 software. Results The main pharmacokinetic parameters of alprostadil group and control were as follows:AUC0-t was (210. 73 ± 50.71) and (201. 79 ±45. 29) μg · h · mL-1 ,MRT0-∞ was (10.25 ±0.96) and (8.89±1.07) h,t1/2 was (7.16 ±0.84) and (6.01 ±1.22) h,tmax was (1.58 ±0.29) and (2.67 ±0.49) h,CL was (0.40 ±0.10) and (0.42 ±0.09) L · h-1 · kg-1 ,Cmax was (22.48 ±4.07) and (21.96 ±4.70) μg · mL-1. There were statistically significant difference in MRT0-∞ , t1/2 and Jmax between two groups ( P < 0. 05 ). Conclusion Alprostadil can significantly affect the pharmacokinetics of calcium dobesilate in rats.%目的 评价前列地尔对健康大鼠体内羟苯磺酸钙的药动学影响.方法 24只大鼠,按照体质量随机分为试验组和对照组,试验组按87.8 mg· kg-1剂量灌胃给予羟苯磺酸钙,并按11.7 μg·kg-1剂量腹腔注射前列地尔,对照组按87.8 mg· kg-1剂量灌胃给予羟苯磺酸钙;采用HPLC法测定血药质量浓度,并用DAS 2.0软件计算药动学参数.结果试验组和对照组的主要药动学参数如下:AUCo-t为(210.73±50.71)、(201.79 ±45.29)μg·h·mL-1,MRTo-x为(10.25 ±0.96)、(8.89±1.07)h,t1/2为(7.16±0.84)、(6.01 ±1.22) h,tmax为(1.58±0.29)、(2.67±0.49) h,CL为(0.40±0.10)、(0.42±0.09)L·h-1·kg-1,Cmax为(22.48 ±4.07)、(21.96±4.70) μg· mL-1.试验组的MRT0-∞、t1/2、tmax与对照组比较,差异均有统计学意义(P<0.05).结论 前列地尔可影响大鼠体内羟苯磺酸钙的代谢.

  4. Determination of the binding constant between alprostadil and alpha-cyclodextrin by capillary electrophoresis: implications for a freeze-dried formulation.

    Science.gov (United States)

    Schipper, Benjamin R; Ramstad, Tore

    2005-07-01

    The binding constant between alprostadil (PGE1) and alpha-cyclodextrin (alpha-CD) was determined at three temperatures by capillary electrophoresis. alpha-CD is an excipient material in Caverject Dual Chamber Syringe (DCS), added to enhance stability. The binding constant was used to calculate the amount of PGE1 free upon reconstitution and injection, the latter of which is critical to product performance. Measurement was made in a pH 7.2 separation buffer to ensure a negative charge on PGE1. The concentration of PGE1 was fixed while the concentration of alpha-CD was varied over a suitable range. As the amount of PGE1 bound to alpha-CD increases, the weighted average of the resultant mobility decreases, thereby allowing a binding isotherm to be generated from which the stability constant was extracted via nonlinear regression analysis. A value of 708 +/- 64 M(-1) was obtained at 27 degrees C, while at physiological temperature (37 degrees C) the value was 537 +/- 27 M(-1). These results compare favorably to values previously obtained by NMR. Calculation of the percent PGE1 free upon reconstitution and injection show it to be near the desired outcome of 100%. Hence, we were able to conclude that the amount of free drug delivered by Caverject DCS is nominally the same as for Caverject S. Po., an earlier-developed product that contains no alpha-CD.

  5. Determination by NMR of the binding constant for the molecular complex between alprostadil and alpha-cyclodextrin. Implications for a freeze-dried formulation.

    Science.gov (United States)

    Ramstad, Tore; Hadden, Chad E; Martin, Gary E; Speaker, Stanley M; Teagarden, Dirk L; Thamann, Thomas J

    2005-05-30

    A binding constant was determined for the complexation reaction between alprostadil (PGE1) and alpha-cyclodextrin (alpha-CD). This constant was used to calculate the fraction PGE1 free upon reconstitution of Caverject dual chamber syringe, indicated for the treatment of erectile dysfunction. The determination was based on the measurement of the chemical shift of the C20 methyl protons of PGE1. The observed chemical shift varies as a linear function of the amount of PGE1 bound. The binding constant was obtained from the binding isotherm, a curve of the observed chemical shift versus free ligand (alpha-CD) concentration, through the application of non-linear regression analysis. A value K11 = 966 M(-1) +/- 130 M(-1) (2s), measured at 27 degrees C, was obtained. This value is in good agreement with those reported in the literature. The percent PGE1 free was subsequently calculated for the reconstituted solution and in the corpora cavernosum after injection. The latter showed PGE1 to be delivered essentially quantitatively to the targeted site.

  6. 前列地尔联合红花注射液治疗眩晕症的临床观察%Clinical Observation of Alprostadil Combined with Safflower Injection in the Treatment of Vertigo

    Institute of Scientific and Technical Information of China (English)

    辛爱华

    2015-01-01

    目的 观察前列地尔联合红花注射液治疗眩晕症的临床疗效.方法 118例眩晕症患者随机分成两组,对照组50例,给予红花注射液20 mL,加入生理盐水250mL静脉点滴;观察组68例,在对照组的基础上加用前列地尔10 mL.均为每天1次.结果 观察组和对照组有效率分别为97%、76%,差异有显著意义(P<0.05).结论 前列地尔联合红花注射液是治疗眩晕症的有效方法 .%Objective Clinical effect of alprostadil combing with saflfower injection in treating vertigo was observed.Methods 118 cases were randomly divided into two groups, 50 cases were in the control group. The patients in the control group were given 20 mL saflfower injection, plus 250 mL saline intravenous drip. 68 cases were on the basis of the control group, the observation group was given alprostadil injection 10 mL. All one time a day.Results The effective rate of the observation group and the control group respectively were 97%, 96%,There was signiifcant difference between the two groups (P<0.05).Conclusion Alprostadil combing with saflfower injection is the effect method in treating vertigo.

  7. 前列地尔联合生长抑素治疗重症急性胰腺炎的临床观察%Effect of alprostadil combined with somatostatin on severe acute pancreatitis

    Institute of Scientific and Technical Information of China (English)

    赵向宁; 刘兴贵

    2013-01-01

    目的 观察前列地尔联合生长抑素治疗重症急性胰腺炎的临床疗效.方法 将68例重症急性胰腺炎患者随机分为生长抑素治疗组(对照组,32例)和前列地尔+生长抑素治疗组(观察组,36例).比较两组患者症状、腹部体征消失时间、血淀粉酶恢复正常的时间.结果 观察组、对照组的有效率分别为94.44 %、65.63 %.两组疗效比较差异有统计学意义,P<0.05.结论 前列地尔联合生长抑素治疗重症急性胰腺炎安全有效.%Objective To investigate the effect of alprostadil combined with somatostatin on severe acute pancreatitis. Methods 68 patients with severe acute pancreatitis were divided into 2 groups: control group ( 32 cases )was treated with somatostatin; treatment group ( 36 cases )was treated with alprostadil combined with somatostatin. The symptoms, signs, AMS in serum of the two groups were observed and compared. Results The effective rates of treatment group and control group were 94. 44 % and 65. 63 % respectively, there was obvious difference between the two groups( P < 0. 05 ). Conclusion Alprostadil combined with somatostatin is safe and effective to treat severe acute pancreatitis.

  8. Observation of clinical effect by early application of alprostadil in the treatment of acute cerebral infarction%早期应用前列地尔治疗急性脑梗死临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    郭建雄

    2016-01-01

    目的:观察早期应用前列地尔治疗急性脑梗死的临床疗效。方法80例急性脑梗死患者,随机分成对照组和实验组,各40例。对照组患者在常规对症治疗的基础上加用长春西汀治疗,实验组患者在常规对症治疗的基础上早期应用前列地尔治疗。对比两组疗效。结果实验组总有效率为97.5%,高于对照组的82.5%,差异具有统计学意义(P<0.05)。结论早期应用前列地尔治疗急性脑梗死临床疗效显著,安全可靠,具有临床推广和应用价值。%ObjectiveTo observe clinical effect by early application of alprostadil in the treatment of acute cerebral infarction.MethodsA total of 80 acute cerebral infarction patients were randomly divided into control group and experimental group, with 40 cases in each group. The control group received additional vinpocetine to conventional symptomatic treatment, and the experimental group received additional alprostadil instead. Curative effects were compared between the two groups.ResultsThe experimental group had higher total effective rate as 97.5% than 82.5% of the control group, and the difference had statistical significance (P<0.05). ConclusionEarly application of alprostadil shows remarkably clinical effect in treating acute cerebral infarction. This method is safe and creditable, and it contains clinical promoting and applying value.

  9. Alprostadil Improve Renal Function in Patients with Chronic Renal Failure Effect%前列地尔改善慢性肾衰竭患者肾功能的作用

    Institute of Scientific and Technical Information of China (English)

    丁捷

    2016-01-01

    目的:研究分析前列地尔对慢性肾衰竭患者肾功能的治疗作用。方法选取n=90例慢性肾衰竭患者,随机分为研究组和对照组,对照组进行常规传统治疗,研究组在常规传统治疗的基础上静脉滴注前列地尔,通过肾功能生化指标、24 h尿蛋白定量和肾脏血流动力学指标,对比分析治疗结果。结果研究组治疗效果显著好于对照组,各种检测指标明显优于对照组(P<0.05)。结论静脉滴注前列地尔注射液,能够改善慢性肾衰竭患者的肾功能。%Objective To study the therapeutic effect of alprostadil on analysis of renal function in patients with chro -nic renal failure.Methods n=90 cases of patients with chronic renal failure were randomly divided into study group and control group , the control group of conventional treatment , the study group intravenous infusion of alprostadil in the conventional treatment based on traditional biochemical indicators of renal function , through the , 24 hours urine protein and renal hemodynamics analysis of treatment results .Results The effect of treatment group was significantly better than the control group , all indexes were significantly better than the control group ( P<0.05 ) .Conclusions Intrave-nous infusion of alprostadil injection can improve renal function in patients with chronic renal failure .

  10. Treatment of Alprostadil-induced Phlebitis with Hydrogel Dressing:A Report of 22 Cases%水凝胶敷料治疗前列地尔所致静脉炎22例

    Institute of Scientific and Technical Information of China (English)

    邓丽纯; 江晓林

    2016-01-01

    Objective To observe the therapeutic effect of hydrogel dressing for alprostadil-induced phlebitis. Methods Forty-three patients with alprostadil-induced phlebitis were randomly divided into two groups:the treatment group (n= 22),in which hydrogel dressing was applied to affected area,and control group(n = 21),in which mucopolysaccharide polysulfate cream was used to coat the surface of the skin. The curative effects were observed and compared between the two groups. Results The therapy effect on day 7 was superior to that on day 3 in both groups.The curative rate was 86.36% in the treatment group and 47.62% in the control group(P<0.05). Conclusion Hydrogel dressing can effectively treat alprostadil-induced by phlebitis.%目的:观察水凝胶敷料对前列地尔所致静脉炎的临床疗效。方法使用前列地尔后发生静脉炎的患者43例,按照随机数字表法分为治疗组22例,对照组21例。治疗组采用水凝胶敷料贴敷患处,对照组采用多磺酸黏多糖乳膏涂抹患处,观察两组静脉炎的治疗效果。结果两组7 d 治疗效果明显高于3 d 治疗效果;治疗组和对照组7 d 后痊愈率分别为86.36%,47.62%(P<0.05)。结论水凝胶敷料对前列地尔所致静脉炎疗效良好。

  11. THE CURATIVE EFFECT OF COMBINED INJECTION OF TANREQING AND ALPROSTADIL ON ACUTE ICTERIC HEPATITIS E%痰热清联合前列地尔治疗急性戊型黄疸性肝炎疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘兴凯

    2016-01-01

    目的:探讨痰热清联合前列地尔治疗急性戊型黄疸型肝炎的疗效。方法将所选择的病例随机分成治疗组和对照组。对照组给予保肝降酶综合治疗,治疗组在综合治疗基础上给予痰热清(20~30ml)加5%葡萄糖250ml静滴,前列地尔10ug加5%葡萄糖250ml静滴。结果治疗组的疗效和肝功能的改善均优于对照组,两组比较差异有统计学意义( P <0.05)。结论痰热清联合前列地尔治疗黄疸型肝炎疗效确切,值得临床上推广应用。%Objective To explore the curative effect of combined injection of tanreqing and alprostadil on acute icteric hepatitis E .Methods The patients were randomly divided into the treatment group and the contrast group .The contrast group were given comprehensive treatment of protecting liver and reducing enzyme ,while the treatment group was additionally given intravenous drip of 20‐30ml of tanreqing plus 250ml of 5% glucose and 10ug of alprostadil plus 250ml of 5% glucose .Results Better curative effect and more improvement in liver functions were obtained in the treatment group than in the contrast group ( P<0 .05) .Conclusion The combined injection of tanreqing and alprostadil can produce good curative effect on acute icteric hepatitis E .

  12. Observation Curative Effect on Alprostadil Combine With Alpha Lipoic in Treatment of Diabetic Foot%前列地尔联合α-硫辛酸治疗糖尿病足疗效观察

    Institute of Scientific and Technical Information of China (English)

    吴昌南

    2015-01-01

    Objective To explore the clinical effect of alprostadil combined with alpha lipoic in the treatment of diabetic foot. Methods Selected 90 cases with diabetic foot in our hospital as the research object, randomly divided into control group and treatment group, 45 cases in each group. Treatment group were treated with alprostadil combined with alpha lipoic treatment, the control group using the traditional treatment methods. Results The total effective rate of the treatment group was higher than that of the control group, P<0.05, had difference statistically significance. Conclusion Alprostadil combined with alpha lipoic acid in the treatment of diabetic foot can improve the treatment efifciency and the symptoms of patients with diabetic foot.%目的:探讨前列地尔联合α-硫辛酸治疗糖尿病足的临床疗效。方法选取我院收治的90例糖尿病足患者为研究对象,随机分成对照组和治疗组,每组各45例。治疗组采用前列地尔联合α-硫辛酸治疗,对照组采用传统的治疗方法。结果治疗组总有效率高于对照组, P<0.05,差异具有统计学意义。结论前列地尔联合α-硫辛酸治疗糖尿病足,可以有效地提高治疗的总有效率,改善糖尿病足患者的症状。

  13. Study on the Effect and Mechanism of Alprostadil in the Treatment of Patients With Chronic Renal Failure%前列地尔治疗慢性肾衰竭患者的疗效及其机制研究

    Institute of Scientific and Technical Information of China (English)

    秦丽芬

    2015-01-01

    Objective To study the curative effect of alprostadil in the treatment of patients with chronic renal failure, and further study of its mechanism.Methods In our hospital in February 2013 to February 2015 were chronic renal failure patients 100 cases as the research object, randomly divided to two groups, the control group was given routine symptomatic treatment, the observation group given alprostadil treatment, therapeutic effects of the two groups were compared and analyzed. ResultsThe difference between the two groups was statistically signiifcant (P<0.05).Conclusion Alprostadil in the treatment of patients with chronic renal failure curative effect is distinct, and the mechanism of renal hemodynamics, reduce urinary protein, improve the blood rheology etc. has a direct correlation.%目的:研究前列地尔治疗慢性肾衰竭患者的疗效,并对其机制进行深入研究。方法选取我院2013年2月~2015年2月收治的慢性肾衰竭患者100例为研究对象,将其随机分为2组,对照组给予常规对症治疗,观察组给予前列地尔治疗,比较分析2组治疗效果。结果两组患者在各临床指标间的差异显著,有统计学意义(P<0.05)。结论前列地尔治疗慢性肾衰竭患者的疗效显著,其机制与肾血流动力学、降低尿蛋白、改善血液流变学等有直接相关性。

  14. Effect of alprostadil and Mecobalamin in treating diabetic peripheral neuropathy%前列地尔与甲钴胺联合治疗糖尿病周围神经病变的疗效观察

    Institute of Scientific and Technical Information of China (English)

    黎华; 杨川

    2013-01-01

      目的观察前列地尔与甲钴胺联合应用治疗糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)的疗效.方法将96例患者随机分为治疗组和对照组,每组各48例,在常规治疗基础上,治疗组给予前列地尔与甲钴胺;对照组单用甲钴胺治疗,共2周,对其疗效进行对比.结果治疗组总有效率为89.6%,对照组为68.8%(P<0.01).在改善肌电图方面,治疗组亦明显优于对照组(P<0.01).结论前列地尔与甲钴胺合用可明显提高DPN的治疗效果.%Objective To observe the therapeutic effect of alprostadil and methylcobalamin for diabetic peripheral neuropathy (DPN). Methods Ninety-six patients with DPN were randomly assigned to the treatment group and the control group, forty-eight in each group. Besides basic treatment, the treatment group was treated with alprostadil and methylcobalamin, while the control group treated with methylcobalamin only, test for two weeks, and then observes the curative effect. Results The total effective rate of the treatment group was obviously superior to the control group(89.6% to 68.8%, P<0.01). In improving the effect of EMG, the treatment group was also obviously superior to the control group (P<0.01). Conclusion Alprostadil in combination with methylcobalamin can significantly improve the therapeutic effect of DPN.

  15. 前列地尔对终末期肝病患者肾保护作用分析%Analysis of renal protective effect of Alprostadil on patients with end-stage liver diseases

    Institute of Scientific and Technical Information of China (English)

    黄橘村; 胡东辉

    2015-01-01

    目的::讨论分析前列地尔对末期肝病患者肾的保护。方法:80例患者依据药剂量分为4组,观察各组患者的临床情况,对比各组患者的治疗结果。结果:在疗程结束后,各组患者的症状都有不同程度的改善,尿量以及肌酐清除增加,并且使用前列地尔每天80μg,可以达到最好的治疗效果。结论:结果显示,每天使用前列地尔80μg是最佳的治疗效果,它对肝病末期患者的肾脏有一定的保护作用。%Objective:To discuss and analyze renal protecctive effect of Alprostadil on patients with end-stage liver diseases. Methods:80 patients were divided into 4 groups according to dose. The clinical situation of each group was observed, and the effeccts of these groups were compared. Results:After the end of treatment, the symptoms of the patients in each group had different degrees of improvement, and increased urine output and creatinine clearance occurred. The use of Alprostadil 80 μg/day, you can achieve the best therapeutic effect. Conclusions:The results show that the use of Alprostadil 80 μg/ day has the best therapeutic effect, and has a certain renal protective effects for the patients with end-stage liver diseases.

  16. Phlebitis caused by intravenous administration of alprostadil: analysis of 246 reports%静脉给予前列地尔致静脉炎:246份报告分析

    Institute of Scientific and Technical Information of China (English)

    高琲; 刘芳; 张俊

    2011-01-01

    with an infusion of alprostadil. Methods: Beijing Adverse Drug Reactions Monitoring Network database from 2003 to 2010 was searched for reports of phlebitis associated with an infusion of alprostadil. The patient's gender, age, family history and past history of phlebitis, primary disease, dosage form of alprostadil, route of administration, dosage, duration of treatment, time to phlebitis onset after drug administrations, clinical manifestations, severity of phlebitis, management and prognosis were analyzed. Results: A total of 246 reports with of phlebitis associated with alprostadil were collected. These patients comprised 167 men with average age (66. 7 ± 16. 1)years and 79 women with average age (68.1 ± 12. 3) years. Of the 246 patients, 23 patients had past history of phlebitis and 5 patients had family history of phlebitis. The main primary diseases were neurological disease(92 cases, 37. 4% ), surgical disease (26 cases, 10.6% ), and cardiovascular disease(25 cases, 10.2% ). Percentage of 99.2(244 cases) of patients received alprostadil injection and 0. 8% (2 cases) of patients received alprostadil powder for injection. The alprostadil injection dosage was 10 μg/d for 87.3% (213 cases) of patients and 20 μg/d for 8.6% (21 cases) of patients. The dosage of alprostadil power for injection was 10 μg/d for 0.8% (2 cases) of patients. The administration of drug was as follows: 97.2% (239 cases) of patients were treated with alprostadil by Ⅳ infusion and 2. 8% (7 cases) of patients were injected with alprostadil intravenously. The median of duration of treatment were 2 days. The median of time to phlebitis onset after drug administration was 20 minutes. When the severity of phlebitis was determined according to the criteria of Intravenous Nurses Society (INS), 145 patients (66.5% ) had grade 1, 57 patients (26.1% ) had grade 2, and 15 patients (6.9% ) had grade 3 phlebitis. The main clinical manifestations were erythema and pain in injection-site with

  17. 前列地尔联合缬沙坦治疗早期糖尿病肾病的临床观察%Alprostadil Valsartan Treatment of Early Diabetic Nephropathy

    Institute of Scientific and Technical Information of China (English)

    阿吉姑里•阿不都热衣木

    2013-01-01

    Objective Valsartan used in early diabetic nephropathy effect of alprostadil combined analysis. Methods Choose my hospital early diabetic nephropathy 78, divided into A, group B, group A, 33 patients of the control group, B group 45 patients for the treatment group were given valsartan drug treatment, and alprostadil Valerian sand randomlyTanzania method to heal. Results Lower in group A after healing, the glomerular filtration rate of the B group of objects, total urinary protein, urinary protein excretion efficient than in group A, the incidence of adverse reactions is lower than the A group. Conclusion Alprostadil combination of valsartan used in early diabetic nephropathy, patients recover better and have higher efficiency.%  目的 对前列地尔结合缬沙坦应用于早期糖尿病肾病效果加以分析。方法随机选择我院早期糖尿病肾病患者78名,分成A、B组, A组33名患者为对照组,B组45名患者为治疗组,分别给予缬沙坦药物医治,和前列地尔结合缬沙坦方法医治。结果经医治,B组对象肾小球滤过率、尿蛋白总量、尿蛋白排除量低于A组,有效率高于A组,不良反应发生率低于A组。结论前列地尔结合缬沙坦应用于早期糖尿病肾病,患者恢复较好,有效率较高。

  18. 联合前列地尔与门冬氨酸鸟氨酸治疗重症肝炎的疗效和安全性%Efficacy and Safety of Alprostadil Plus Ornithine Aspartate in Severe Hepatitis

    Institute of Scientific and Technical Information of China (English)

    蔡霞

    2015-01-01

    Objective To explore clinical efficacy and safety of alprostadil combined with ornithine aspartate in the treatment of severe hepatitis.Methods In our hospital were selected from 56 cases of severe hepatitis patients,randomly divided into two groups. Control group received routine treatment, the experimental group received alprostadil and ornithine aspartate combined treatment,observation clinical efficacy and safety of two groups patients. Results In the experimental group,the total effective rate was 92.85%,control group,the total efficiency of 67.86%; the experimental group,the adverse reaction rate was 7.14%,control group,the adverse reaction rate was 3.57%.ConclusionThe alprostadil and ornithine aspartate in the treatment of severe hepatitis,the exact effect,high safety.%目的:探讨重症肝炎治疗中,联合应用前列地尔与门冬氨酸鸟氨酸的临床效果及安全性。方法从我院选取重症肝炎患者56例,随机分为两组,对照组常规治疗,实验组,前列地尔与门冬氨酸鸟氨酸联合治疗,观测两组患者临床效果及安全性。结果实验组总有效率为92.85%,对照组总有效率为67.86%;实验组不良反应率为7.14%,对照组不良反应率为3.57%。结论前列地尔联合门冬氨酸鸟氨酸治疗重症肝炎,效果确切,安全性高。

  19. Research on alprostadil preventing contrast-induced nephropathy after cerebral angiography%前列地尔对脑血管造影术后造影剂肾病的预防研究

    Institute of Scientific and Technical Information of China (English)

    张良红; 张亮; 唐显俊; 谭秀琼; 林少容

    2014-01-01

    目的:探讨前列地尔对脑血管造影术后造影剂肾病的预防作用及其使用方法。方法随机选择脑血管造影患者169例,分为对照组(49例)、前列地尔组(52例)、试验组(68例);对照组患者接受脑血管病二级预防治疗,前列地尔组患者在对照组基础上于术前给予患者静脉滴注1次10μg前列地尔,试验组患者在对照组基础上于术前给予患者静脉滴注2次10μg前列地尔,检测三组患者术前、术后连续3天及第5天的血清肌酐、胱抑素C水平,术前及术后72小时出现尿蛋白的例数。结果试验组和对照组患者术后第24、48、72小时及第5天血清肌酐、胱抑素C升高值比较差异有显著性(P<0.05);试验组和前列地尔组患者第48、72小时及第5天血清肌酐、胱抑素C升高值比较差异有显著性(P<0.05);术后尿蛋白发生情况,试验组与对照组、前列地尔组相比均有明显差异(P<0.05);前列地尔组和对照组第48、72小时血清肌酐、胱抑素C升高值比较差异有显著性(P<0.05)。结论行脑血管造影术前使用前列地尔注射液,能有效改善患者术后肾功能,降低术后造影剂肾病的发生率,具有较高的临床应用价值。%Objective To investigate the preventive effect of alprostadil on contrast-induced nephropathy after cerebral angiography and methods of use. Method 169 cases of patients underwent cerebral angiography were randomly divided into three groups, the control group (49 cases), alprostadil group (52 cases), and the experimental group (68 cases). Patients in the control group accepted therapy for secondary prevention of cerebrovascular disease, patients in the alprostadil group based on the control group, were given intravenous infusion of 10μg alprostadil before surgery once, and the experimental group were intravenously administered 10μg alprostadil twice on the basis of the control group, 3

  20. Alprostadil combined with Irbesartan in the treatment of patients with early diabetic nephropathy%前列地尔联合厄贝沙坦治疗早期糖尿病肾病

    Institute of Scientific and Technical Information of China (English)

    李克儒

    2012-01-01

    Objective: To observe the clinical efficacy of Alprostadil combined with Irbesartan in the treatment of early di -abetic nephropathy (DN). Methods: 120 patients with early type 2 diabetes of hospitalization were collected and randomly di -vided into 3 groups: Irbesartan group (40 cases), Alprostadil group (40 cases), combined therapeutic group (40 cases). All cases were observed for 2 weeks. The changes of serum creatinine (Cr), blood urea nitrogen (BUN), 24 hour urine micro albumin (24 h LJ-mAlb) before and after the treatment were compared. Results: After treatment for 2 weeks, the treatment of combined therapeutic group [(155.69±30.56) μg/24 h] in decreasing 24 h LJ-mAlb was better than Irbesartan group [(224.75 ± 36.42) μg/24 h] and Alprostadil group [(219.36±34.75) μg/24 h], the differences were significant (P0.05). Conclusion: The treatment of Alprostadil combined with Irbesartan in early diabetic nephropathy is an effective way.%目的:观察前列地尔联合厄贝沙坦治疗早期糖尿病肾病(DN)的临床疗效.方法:收集早期2型糖尿病患者120例,随机分成厄贝沙坦组(40例)、前列地尔组(40例)和联合治疗组(40例).全部病例进行临床观察2周,分别比较三组血肌酐(Cr)、尿素氮(BUN)、24 h尿微量白蛋白(24 h U-mAlb)治疗前后的变化.结果:治疗2周后,联合治疗组[(155.69±30.56)μg/24 h]降低24 h U-mAlb的作用优于厄贝沙坦组[(224.75±36.42)μg/24 h]和前列地尔组[(219.36±34.75)μg/24 h],差异有统计学意义(P<0.05).厄贝沙坦组和前列地尔组比较,差异无统计学意义(P>0.05).结论:前列地尔与厄贝沙坦联合应用是治疗早期糖尿病肾病的有效方法.

  1. 1767例住院患者使用前列地尔注射液回顾性调查%A Retrospective Survey of Alprostadil Injection Application in 1 767 Inpatients

    Institute of Scientific and Technical Information of China (English)

    夏迎春

    2014-01-01

    Objective:To understand the application status of alprostadil injections in a hospital to promote the rational drug use. Methods:A retrospective survey was carried out on the application of alprostadil injections in 1 767 hospitalized patients in a hospital in 2013. The main clinic diagnosis, usage and dosage, course of treatment and adverse reactions were statistically analyzed. Results:Alprostadil injections were used widely in all the clinical departments, and the most frequently applied in encephalopathy department and nephrology department. The irrational drug use chiefly included inappropriate indications, usage and dosage, treatment course and solvents. Conclusion:More attention should be paid to the unreasonable use of alprostadil injections, and it is very important to retro-spectively analyze the rationality for guiding rational drug use.%目的:了解某院前列地尔注射液的使用情况,以促进合理用药。方法:回顾性调查某院2013年住院患者使用前列地尔注射液的病例,共计1767例,对其临床主要诊断、用法用量、使用疗程、不良反应等方面进行统计分析。结果:前列地尔注射液在临床各科室使用广泛,应用最多的是脑病科、肾内科。临床不合理用药主要表现在适应证不适宜、用法用量不当、疗程过长、溶媒选择错误等。结论:前列地尔注射液不规范使用的情况须引起重视。用药调查分析对指导临床合理用药具有非常重要意义。

  2. Curative effect observation of alprostadil in the treatment of pulmonary heart disease when the cardiac decompensa-tion period%前列地尔对心功能失代偿期肺心病的疗效观察

    Institute of Scientific and Technical Information of China (English)

    寇民生

    2015-01-01

    目的:探讨前列地尔在心功能失代偿期肺心病的疗效.方法:收治肺心病患者98例,随机分为对照组(48例)与治疗组(50例),对照组给予常规治疗.治疗组在常规治疗的基础上,给予脂微球前列地尔静脉滴注.结果:治疗组临床症状的改善、心功能的改善显著优于对照组(P<0.05);治疗组血氧分压、二氧化碳分压、肺动脉压、射血分数等指标与对照组比较,有明显改善(P<0.05).结论:前列地尔治疗心功能失代偿期肺心病有较好的效果.前列地尔是治疗慢性失代偿期肺心病的有效药物.%Objective:To investigate the effect of alprostadil in the treatment of pulmonary heart disease when the cardiac decompensation period.Methods:98 patients with pulmonary heart disease were selected,they were randomly divided into the control group(48 cases) and the treatment group(50 cases),the control group received the conventional treatment.The treatment group given the lipid microsphere alprostadil intravenous infusion on the basis of the conventional treatment.Results:The improvement of clinical symptoms and heart function of the treatment group were significantly better than those of the control group(P<0.05);the blood oxygen partial pressure,carbon dioxide partial pressure,pulmonary arterial pressure,ejection fraction and other indexes of the treatment group were significantly improved compared with the control group(P<0.05).Conclusion:Alprostadil in the treatment of pulmonary heart disease when the cardiac decompensation period has a better curative effect. Alprostadil is an effective drug for the treatment of chronic decompensated pulmonary heart disease.

  3. Effects of Alprostadil on coagulation system in patients undergoing skin flap transplantation%前列地尔对皮瓣移植患者术后凝血系统的影响

    Institute of Scientific and Technical Information of China (English)

    石健; 赵钢; 程春生; 查朱青

    2016-01-01

    目的:探讨前列地尔对游离皮瓣移植患者术后凝血系统的影响。方法将哈尔滨市第五医院2012年2月~2014年8月收治的200例四肢游离皮瓣移植术后患者纳入观察范围,根据随机原则分为常规治疗组与前列地尔组,每组各100例。常规治疗组使用低分子右旋糖酐、肝素以扩容、抗凝,前列地尔组在常规治疗的基础上于手术当天给予前列地尔注射液(曼新妥,10μg溶于100mL生理盐水)静脉点滴,连续7d。观察患者术后24、72h皮瓣肿胀程度、疼痛评分、患者术后凝血功能检测及72h血管危象发生率。结果前列地尔组术后24h和72h的皮瓣肿胀程度评分、术后72h疼痛评分明显低于常规治疗组( P<0.05);前列地尔组术后72h血管危象发生率(1.0%)明显低于常规治疗组发生率(5.71%,P=0.02);两组患者术后同一时间点,凝血各项指标的检测结果比较,差异无显著性( P=1.18)。结论游离皮瓣移植术后应用前列地尔能有效维持皮瓣移植患者术后凝血系统的稳定,抑制血小板聚集,防止肢体肿胀与减轻疼痛,减少血管危象的发生,具有临床应用价值。%Objective To investigate the effects of Alprostadil at different time points on coagulation system in patients undergoing skin flap transplantation.Methods Two-hundred patients undergoing free skin flap trans-plantation from Feb.2012 to Aug.2014 in our department were selected and equally divided into conventional treat-ment group and Alprostadil group.Patients in the conventional group were treated with low molecular dextran and heparin for expansion and anticoagulation.Patients in the Alprostadil group were added with intravenous injection of Alprostadil on the basis of conventional treatment from the day of surgery for 7d.The turgidity of skin flap,pain score,vascular crisis occurrence,and determination of coagulation function in patients were

  4. 前列地尔对兔肾缺血再灌注时细胞凋亡的保护作用%Alprostadil effects of prostavasin on apoptosis by renal ischemia-reperfusion injury in rabbits

    Institute of Scientific and Technical Information of China (English)

    郭凌燕; 胡世雄

    2011-01-01

    Objective To study the alprostadil effects of alprostadil on apoptosis by renal ischemia-reperfusion injury (IR[) in rabbits. Methods The rabbit IRI models were made, and randourly divided into three groups: control group, IR[group and prostavasin intervention group. The creatinine (Ct) and blood urea nitrogen (BUN) were determined. Malondialdehyde ( MDA), superoxide dismutase (SOD),myeloperoxidase ( MPO), bcl-2, bax, Caspase-3 and apoptosis were assayed at 60 min after reperfusion.Results The Cr and BUN levels in plasma in IRI group and Prostavasin intervention group were increased obviously after reperfusion. The Cr levels at 60 min after repeffusion in alprostadil intervention group (231.32 + 17. 57 ) μmol/L were significantly lower than in IRI group ( 390. 61 ± 20. 42 ) μ mol/L, ( P <0. 05 ). The levels of bcl-2, bax, Caspase-3 in the renal tissue in IRI group were significantly higher than in control group ( P < 0. 05 ), and those in alprostadil intervention group were lower than in IRI group, but markedly higher than in control group (P < 0. 05 ). The number of apoptotic cells in alprostadil intervention group and IRI group was increased as compared with control group, and that in alprostadil intervention group was reduced as compared with IRI group. The contents of MDA, SOD and MPO in renal tissue of IRI group and Prostavasin intervention group were significantly higher than in control group ( P < 0. 05 ), and those in IRI group were significantly lower than in alprostadil intervention group (P <0. 05 ). Conclusion Alprostadil could be used to protect renal ischemia-reperfusion injury probably by decreasing oxygen free radicals generation, inhibiting neutrophils aggregating and activating in the renal tissues, thereby inhibiting the expression of bcl-2, bax, Caspase-3.%目的 观察前列地尔对兔肾缺血再灌注损伤时肾小管上皮细胞凋亡的保护作用.方法 建立兔肾缺血再灌注损伤动物模型,将实验兔随机分为3

  5. Protective effects of alprostadil on hepatocyte apoptosis by Liver Ischemia-Reperfusion Injury in rabbits%前列地尔对兔肝缺血再灌注时肝细胞凋亡的保护作用

    Institute of Scientific and Technical Information of China (English)

    郭凌燕; 赵刚

    2011-01-01

    Objective To study the protective the positive effects of alprostadil Hepatocyte Apoptosis by Liver Ischemia-Reperfusion Injury in rabbits. Methods Thirty-six rabbits were made the model of liver ischemia-reperfusion injury, and randourly divided into three groups:Control group, Ischemia-Reperfusion Injury group and Alprostadil intervention group. The alanine aminotransferase (ALT) , aspartate aminotransferase (AST) , lactate dehydrogenase (LDH) were determined; Each group inducible nitric oxide synthase (iNOS) , myeloperoxidase (MPO) and bcl-2, bax, Caspase-3 and apoptosis of the hepatocyte by TUNEL were assayed at 60 and 90 min after reperfusion. Results The ALT, AST, LDH concentration in plasma in Ischemia-Reperfusion Injury group and Alprostadil intervention group were increased obviously at 60, 90 min after reperfusion and it was significantly higher than that in the Control group in the same time point (P<0.05). And the ALT, AST, LDH concentration in plasma in Alprostadil intervention group was significantly lower than that in the in Ischemia-Reperfusion Injury group in the same time point (P<0.05). The level of bcl-2, bax, Caspase-3 in the liver tissue in the Control group was smaller, but the obvious increase of the expression those was found in the Ischemia-Reperfusion Injury group and Alprostadil intervention group. Compared with those in the Ischemia-Reperfusion Injury group group, the expression of bcl-2, bax, Caspase-3 in the Alprostadil intervention group werw obviously smaller (P<0.05). The contents of iNOS and MPO in liver tissue in the Ischemia-Reperfusion Injury group and Alprostadil intervention group were significantly higher than that in the Control group (P<0.05). Conclusion Alprostadil could be used to protect liver ischemia-reperfusion injury, it could decrease oxygen free radicals generation, inhibit neutrophils aggregating and activating in the liver, thereby inhibiting expression of bcl-2, bax, Caspase-3.%目的 探讨前列地尔对兔

  6. 前列地尔注射液治疗椎动脉型颈椎病的短期疗效观察%Observation of short term effect of Alprostadil Injection on cervical spondylotic vertebral arteriopathy

    Institute of Scientific and Technical Information of China (English)

    袁忠治; 李继云; 汤晨逢; 杨昀焯; 刘刚

    2009-01-01

    目的 探讨前列地尔注射液治疗椎动脉型颈椎病的短期疗效.方法 选取我院骨科住院和门诊治疗的椎动脉型颈椎病患者52例,平均年龄47岁.将患者随机分为治疗组28例和对照组24例.给对照组患者颈椎牵引、颈部理疗和功能锻炼.将丹参20 ml溶于低分子右旋糖酐500 ml静脉点滴,1次/d,连用10 d.给治疗组患者除对照组所用治疗措施外,另加前列地尔注射液10 μg溶于5%葡萄糖液250 ml缓慢静脉点滴,1次/d,连用10 d.用椎动脉型颈椎病功能评定量表进行疗效评价.治疗组或对照组组内作治疗前后自身对比,治疗组与对照组作治疗后对比.结果 治疗组或对照组治疗前后的功能状态和心理功能均有明显差异(P<0.05);治疗组与对照组治疗后比较,在功能状态和心理功能两方面均有明显差异(P<0.05).结论前列地尔注射液对椎动脉型颈椎病有明显短期疗效.%Objective To study the short term effects of Alprostadil Injection on cervical spondylotic vertebral arteriopathy(CSA). Methods 52 cases of patients with CSA, average age of 47 years old, were ran-domly divided into treatment group (n=28 ) with Alprostadil Injection and control group (n=24). The control group were treated with cervical traction, physical therapy, functional exercise, and 20 ml Danshen solusion plus 500 ml Dextran 40 iv drop once a day for 10 days. The treatment group were treated with 20 μg Alprostadil In-jection plus 250 ml 5% glucose iv drop, besides control group treatments, once a day for 10 days. The curative effects of Alprostadil Injection were evaluated by CSA functional scale, compared before and after treatment in the same group and between two groups after treatment. Results The reshs display significant difference before and after treatment both in the treatment group and the control group(P<0.05) ;while the effects of the treat-ment group are better than the control group (P<0.05 ). Conclusion Alprostadil

  7. Comparision of Curative Effect of Alprostadil Injection Combined with Fleabane Injection on Cerbral Infarction%前列地尔联合灯盏细辛治疗急性脑梗死的疗效分析

    Institute of Scientific and Technical Information of China (English)

    陈国梁

    2014-01-01

    目的:探讨前列地尔针联合灯盏细辛治疗急性脑梗死的疗效分析。方法:选择确诊为急性脑梗死的患者120例分为以下4组,每组各30例:(1)A组:常规治疗,予常规护理、补充B族维生素、胞二磷胆碱、抗血小板以及对症处理;(2)B组:常规治疗的基础上,辅助静脉注射前列地尔注射液10μg;(3) C组:常规治疗的基础上,辅助静脉滴注灯盏细辛注射液30ml;(4) D组:常规治疗的基础上,联合静脉滴注前列地尔注射液10μg和灯盏细辛注射液30 ml。4组疗程均为14天。结果:4组的基本痊愈率分别为6.7%、20.0%、13.3%、27.0%;总有效率为86.7%、93.3%、90.0%、100.0%。结论:单独或联合前列地尔针或灯盏细辛针治疗急性脑梗死疗效优于常规疗法;联合应用前列地尔和灯盏细辛的的疗效最佳。%Objective:To compare the curative effect of alprostadil injection combined with fleabane injection on cerbral infarction . Methods:One hundred and twenty patients with cerbral infarction were divided into 4 different groups with 30 patients each: group A, conventional therapy including usual care , oxygen inhalation , decreasing intracranial pressure , symptomatic treatment;group B, conven-tional therapy with alprostadil injection 10μg;group C, conventional therapy with fleabane injection 30ml;group D, conventional therapy with alprostadil injection 10μg and fleabane injection 30ml.Courses of all treatments are 14 days.Results:The cure rates in the four dif-ferent groups were 6.7%, 20.0%, 13.3%and 27.0%, while total effective rates were 86.7%, 93.3%, 90.0%and 100.0%.Con-clusion:Effects of therapies with alprostadil injection or fleabane injection on cerbral infarction are better than the conventional therapy and therapies of alprostadil injection combined with fleabane injection has the best curative effect .

  8. 前列地尔对心力衰竭患者心脏功能和心室重构影响%The Effect of Alprostadil on Cardiac Function and Ventricular Remodeling of Patients with Cardiac Failure

    Institute of Scientific and Technical Information of China (English)

    朱鹏程; 林镇荣; 陈庆超; 杨锡泉; 张琳

    2015-01-01

    Objective:To explore the effect of alprostadil on cardiac function and ventricular remodeling of patients with cardiac failure. Method:80 patients with cardiac failure in Overseas Chinese Hospital of Raoping County were divided into research group (n=40) and control group (n=40) randomly from Aug 2013 to May 2015. The research group was treated by alprostadil based on the conventional methods in the control group. There were no differences in the baseline data including age, history, primary disease and ventricular rate between the two groups. Alprostadil was added 10 μg/d for 10-14 days in research group. The differences on cardiac function and ventricular remodeling were compared after 2 weeks after treatment between the two groups. Results:Compared with the control group,there were shorter left ventricular end diastolic diameter,larger left ventricular ejection fraction, longer walking distance in 6 minutes and slower resting heart rate,and higher the total effective rate in the research group,all P<0.01.There were no severe side actions in the research group. Conclusion:It is effective and safe in patients with cardiac failure treated by Alprostadil. Alprostadil could increase cardiac function and improve ventricular remodeling and could be used more popular in patients with cardiac failure.%目的:探讨前列地尔对心力衰竭患者心脏功能和心室重构的影响。方法:将2013年8月至2015年5月广东省潮州市饶平县华侨医院心内科收治的心力衰竭患者80例随机分为对照组和研究组各40例,两组年龄、病程、原发病和心室率等差异无显著性(P >0.05);对照组按常规治疗,研究组在对照组治疗的基础上加用前列地尔10 ug/次,每日1次,持续10-14 d,2周后比较两组治疗前后心脏功能和心室重构的变化。结果:与对照组相比,治疗后研究组的左室舒张末期内径缩小,左室射血分数增高,6 min步行距离延长,静

  9. Effect and Safety of Alprostadil Injection on Ischemic Stroke:A Meta-analysis%前列地尔注射液治疗缺血性脑卒中的疗效和安全性Meta分析

    Institute of Scientific and Technical Information of China (English)

    刘琳; 霍墨菲; 孙瑞华; 王媛媛

    2012-01-01

    Objective To investigate the efficacy of alprostadil injection for treatment of ischemic stroke. Methods The electronic databases of Weipu and CNKI were searched to collect the published randomized controlled trials (RCT) with interventions of alprostadil injection for ischemic stroke. Results Nine papers of literature were adopted, including 633 patients. Three hundreds and twenty four patients in treatment group were treated with alprostadil injection and the others treated with traditional Chinese medicine (but single parameter) were in control group. Meta analysis showed that the patients in alprostadil injection group were better than that in control group. After treatment, the clinical curative rate of 95% CI was 5. 24 (3. 12, 8. 80). There was no difference in daily life ability score between treatment group and control group(P=0. 26), weighted mean difference (WMD) and 95% CI were -0. 13(-0. 37, 0. 10). Conclusion Alprostadil injection was more effective than traditional Chinese medicine for treatment of ischemic stroke.%目的 评价前列地尔注射液治疗缺血性脑卒中的临床疗效和安全性.方法 检索已在维普、CNKI数据库公开发表的、以前列地尔注射液为干预措施、中药注射液(除丹参注射液外)为对照治疗缺血性脑卒中的随机对照试验(RCT),评价纳入文献的方法质量学,提取有效数据,采用Cochrane协作网提供的RevMan5.1软件进行Meta分析.结果 共纳入9篇文献,研究对象共633例,试验组324例,对照组309例.Meta分析结果,前列地尔注射液治疗缺血性脑卒中的有效率高于中药注射液(P<0.000 01),OR及其95%置信区间(CI)为5.24(3.12,8.80);两组日常生活能力评分差异无统计学意义(P=0.26),加权均数差(WMD)及其95%CI为-0.13(-0.37,0.10).两组不良反应差异有统计学意义(P=0.01),OR及其95%CI为4.04(1.33,12.28).结论 前列地尔注射液治疗缺血性脑卒中患者的有效率高于中药注射液.

  10. 凯时联合金纳多治疗突发性聋协同疗效的探讨%Synergic effect of Alprostadil injection and ginaton in treating sudden deafness

    Institute of Scientific and Technical Information of China (English)

    江继平; 王淑云; 佟康

    2011-01-01

    Objective..To explore synergic effect of Alprostadil injection and ginaton in treating sudden deafness.Method:ninty one patients with sudden deafness were divided into group A,group B and group C at random;33 ears of group A were treated with 70 mg ginaton by vein , 30 ears of group B were treated with 10μg Alprostadil injection by vein,31 ears of group C were treated with 10μg Alprostadil injection and ginaton by vein,once a day,the time of treatment is 14 days.Result..the effective rate of group A is 60.61%, the effective rate of group B is 60.00%, the effective rate of group C is 87.09% the treating effect was significantly different in the group A and C(P<0.05) ,it was significantly different in the group B and C(P<0.05)).Conclusion: It is effective for Alprostadil injection and ginaton to treat sudden deafness,.and it has significantly Synergic effect in treating sudden deafness with Alprostadil injection and ginaton.%目的:探讨凯时联合金纳多治疗突发性聋的协同效应.方法:将91例(94耳)突发性聋患者随机分为甲组(33耳)、乙组(30耳)、丙组(31耳).治疗方案甲组为:0.9%氯化钠注射液250 ml加金纳多注射液70 mg静脉滴注,1次/d,共14 d,地塞米松10 mg加入上液,1次/d,共3 d;乙组为:0.9%氯化钠注射液100 ml加凯时注射液10 μg静脉滴注,1次/d,共14 d,地塞米松10 mg加入上液,1次/d,共3 d;丙组为:0.9%氯化钠注射液250 ml加金纳多注射液70 mg静脉滴注,1次/d,0.9%氯化钠注射液100 ml加凯时注射液10 μg静脉滴注,1次/d,共14 d,地塞米松10 mg加入上液,1次/d,共3 d.结果:甲、乙、丙组总有效率分别为60.61%、60.00%、87.09%,甲、丙组间及乙、丙组间疗效均差异有统计学意义(均P<0.05),甲、乙组间疗效差异无统计学意义(P>0.05).结论:凯时及金纳多治疗突发性聋有效,凯时联合金纳多治疗突发性聋效果更好,有显著的协同效应.

  11. Effect of combination of valsartan and alprostadil on diabetic nephropathy: A meta-analysis%缬沙坦联合前列地尔治疗糖尿病肾病的meta分析

    Institute of Scientific and Technical Information of China (English)

    卞丽丽; 尚文斌

    2015-01-01

    The randomized controlled trials (RCTs) of treating diabetic nephropathy (DN) with alprostadil and valsartan were collected from CNKI,Wan fang date,VIP,PubMed,Embase,and Cochrane Library.The selected data was analyzed with RevMan 5.1 software.The effect of combination of valsartan and alprostadil in treating DN was evaluated.In 19 RCTs,675 cases were co-treated with alprostadil and valsartan and 670 were treated with valsartan.The results indicated that 24 h urine microalbumin excretion [WMD =-53.23,95% CI (-67.55,-38.91),P<0.01] and24 h urine protein[WMD=-0.38,95% CI(-0.69,-0.07),P=0.02] in patients treated with combination of valsartan and alprostadil were reduced more markedly than in those treated with valsartan alone.There was no significant difference in blood urea nitrogen [WMD =-0.791,95 % CI (-20.62,4.79),P =0.22] and serum creatinine[WMD=-5.82,95% CI(-19.22,7.58),P=0.39] between two kinds of treatment.These results suggest that combined treatment with valsartan and alprostadil shows advantageous effect on reducing urinary protein in DN.%检索中国期刊全文数据库(CNKI)、万方数据在线知识服务平台、中文科技期刊全文数据库(VIP)、Pubmed、Cochrane、Embase公开发表的缬沙坦联合前列地尔治疗糖尿病肾病(DN)的随机对照临床试验(RCT)资料,采用RevMan 5.1软件对纳入资料进行meta分析,评价缬沙坦联合前列地尔对DN的治疗效果.纳入meta分析的文献共19篇,缬沙坦联合前列地尔治疗组675例,缬沙坦组670例.结果显示与单用缬沙坦相比,缬沙坦联合前列地尔治疗降低24 h尿微量白蛋白[WMD=-53.23,95% CI(-67.55,-38.91),P<0.01]和24 h尿蛋白[WMD=-0.38,95% CI(-0.69,-0.07),P=0.02]更显著,而对于尿素氮[WMD=-0.791,95% CI(-20.62,4.79),P=0.22]和血肌酐[WMD=-5.82,95% CI(-19.22,7.58),P=0.39]的影响,两者之间无显著性差异.提示缬沙坦联合前列地尔在降低DN尿蛋白上具有一定的优势.

  12. Alprostadil combined with Irbesartan in treatment of early diabetic nephropathy%前列地尔联合厄贝沙坦治疗早期糖尿病肾病效果观察

    Institute of Scientific and Technical Information of China (English)

    孙志芬; 邵鹏; 邢喜芝; 李朋霞; 刘玉斌; 刘金鹏; 王彦敏

    2011-01-01

    目的 观察前列地尔联合厄贝沙坦治疗早期糖尿病肾病(DN)的临床疗效。方法 收集早期DN患者120例,随机分成3组:厄贝沙坦组40例(厄贝沙坦150 mg,1次/d),前列地尔组40例(生理盐水+前列地尔10 μg静脉滴注),前列地尔联合厄贝沙坦组40例(剂量用法同前)。全部病例进行临床观察4周。分别比较3组血肌酐(Cr)、尿素氮(BUN),24h尿微量白蛋白(24 hUAE)治疗前后的变化。结果 3组患者治疗前后24 hUAE比较差异有统计学意义(t=2.07、t=2.01、t=3.15,P均<0.05),联合治疗组降低24 hUAE[(252.69±33.56) mg/24 h]的作用优于厄贝沙坦组[(268.75±34.42)mg/24 h](t=2.11,P<0.05),也优于前列地尔组[(267.95±34.75) mg/24 h](t=1.998,P<0.05);厄贝沙坦和前列地尔组间差异无统计学意义(P>0.05)。治疗过程中,前列地尔静脉滴注时个别患者出现滴注部位肿胀、不适,调整滴速后患者上述症状好转,未见其他不良反应。结论 前列地尔与厄贝沙坦联合应用是治疗早期DN的有效方法。%Objective To observe the clinical efficacy of combined irbesartan and alprostadil treatment of early diabetic nephropathy (DN).Methods A total of 120 patients with early type 2 diabetes of hospitalization were randomly divided into 3 groups: irbesartan group of 40 patients (150 mg, once per day)(group irbesartan),40 patients treated with alprostadil (physiological saline and alprostadi 10 μg))(group alprostadi) ,40 patients treated with alprostadil combined irbesartan (dose same as the other two groups)(combined group).All cases were observed for 4 weeks.Comparison of serum creatinine (Cr), blood urea nitrogen(BUN) ,24 hour urinary albumin(24hUAE) changes after treatment.Results After treatment 4 weeks 24hUAE of the three groups were significantly decreased (t = 2.07, t = 2.01 and t = 3.15, Ps < 0.05) .The decrease of 24hUAE in the combined treatment group ([252.69 ± 33.56]mg/24h) was better than that in the irbesartan

  13. 前列地尔注射液干预显微外科术后血管危象的实验研究%Effect of Alprostadil Injection On Vascular Crisis Following Microsurgery

    Institute of Scientific and Technical Information of China (English)

    查朱青; 程春生

    2015-01-01

    目的:探讨前列地尔注射液对显微外科术后血管危象的影响。方法切断大鼠颈总动脉,采用端端吻合法,吻合动脉,检测吻合情况,止血,缝合,根据动物分组采用尾静脉注射法向大鼠体内分别注入前列地尔注射液、肝素钠注射液或生理盐水。观察吻合口血栓形成,并进行全血高切黏度、全血低切黏度、全血黏度及红细胞刚性指数检测,扫描电镜观察吻合口内壁。结果前列地尔组术后吻合口血栓出现率较模型组明显减少(P <0.05),与肝素钠组相比差异无统计学意义(P >0.05)。前列地尔组术后全血高切黏度、全血低切黏度、血浆黏度和红细胞刚性指数显著低于模型组(P <0.05),与肝素钠组相比有降低,但差异不显著(P >0.05)。肝素钠组、前列地尔组,吻合口处纤维素覆盖,血小板黏附及内皮细胞修复上,总体差别不大。术后30 min 和术后第7天时前列地尔和肝素钠抑制红细胞黏附略优于模型组。结论前列地尔注射液能够降低吻合口血栓的形成,降低术后血液黏度和红细胞刚性,抑制红细胞及血小板黏附聚集,对血管危象的发生有预防和治疗的作用。%Objective To investigate the effect of alprostadil injection on vascular crisis following microsurgery. Methods Common carotid artery of rats was cut off and anastomosed using end-to-end vascular anastomosis. Hemostasis and suture were administrated after anastomosis status was determined. Then alprostadil injection,heparin sodium and normal saline were injected with tail vein injection according to the animal grouping,respectively. Thrombogenesis in anastomotic stoma was ob-served and whole high blood viscosity,whole low blood viscosity,whole blood viscosity and erythrocyte mechanical fragility were detected. The inner membrane was observed with scanning electron microscope. Results The thrombus occurrence rate

  14. 缬沙坦和前列地尔联合治疗糖尿病肾病的疗效研究%The efficacy of combination therapy with vasartan and alprostadil for diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    邓恩平; 梁一江; 黄汉光

    2011-01-01

    Objective To explore the efficacy of vasartan combined with alprostadil for diabetic nephropathy. Methods 90 patients with diabetic nephropathy were randomly assigned to receive vasartan alone ( 80-120 mg daily ), alprostadil alone ( 10 ug daily ), or vasartan plus alprostadil ( 80-120 mg and 10 ug daily ) for four weeks ( 30 patients for each group ). Blood pressure ( BP ) was controlled be low 125/75 mmHg in all the patients. BP, 24-hour urinary protein, serum creatinine ( SCr ),blood urea nitrogen( BUN )were measured before and after treatment. Severe adverse reactions were noted.Results No severe adverse reactions occurred in all the patients. After 4-week treatment, levels of 24-hour urinary protein differed significantly among the three groups [from 3.3 ± 1.3 ( g/24h ) to 1.9 ± 0.8 ( g/24h ) in the combination group, 3.3 ± 1.2 ( g/24h ) to 2.6 ± 1.1 ( g/24h ) in valsartan group, 3.3 ± 1.1 ( g/24h ) to 2.7 ± 1.2 ( g/24h ) in alprostadil group; P<0.05]. Urinary protein level was lower in the combination group than in both valsartan group and alprostadil group ( P< 0.05 ). Conclusions Valsartan and alprostadil can both reduce urine protein excretion in patients with diabetic nephropathy; and combination therapy is better than monotherapy with valsartan or alprostadil.%目的 观察缬沙坦和前列地尔联合治疗糖尿病肾病的临床疗效.方法采用随机、双盲、平行的方法将糖尿病肾病患者90例分为3组,每组30例,分别进行单用缬沙坦(80~160 mg/d),单用前列地尔(10 μg/d)以及联合缬沙坦(80~120 mg/d)和前列地尔(10 μg/d)治疗,血压均控制在125/75mmHg以下,疗程4周,治疗前后测定3组患者血压、24 h尿蛋白定量、血清肌酐、尿素氮水平,同时观察治疗期间有无严重不良反应.结果 90例患者治疗期间无严重不良反应发生.经过4周治疗后3组患者24 h尿蛋白定量间差异均有统计学意义(P<0.05),如联合治疗组从(3.3±1.3)g/24 h下降至(1

  15. Study on Clinical Effect of Alprostadil on Patients with Myocardial Infarction and its Influence Towards Hemorheology%前列地尔治疗心肌梗死疗效和对血液流变学的影响

    Institute of Scientific and Technical Information of China (English)

    梁裕聪; 梁嘉辉; 胡经航; 揭英彪

    2016-01-01

    Objective To study the clinical effect of Alprostadil on the patients with coronary heart disease ( CHD) and its influ-ence towards hemorhrology. Methods 106 CHD patients treated from March 2014 to March 2015 in our hospital were selected and randomly divided into two groups, 53 cases in each group. The patients in the control group were treated with the conventional thera-py, while those in the observation group were given Alprostadil on the basis of the conventional therapy. The clinical effect, blood lip-id, hemorheology and adverse reactions of two groups were observed. Results The total effective rate of observation group (86. 79%) was significantly higher than that of control group (69. 81%, P0. 05 ) . Conclusion Alprostadil has an obvious effect on the patients with myocardial infarction, effectively reducing the blood lipid level and improving the abnormal blood stream. It is safe and worthy of clinical application and promotion.%目的:研究冠心病心肌缺血患者采用前列地尔治疗对血液流变学的影响及疗效。方法临床纳入106例我院2014年3月至2015年3月期间收治的心肌梗死患者,所有患者按随机数字表法分为两组各53例。其中53例患者采用常规治疗作为对照组,另53例患者在上述基础上加用前列地尔治疗作为观察组。观察两组患者治疗效果、治疗前后血脂差值情况、治疗前后血液流变学差值情况以及不良反应情况等。结果观察组、对照组总有效率分别为86.79%、69.81%,观察组高于对照组, P0.05。结论前列地尔对心肌梗死患者治疗效果显著,有效降低血脂水平,改善血流异常情况,安全性高,值得临床应用及推广。

  16. Clinical observation of alprostadil combined with mecobalamine in the treatment of diabetic peripheral neuropathy%前列地尔联合甲钴胺治疗糖尿病周围神经病变临床观察

    Institute of Scientific and Technical Information of China (English)

    杨诗锋; 曾天艳

    2016-01-01

    Objective To investigate clinical effect by alprostadil combined with mecobalamine in the treatment of diabetic peripheral neuropathy.Methods A total of 74 patients with diabetic peripheral neuropathy were randomly divided into experimental group and control group, with 37 cases in each group. The control group received mecobalamine injection for treatment, and the experimental group received mecobalamine combined with alprostadil injection. Comparison was made on clinical effects and sensory nerve conduction velocity between the two groups.Results The experimental group had obviously higher total effective rate as 94.59% than 64.86% of the control group (P<0.05), and the experimental group had much faster sensory nerve conduction velocity than the control group (P<0.05).Conclusion Implement of mecobalamine combined with alprostadil can provide good clinical effect in treating diabetic peripheral neuropathy patients. This method can relieve pain in patients and lower financial cost, and it is worth promoting and applying.%目的:探究前列地尔联合甲钴胺治疗糖尿病周围神经病变临床效果。方法74例糖尿病周围神经病变患者,随机分为实验组与对照组,各37例。对照组采用甲钴胺注射液进行治疗,实验组采用甲钴胺注射液联合前列地尔注射液进行治疗。对比两组患者的临床治疗效果以及感觉神经传导速度等。结果实验组治疗总有效率为94.59%,显著高于对照组的64.86%(P<0.05);治疗后实验组患者感觉神经传导速度显著快于对照组(P<0.05)。结论对于糖尿病周围神经病变患者实施甲钴胺联合前列地尔治疗可以取得良好的临床效果,能够减轻患者的疼痛以及家庭经济负担。值得推广使用。

  17. 前列地尔联合甲钴胺治疗糖尿病周围神经病变的临床研究%Clinical research of alprostadil combined mecobalamin in threatment of diabetic peripheral neuropathy

    Institute of Scientific and Technical Information of China (English)

    刘静

    2014-01-01

    目的:探讨前列地尔联合甲钴胺治疗糖尿病周围神经病变的疗效。方法选择糖尿病周围神经病变患者80例,对照组予甲钴胺,治疗组同时联合前列地尔,连用4周。比较两组的疗效及神经传导速度的变化情况。结果治疗组与对照组的总有效率比较,差异有统计学意义(92.5%vs 70.0%,χ2=6.348,P<0.05)。两组患者治疗后的腓总神经、正中神经的MCV、SCV与治疗前比较明显提高,且治疗组患者治疗后的腓总神经、正中神经MCV、SCV与对照组治疗后比较改善更显著(P<0.05)。结论糖尿病周围神经病变的治疗除常规降糖治疗外辅助前列地尔联合甲钴胺治疗的疗效确切,二者具有协同作用,可以明显提高疗效。%Objective To investigate effect of alprostadil combined mecobalamin in threatment of diabetic peripheral neuropathy. Methods A total of 80 cases diabetic peripheral neuropathy patients were selected, the control group was given mecobalamin,treatment group added alprostadil four weeks. The efficacy nerve conduction velocity were com-pared. Results The total effective rate of the treatment group and the control group was 92.5%,70.0%(χ2=6.348,P<0.05). Peroneal nerve in the treactment group and control group patients after treatment of the common peroneal nerve, median nerve MCV,former SCV comparison with significantly improved treatment and observation of patients after treatment, the median nerve MCV,SCV after treatment with the control group(P<0.05). Conclusion Alprostadil com-bined mecobalamin diabetic peripheral neuropathy has exact effect,with a synergistic effect, worthy of promotion and application.

  18. 凯时用于断指再植术后血管危象防治的临床研究%Clinical study of alprostadil injection for the prevention and treatment for vascular crisis after severed fingers replantation

    Institute of Scientific and Technical Information of China (English)

    戎晓敏; 李俊

    2014-01-01

    Object:to explore the effect of alprostadil injection used for the prevention of vascular crisis after replantation of severed fingers. Method:86 patients with 112 replanted fingers were randomly devided into 2 groups. The control group was given conventional treatment and the patients in treatment group were given alprostadil injection besides the conventional treatment. The incidence of vascular crisis, the coagulation function and blood rheology were analyze to evaluate the curative effect. Result:Compared with the control group, the treatment group was with low incidence of vascular crisis and reduce blood viscosity. The coagulation function was no significant difference between the 2 groups. Conclusion:It suggests thar in the finger replantation surgery, the alprostadil was of great clinical value for its prevention of thrombosis and reduction of the vascular crisis.%目的:凯时(前列腺素E1)在手足外科中用于断指再植术后预防血管危象的临床效果。方法我科86例112指断指再植病例,随机分为两组,对照组给予常规治疗,实验组在常规治疗的基础上使用凯时。对两组患者术后血管危象发生率、凝血功能及血液流变学进行统计分析,比较两组疗效。结果与对照组相比,实验组血管危象发生率低,血液粘度降低,两组凝血功能无明显差别。讨论凯时用于断指再植手术,能够预防血栓形成,降低血管危象的发生率,有较好的临床应用价值。

  19. Application Experience of Alprostadil Medication in Treatment of Hepatorenal Syndrome%前列地尔在肝肾综合征治疗中的应用体会

    Institute of Scientific and Technical Information of China (English)

    刘臣

    2015-01-01

    目的:探究肝肾综合征患者采用前列地尔治疗的方法和效果。方法选取2013年4月~2014年8月收治的35例肝肾综合征患者进行治疗,随机分组,实验组19例患者选择前列地尔的治疗,对照组16例患者给予常规治疗,观察患者的治疗效果。结果实验组治疗有效率为94.74%,不良反应率为5.3%,对照组治疗有效率为75.0%,不良反应率为18.8%,差异有统计学意义(P<0.05)。结论肝肾综合征患者采用前列地尔的治疗能够控制感染,效果显著,减少并发症,并使肝脏血流量的情况得到改善。%ObjectiveTo explore alprostadil medication treatment method and its effect in treatment of hepatorenal syndrome.Methods Choose 35 patients of hepatorenal syndrome who are treated in hospital from April 2013 to August 2014 and separate them into two groups at random, 19 patients in study group are given alprostadil medication treatment, while 16 patients in control group are given conventional treatment, and then observe and compare treatment effects between two groups.Results In study group, treatment efficacy is 94.74% and side-effect incidence is 5.3%, while, in control group, treatment efficacy is 75.0%, and side-effect incidence is 18.8%, there is a signiifcant treatment differential between two groups and such a differential has statistic value (P<0.05).Conclusion Alprostadil medication is of efficacy in treatment of hepatorenal syndrome, it is conducive to controlling infection and reducing complication incidence, and in addition, it is effective to improve hepatic blood circulation, thus, such a medication treatment is quite worthwhile to be applied clinically.

  20. Clinical study of alprostadil combined with astragalus in treatment of diabetic nephropathy%前列地尔联合黄芪治疗糖尿病肾病疗效观察

    Institute of Scientific and Technical Information of China (English)

    查芳芳

    2011-01-01

    Objective To observe the clinical efficacy of alprostadil combined with astragalus In treatment of diabetic nephropathy. Methods 55 patients with diabetic nephropathy were randomly divided into combined treatmentgroup (27 cases) and control group(28 ases). The patients in the control group were only treated by alprostadil,while those in the combined treatment group were treated by astragalus on the basis of control group. The cure time of two groups was 2 weeks. The level of 24 h-UAER, Scr, BUN and ALB in two groups before and after treatment were detected and compared. Results The total effective rates of two groups were 81.5 % and 71.4%, there was a significant difference between the groups(P< 0. 05);The level of 24 h-UAER, ALB in combined treatment group after treatment declined more significantly than that in control group(P<0.05). Conclusion The treatment of alprostadil combined with astragalus has a significant effect on the treatment of diabetic nephropathy and no adverse effects,it would be valuable to widespread popularization.%目的 观察前列地尔联合黄芪治疗糖尿病肾病的临床疗效.方法 55例糖尿病肾病患者随机分为联合治疗组(27例)和对照组(28例),对照组单用前列地尔治疗,联合治疗组在此基础上加用黄芪,各组疗程均为2周,治疗前后检测和比较各种生化指标.结果 联合治疗组的治疗总有效率为81.5%,明显高于对照组71.4%(P<0.05);两组治疗后联合治疗组24 h-UAER和ALB较对照组下降明显(P<0.05).结论 前列地尔联合黄芪治疗治疗糖尿病肾病疗效显著,且无明显不良反应,值得临床推广.

  1. 前列地尔治疗慢性肾小球肾炎的临床效果观察%Clinical Study on Alprostadil Medication Effect in Treatment of Chronic Glomerulonephritis

    Institute of Scientific and Technical Information of China (English)

    杜梦军

    2015-01-01

    目的:探讨前列地尔治疗慢性肾小球肾炎的临床效果观察。方法选取2013年11月~2014年12月我院接诊的43例慢性肾小球肾炎患者,按照入院的先后顺序分为两组,22例实验组给与前列地尔药物,21例对照组给予缬沙坦,观察两组患者的治疗效果。结果实验组患者的治疗总有效率、肾功能指标改善情况及不良反应的发生率优于对照组,差异有统计学意义(P<0.05)。结论前列地尔治疗慢性肾小球肾炎的临床效果显著,可以有效提高患者治疗有效率,改善患者的肾功能。%Objective Alprostadil medication effect in treatment of chronic glomerulonephritis is to be studied. Methods We chose 43 patients of chronic glomerulonephritis who were received and treated in hospital from November 2013 to December 2014 and separated them into two groups according to their hospitalization sequence,twenty-two patients in study group were given alprostadil medication treatment,while 21 patients in control group were given valsartan medication treatment,and then observed and compared treatment effects between two groups. Results Patients’treatment efficacy,renal function improvements and side-effect incidence in study group were much more favorable than counterparts in control group; there was a treatment differential between two groups,and such a differential had statistic value(P<0.05). Conclusion Alprostadil medication is of efficacy in treatment of chronic glomerulonephritis;it is conducive to increasing treatment efficacy and improving patients’renal function; thus,such a medication treatment is quite worthwhile to be promoted and applied clinically.

  2. 前列地尔治疗糖尿病周围神经病变的疗效观察%Observation on the Efficacy of Alprostadil in the Treatment of Diabetic Pe-ripheral Neuropathy

    Institute of Scientific and Technical Information of China (English)

    陈国崇; 马燕锋

    2014-01-01

    Objective To study and analyze the effect of alprostadil on diabetic peripheral neuropathy. Methods 102 patients with diabetic peripheral neuropathy were randomly divided into two groups, the control group was treated with mecobalamine, the ex-perimental group was treated with alprostadil on the basis of the treatment of the control group. The efficacy of two groups was ob-served and compared. Results The total effective rate of 51 cases in the experimental group was 94.23%, higher than that of the patients in the control group(P<0.05);median nerve motor conduction velocity and sensory conduction velocity were higher than those of the control group (P<0.05), the differences were statistically significant. Conclusion Alprostadil has good effect on diabetic pe-ripheral neuropathy, which can improve the therapeutic effect, accelerate nerve conduction velocity, and is worthy of application.%目的:研究分析前列地尔(曼新妥)对糖尿病周围神经病变的治疗效果。方法随机将糖尿病周围神经病变的患者102例分为2组,对照组采用甲钴胺治疗,实验组在对照组基础上使用前列地尔治疗,对比观察两组疗效。结果实验组51例,总有效率为94.23%,高于对照组患者,差异有统计学意义(P<0.05);患者正中神经运动传导速度和感觉传导速度均高于对照组,差异有统计学意义(P<0.05)。结论使用前列地尔对糖尿病周围神经病变具有较好的疗效,可以提高治疗效果,加快神经传导速度,值得应用。

  3. Clinical effects of alprostadil combined with oxiracetam on acute cerebral infarction%前列地尔联合奥拉西坦治疗急性脑梗死的临床疗效

    Institute of Scientific and Technical Information of China (English)

    凌大军; 阚鲁; 马玉苹

    2014-01-01

    目的 探讨前列地尔联合奥拉西坦治疗急性脑梗死的疗效及安全性。方法 选取80 例急性脑梗死患者,随机分为对照组和治疗组,在常规治疗的基础上,对照组给予前列地尔注射液治疗,治疗组在对照组的基础上加用奥拉西坦注射液治疗,两组均连续治疗2 w,观察两组治疗前后美国国立卫生研究院卒中量表( NIHSS)及巴塞尔( Barthel)指数评分结果、血清中CRP 的浓度及安全性。结果 治疗后,治疗组NIHSS 评分明显低于对照组( P < 0. 05);Barthel 评分明显高于对照组(P<0.05);治疗7 d、14 d后,治疗组血清CRP浓度明显低于对于对照组(P<0.05);两组均未出现严重不良反应。结论在常规治疗的基础上,采用前列地尔联合奥拉西坦治疗急性脑梗死,可显著提高患者的生活自理能力,降低血清中CRP的浓度,提高临床治疗的效果,且安全、可靠,具有较大的临床借鉴意义。%Objective To investigate the clinical effects and safety of alprostadil combined with oxiracetam in treatment of acute cerebral infarction. Methods Total 80 patients with acute cerebral infarction were selected and divided randomly into the treatment group and the control group. On the basis of conventional therapy,the control group was provided with alprostadil injection treatment and the treatment group was provided with oxiracetam injection treatment in addition to alprostadil injection. Both groups were treated for two weeks;and then,America National Institute of Health Stroke Scale( NIHSS)and Barthel index score,concentration of serum CRP before and after the treatment were observed. Results After treatment,NIHSS score of the treatment group was significantly lower than that of the control group(P<0. 05);the Barthel index score of the treatment group was significantly higher than that of the control group(P <0. 05). After seven days and fourteen days of treatment

  4. Effects of alprostadil injection on plasma ET, NO and FN in patients with diabetic nephropathy%前列地尔注射液对糖尿病肾病患者血浆ET、NO、FN的影响

    Institute of Scientific and Technical Information of China (English)

    黄娟; 陈文莉; 黄云芳; 吴丹; 段晓宇

    2011-01-01

    Objective To observe the effects of alprostadil injection on diabetic nephropathy (DN) in patients with plasma endothelin (ET), nitric oxide (NO) and fibrinogen (FN). Methods Serum ET, NO and FN of 28 patients with diabetes without nephropathy and 50 patients with diabetic nephropathy were measured. The 50 patients with diabetic nephropathy were randomly divided into two groups, including conventional treatment group and alprostadil-treated group.Results The serum ET and FN of patients with diabetic nephropathy were significantly elevated ( P<0. 01) compared with diabetic patients without nephropathy, but the serum NO of patients with diabetic nephropathy was were significantly lower than that without diabetic nephropathy ( P<0. 01 ). Alprostadil could decrease serum ET and FN and increase serum NO (P<0.01). Conclusion Serum ET, FN and NO levels play an important role on incidence of diabetic nephropathy. Alprostadil can plasma of patients with diabetic nephropathy rectify ET, NO and FN imbalance and reduce UAER.%目的 现察前列地尔注射液对糖尿病肾病(DN)患者血浆内皮素(ET)、一氧化氮(NO)、纤维蛋白原(FN)的影响.方法 测定28例无肾病糖尿病患者、50例临床糖尿病肾病患者血浆ET、NO和FN水平,探讨血浆ET、NO和FN水平变化在糖尿病肾病发病中的可能作用.将50例糖尿病肾病患者随机分为两组,常规治疗组(对照组)和前列地尔治疗组(治疗组),测定两组治疗前后血浆ET、NO及FN水平、尿白蛋白排泄率(UAER)的变化.结果 糖尿病肾病患者较无肾病糖尿病患者血浆ET、FN水平明显升高(P<0.01),血浆NO水平明显降低(P<0.01).与对照组比较应用前列地尔治疗可使糖尿病肾病患者血策ET、FN水平明显降低(均P<0.01),血浆NO水平明显升高(P<0.01),UAER明显降低(P<0.01).结论 血浆ET、FN水平升高,NO水平降低在糖尿病肾病的发病中发挥重要作用.前列地尔治疗可纠正糖尿病肾病

  5. Efficacy of erigeron breviscapus combined with alprostadil in treating senile diabetic arteriosclerosis obliterans of the lower extremities: A clinical analysis of 25 cases%灯盏细辛联合前列地尔治疗老年糖尿病下肢动脉硬化闭塞症25例疗效观察

    Institute of Scientific and Technical Information of China (English)

    陈燕霞

    2012-01-01

    Objective To explore the clinical efficacy of erigeron breviscapus combined with alprostadil in treating senile diabetic arteriosclerosis obliterans of lower extremities. Methods Fifty patients with senile diabetes complicated with arteriosclerosis obliterans of lower extremities were randomly divided into two groups. The treatment group received lamps asarum injection combined with alprostadil. The control group (n = 25) received alprostadil treatment. The course of treatment was 2 weeks. Results The total efficacy rate of the treatment group was 96% , and the control group was 76% . The two groups had statistical difference (P<0. 05). The treatment group was significantly better than the control group. Conclusion Erigeron breviscapus combined with alprostadil in treatment of elderly patients with diabetic arteriosclerosis obliterans of lower extremities has better curative effect.%目的 针对灯盏细辛注射液联合前列地尔治疗老年糖尿病下肢动脉硬化闭塞症的疗效观察.方法 50例老年糖尿病合并下肢动脉硬化闭塞症患者随机分为2组,治疗组采用灯盏细辛注射液联合前列地尔,对照组25例采用前列地尔治疗,疗程2周.结果 治疗组总有效率96%,对照组总有效率76%,两组比较有统计学差异(P<0.05),治疗组明显优于对照组.结论 灯盏细辛联合前列地尔治疗老年糖尿病下肢动脉硬化闭塞症有较好的疗效.

  6. Clinical Observation of Alprostadil Combined with Lipoic Acid in the Treat-ment of Diabetic Peripheral Neuropathy%前列地尔联合硫辛酸治疗糖尿病周围神经病变的临床探讨

    Institute of Scientific and Technical Information of China (English)

    车微娟

    2015-01-01

    目的:探讨前列地尔联合硫辛酸治疗糖尿病周围神经病变的疗效。方法选择该院就诊的糖尿病周围神经病变患者62例,随机分为两组。其中对照组30例采用前列地尔治疗;观察组32例采用前列地尔联合硫辛酸治疗。结果治疗2周后,观察组神经传导速度及临床效果均优于对照组,差异有统计学意义(P<0.05)。结论前列地尔联合硫辛酸应用可改善糖尿病周围神经病变神经传导阻滞。%Objective To investigate the curative effect of alprostadil combined with lipoic acid in treatment of diabetic pe-ripheral neuropathy. Methods 62 patients with diabetic peripheral neuropathy were randomly divided into 2 groups. The control group of 30 cases treated by alprostadil; observation group of 32 cases, treated by alprostadil combined with lipoic acid. Results After 2 weeks of treatment, the nerve conduction velocity and clinical effect of the observation group were bet-ter than those of the control group, the difference was statistically significant (P<0.05). Conclusion Alprostadil combined with lipoic acid can improve nerve conduction block lesions of diabetic peripheral nerve.

  7. The Effectiveness of Ligustrazine Combined with Alprostadil Treatment on Background Diabetic Retinopathy%川芎嗪联合前列地尔治疗背景性糖尿病视网膜病变疗效的临床观察

    Institute of Scientific and Technical Information of China (English)

    周伟彧; 闫爽; 刘思颖; 朗宁; 李志平; 吉宗珊; 张瑛琪; 王玉晶

    2012-01-01

    Objective: Diabetic retinopathy (DR) is a blinding oculopathy which seriously influence human health and the leading cause of blind in old patient beyond the age of 50 in China. This study aimed to observe the therapy effectiveness of Ligustrazine combined with Alprostadil for background DR and discuss the mechanism. Methods:Select background DR patients (n=73). To treat the retinopathy eyes (n=112), we set treatment group by using Ligustrazine combined with Alprostadil and control group by using Ligustraza-ine and Aspirin. Compare the eyeground pathological changes before and after treatment. Results: Treatment using Ligustrazine combined with Alprostadil had a better performance after thyrapy compared before than Ligustrazaine and Aspirin. The overall efficacy was .68.97% in treatment group, while 38.89% in control group. Fluorescein fundus angiography showed that improvement for treatment was obvious better than control, (P<0.05). Conclusion: Ligustrazine combined with Alprostadil therapy is effective for treat diabetic background retinopathy. Conservative medical management plays an important role in DR.%目的:探讨川芎嗪(Ligustrazine)联合前列地尔(Alprostadil)治疗背景性糖尿病视网膜病变(Diabetic retinopathy,DR)的作用与疗效.方法:收集近年我院糖尿病伴背景性DR共73例(112只眼),分别按治疗中应用川芎嗪联合前列地尔或拜阿司匹林分为治疗组与对照组,比较两组治疗前后患者眼底病变改善情况.结果:川芎嗪联合前列地尔的治疗组疗效比拜阿司匹林的对照组好;眼底荧光检查表明,治疗组眼底病变改善明显好于对照组,差异显著(P<0.05).结论:川芎嗪联合前列地尔对DR有较好的疗效.

  8. Clinical observations on aerodynamic wave plus Alprostadil for the treatment of diabetes lower limb arteriosclerosis obliterans%空气动力波联合前列地尔治疗糖尿病下肢动脉硬化闭塞症的临床观察

    Institute of Scientific and Technical Information of China (English)

    余红梅; 胡清; 曾玉琴; 汪晓芬; 王娜娜; 龚丽; 李雪锋

    2014-01-01

    目的:观察空气动力波联合前列地尔治疗糖尿病下肢动脉硬化症的临床疗效,并探讨其治疗机制。方法将符合纳入标准的54例患者随机分为2组,治疗组30例采用空气动力波联合前列地尔治疗,对照组28例仅采用前列地尔治疗,治疗2个疗程后评定2组临床疗效,并观察治疗前后下肢动脉血管内径、血流量及踝肱指数的变化情况。结果治疗2个疗程后,治疗组疗效优于对照组(P<0.05);治疗组下肢血管内径、血流量、踝肱指数改善程度均优于对照组(P均<0.05)。结论空气动力波联合前列地尔治疗糖尿病下肢动脉硬化症安全有效,其疗效优于单一前列地尔治疗。%Objective It is to observe the clinical efficacy of aerodynamic wave plus Alprostadil on diabetic lower limb ar -teriosclerosis obliterans ,and to explore its mechanism .Methods 54 patients with diabetic lower limb arteriosclerosis obliterans were randomly allocated to treatment groups of 34 cases and control groups of 20 cases, the treatment group were treated with Aerodynamic wave plus Alprostadil , the control group were treated with Alprostadil only .After two treatment courses , the clin-ical curative effects of both groups were assessed , and the changes of blood vessel diameter of lower extremity artery , blood flow and ankle brachial index ( ABI) before and after treatment were observed .Results After two treatment courses , the cura-tive effect of treatment group was better than that of control group (P<0.05), and the improvements of blood vessel diameter of lower extremity artery, blood flow and ABI were also better than those of control group (P<0.05).Conclusion Aerody-namic wave plus Alprostadil is effective and safe in the treatment for diabetic lower limb arteriosclerosis obliterans .Its effect is superior to that of treatment with Alprostadil only .

  9. Analysis of the Effect of Alprostadil Combined Angiotensin Ⅱ Receptor Blocker on Diabetic Nephropathy%前列地尔联合血管紧张素Ⅱ受体阻滞剂治疗糖尿病肾病的临床疗效分析

    Institute of Scientific and Technical Information of China (English)

    李有佳; 徐小彭; 麦高阳

    2012-01-01

    目的 探讨前列地尔联合血管紧张素Ⅱ受体阻滞剂(ARB)治疗糖尿病肾病的临床疗效,分析影响临床疗效的相关因素.方法 我院88例诊断为糖尿病肾病患者,随机分为两组:ARB组(48例),单纯给予ARB类药物以控制血压及改善肾功能;前列地尔联合ARB组(40例),给予ARB类药物的同时,给予静脉注射前列地尔连续14天,每四周随访各项指标变化,并根据临床效果运用Logistic回归分析可能的影响因素.结果 两组患者在随访至8周时,蛋白尿及肾功能均明显改善;相比ARB组,前列地尔联合ARB治疗能更快(4周时显示有差异P<0.05)、更好的改善患者肾功能及降低尿蛋白的排泄(P<0.05);Logistic回归分析显示,治疗前尿蛋白定量水平及是否应用前列地尔是影响治疗疗效的主要因素(P<0.05).结论 前列地尔联合血管紧张素Ⅱ受体阻滞剂能明显降低糖尿病肾病患者蛋白尿,改善肾功能;在控制血糖、血压、血脂稳定的基础上,治疗前尿蛋白定量水平及是否应用前列地尔是影响患者疗效的主要因素.%Objective: To analyze the efficacy of alprostadil combined angiotensin II receptor blocker in ( ARB ) treatment of diabetic nephropathy and analyze possible risk factors affecting the clinical efficacy. Method: In our hospital, 88 patients diagnosed as diabetic nephropathy were randomly divided into two groups : ARB group ( 48 patients ), ARB was given to control blood pressure and improve renal function; alprostadil combined ARB group ( 40 patients ), while ARB was given, alprostadil was given for 14 consecutive days by intravenous injection. Some indexes were compared between two groups. The possible effect factors were analyzed by Logistic regression analysis. Result: After 8 weeks of treatment, all patients in two groups, proteinuria and renal function were significantly improved; while compared to the ARB group, alprostadil combined ARB therapy can faster ( 4 weeks

  10. 前列地尔注射液联合丹参注射液治疗早期糖尿病肾病的临床观察%Effects of Alprostadil Injection Combined with Danshen Injection on Early Diabetic Nephropathy

    Institute of Scientific and Technical Information of China (English)

    周方敏; 来芳

    2012-01-01

    To observe the effect of Alprostadil injection combined with Danshen injection in the treatment of early diabetic nephropathy. Methods 120 patients with early diabetic nephropathy were randomly divided into Alprostadil group ( 60 cases ) and combined treatment group ( 60 cases ) . All the patients were given diabetes diet, blood sugar control and blood pressure control as well as blood fat adjustment. The Alprostadil group was given Alprostadil injection ( 20 μg, once/day )The combined treatment group was given Alprostadil injection ( 20 μg, once/day ) and Danshen injection ( 20 ml, once/day ). The course of treatment was four weeks. The changes of total cholesterol ( TC ), triglyeride ( TG ), high density lipoprotein ( HDL - C ), low density lipoprotein ( LDL - C ), blood urea nitrogen ( BUN ), serum creatinine ( Cr ), urinary albumin excretion rate ( UAER ) and p, - MG in the two groups were observed before the treatment and after the four weeks treatment. Results The levels of TC, TG, LDL - C, Cr, BUN, UAER and p, - MG- in the two groups were all significantly decreased after treatment ( P < 0. 05 ), while the level of HDL - C was significantly increased after treatment ( P < 0. 05 ) . The improvement level of the above mentioned parameters was significantly better in the combined treatment group than in the Alprostadil group ( P <0. 05 ) . Conclusion Combined treatment of Alprostadil injection and Danshen injection is effective in the treatment of early diabetic nephropathy.%目的 观察前列地尔注射液联合丹参注射液治疗早期糖尿病肾病(DN)的疗效.方法 将120例早期DN患者随机分为两组:前列地尔组(60例)和丹参注射液+前列地尔联合治疗组(联合治疗组,60例).两组患者均接受糖尿病饮食、降糖、控制血压及调脂治疗;前列地尔组另静脉滴注前列地尔注射液(20 μg,1次/d);联合治疗组另静脉滴注前列地尔注射液(20 μg,1次/d)及丹参注射液(20 ml,1次/d),总疗程4

  11. Efficacy Observation of Lipo-alprostadil Injection in the Treatment of Progressive Cerebral Infarction%前列地尔脂微球注射液治疗进展性脑梗死的疗效观察

    Institute of Scientific and Technical Information of China (English)

    梁涛; 张建文

    2012-01-01

    OBJECTIVE: To investigate the application of Lipo-alprostadil injection in the treatment of progressive cerebral infarction. METHODS: 120 patients with progressive cerebral infarction in our hospital during Jan. 2010 -Jan. 2011 were randomly divided into experiment group and control group. Control group was given Danshen injection(20 mL·d-1), and experiment group was additionally given Lipo-alprostadil injection(10 ug·d-1) on the basis of the treatment for control group. The efficacy and ADRs were observed in 2 groups. RESULTS: Total effective rate of experiment group was 85.00% and that of control group was only 66.67% , which indicated clinical efficacy of experiment group was better than that of control group (P0.05). CONCLUSION: Lipo-alprostadil injection is safe and reliable in the treatment of progressive cerebral infarction with sound efficacy and little ADR.%目的:观察前列地尔脂微球注射液治疗进展性脑梗死的临床效果.方法:将2010年1月-2011年1月我院收治的进展性脑梗死患者120例,随机均分为试验组与对照组:对照组采用丹参注射液20 mL·d-1治疗,试验组在对照组基础上加用前列地尔脂微球注射液10 μg·d-1治疗.观察2组疗效及不良反应.结果:试验组患者临床疗效总有效率为85.00%,对照组为66.67%,2组比较差异有统计学意义(P<0.05);治疗前、后2组患者的NIHSS评分及Barthel评分组内比较差异均具有统计学意义(P<0.05),且治疗30 d后试验组患者的NIHSS评分显著低于对照组(P<0.05),Barthel评分显著高于对照组(P<0.05);2组患者的不良反应发生率比较差异无统计学意义(P>0.05).结论:前列地尔脂微球注射液治疗进展性脑梗死疗效较好、不良反应较小.

  12. 前列地尔注射液治疗后循环缺血性眩晕的临床疗效观察%Clinical observation of treatment with Alprostadil injection on posterior circulation ischemic vertigo

    Institute of Scientific and Technical Information of China (English)

    徐姣

    2014-01-01

    Objective To investigate and assess the therapeutic effect of treatment with Alprostadil injection on posterior circulation is-chemic vertigo. Method 60 Patients who suffered from posterior circulation ischemic vertigo were randomly divided into two groups:treat-ment group(30 cases)and control group(30 cases). The treatment group was treated with Alprostadil injection and the control group was treated with Vinpocetin injection,the efficacy was observed after ten days treatment. Results 10 cases were cured,12 markedly effective,6 effective and 2 ineffective in the treatment group,and the corresponding figures were 4,6,12 and 8 in the control group,total effective rates in treatment group and control group were 93. 3% and 73. 3%,respectively,showing significant difference between two groups( P﹤0. 05) . The mean time of initiation of effect in treatment group was(3. 5 ± 1. 4)d and that of control group was(4. 7 ± 1. 9)d,comparison of the two groups,the difference was statistically significant( P﹤0. 05). Conclusion The effect of Alprostadil injection in the treatment of posteri-or circulation ischemic vertigo has the benefits of reacting fast and showing better effect. It is very safe and is worth popularizing in clinical application.%目的:观察前列地尔注射液对后循环缺血性眩晕的治疗效果。方法:选择后循环缺血性眩晕患者60例,随机分为两组,治疗组30例,对照组30例。治疗组给予前列地尔注射液治疗,对照组给予长春西汀针治疗,10 d后评估疗效。结果:治疗组痊愈10例,显效12例,有效6例,无效2例,总有效率93.3%。对照组痊愈4例,显效6例,有效12例,无效8例,总有效率73.3%。两组总有效率差异有统计学意义( P﹤0.05)。治疗组平均起效时间(3.5±1.4)d,对照组为(4.7±1.9)d,差异有统计学意义( P﹤0.05)。结论:前列地尔注射液治疗后循环缺血性眩晕起效快疗效好,且使用安

  13. Effects of Combination of Mecobalamin and Alprostadil on Diabetic Peripheral Neuropathy%甲钴胺联合前列地尔治疗糖尿病周围神经病变的疗效观察

    Institute of Scientific and Technical Information of China (English)

    周琳; 陈菊萍; 王丹丹; 赵一鸣; 刘玲; 杨玲

    2011-01-01

    Objective:To observe the effects of combination of mecobalamin and alprostadil (PGE1), mecobalamin only and vitamin 12 only on the patients with diabetic peripheral neuropathy (DPN). Methods: A total of 60 patients with DPN were divided into three groups (Group1, Group 2, and control group). Twenty patients in group1 were given mecobalamin (0. 5 mg IM. qd. ) and alprostadil (10 tg Ⅳ. qd. ) for consecutive 2 weeks. Twenty patients in Group2 were only given mecobalamin (0. 5 mg IM. qd. ) for consecutive 2 weeks. Twenty patients in control group were only given vitamin (0. 5 mg IM. qd. ) for consecutive 2 weeks. All patients were received adjuvant therapy with salvia injection. Results: Compared with control group, complains and physical signs of patients and every nerve conduction velocity (NCV) improved. The effects of Groupl were better than that of Group2. No side effect was found in three groups. Conclusions: The combination of mecobalamin and alprostadil could obtain better effects in patients with DPN.%目的:观察比较甲钴胺联合前列地尔,单用甲钴胺及单用维生素B12治疗糖尿病周围神经病变的疗效.方法:将60例糖尿病周围神经病变患者随机分为3组,治疗组1(20例)给予甲钴胺0.5 mg肌内注射,每天1次,同时给予前列地尔10 μg + 0.9 %氯化钠液10 mL静脉推注,每天1次,连续2周;治疗组2(20例)给予甲钴胺0.5 mg肌内注射,每天1次,连续2周;对照组(20例)用维生素B12 0.5 mg肌内注射,每天1次,连续2周.每组均辅以丹参针剂静脉滴注治疗.结果:治疗组1、治疗组2患者症状和体征、各项神经传导速度与对照组相比均显著改善,而治疗组1与治疗组2之间临床疗效差异有统计学意义,且各组均无明显不良反应.结论:甲钴胺联合前列地尔治疗糖尿病周围神经病变疗效更好.

  14. 前列地尔与依那普利联合治疗早期糖尿病肾病的疗效%Effect of Alprostadil Combined Enalapril Treat Early Diabetic Nephropathy

    Institute of Scientific and Technical Information of China (English)

    李大勇

    2011-01-01

    目的:观察前列地尔(凯时注射液)联合依那普利治疗早期糖尿病肾病(DN) 的疗效.方法:将本院门诊和住院病人138 例早期DN 患者,随机均分为2组,2 组患者均接受糖尿病饮食、降糖、控制血压及调脂治疗,均服用依那普利10mg,每日1次.治疗组(n=69 例)在对照组基础上加用前列地尔注射液治疗,分别比较2组患者在治疗前后血压(MBP) 、空腹血糖(FBG) 、糖化血红蛋白(HbA1c) 、尿微量白蛋白排泄率(UAER) 、血肌酐(Scr) 、尿素氮(BUN) 的变化.结果:2 组在治疗前各项指标均无明显差异(P>0.05); 治疗2周后,2 组FBG 、HbA1c 、MAP 、BUN 无明显变化,24h-UAER 、Scr 较治疗前均明显好转;而治疗组的24h-UAER 较对照组改善更明显(P<0.01).结论:前列地尔联合依那普利治疗早期DN 疗效显著,能有效减少UAER,有利于延缓甚至防止糖尿病肾病的发生和发展,值得临床推广和应用.%Objective:TO observe the early effect of Alprostadil (Kaishi injection)combined Enalapril in treating early diabetic nephropathy.Methods: Divide 138 patients with early diabetic nephropathy into two groups randomly, two groups of patients accept diabetes diet,control blood sugar, control blood pressure and adjusting blood-fat. They both be treated with Enalapril 10mg, one time a day. At the basic treatment of control group(69 cases), therapy group(69 cases), be treated with Alprostadil 10 μ g one time a day.Receive the same treatment for two weeks without a stop.Changes before and after treatment in levels of blood pressure,FBG, HbA1C,urine albumin excretion rate(UAER), Scr and BUN were observed and compared between the two groups. Results: The two groups showed similar levels of the indexes at baseline (P>0.05). After two weeks' treatment,UAER and Scr were significantly improved in two groups(P<0.05). Compared with the control group,the therapy group showed greater improvement in UAER(P<0.01); MBP, BUN, FPG and HbA1C

  15. 甲钴胺联合前列地尔治疗糖尿病周围神经病变的临床观察%Clinical Observation of Mecobalamin Alprostadil in the Treatment of Dia-betic Peripheral Neuropathy

    Institute of Scientific and Technical Information of China (English)

    车微娟

    2016-01-01

    Objective To observe and analysis of Mecobalamin Combined with prostaglandin PGE1 in the treatment of dia-betic peripheral neuropathy clinical efficacy and safety. Methods A total of 64 patients with diabetic peripheral neuropathy from May 2015 to March 2014, were randomly divided into observation group (33 cases) and control group (31 cases).Two groups of patients were given basic treatment and intravenous injection of alprostadil. On the basis of the observation group plus mecobalamin. Results Before treatment, the difference of temperature, pressure, vibration and the score of Toronto was not significant(P>0.05). After 2 weeks treatment, compared with the control group, the observation group was less than that of the observation group (P< 0.05). Conclusion Mecobalamin alprostadil can significantly improve patients feel, limb motor nerve reaction, improve the clinical efficacy.%目的:观察和分析甲钴胺联合前列地尔治疗糖尿病周围神经病变的临床效果和安全性。方法选择2014年3月-2015年5月该院收治的64例糖尿病周围神经病变患者,随机分为观察组31例和对照组33例。两组患者均给予基础治疗和前列地尔静脉注射。观察组在此基础上加用甲钴胺治疗。治疗2周后记录两组患者治疗前后的温度觉、压力觉、振动觉及多伦多评分变化。结果治疗2周后,与对照组相比,观察组温度觉、压力觉、振动觉异常案例少,多伦多评分低,差异有统计学意义(P<0.05﹚。结论甲钴胺联合前列地尔可显著改善患者四肢感觉、运动神经反应,提高临床疗效。

  16. Effect of alprostadil on patients with acute kidney ynjury%前列地尔治疗急性肾损伤疗效观察

    Institute of Scientific and Technical Information of China (English)

    李文宁; 詹锋; 武伟; 林书典

    2012-01-01

    目的 探讨前列地尔(PGE1)治疗急性肾损伤(Acute Kidney Injury,AKI)的临床疗效.方法 收集海南省人民医院肾病风湿科自2010年1月~2012年1月住院治疗的急性肾损伤患者56例,随机分为治疗组(28例)和对照组(28例).两组常规用药相同,治疗组加用PGE1静脉滴注,每天1次,连续2周.比较两组患者治疗前后尿NAG酶、尿渗透压、血肌酐、尿素氮、尿β2微球蛋白以及肾衰指数、肾小球滤过率及进入透析人数的变化.结果 治疗组治疗后,尿NAG酶、血肌酐、尿素氮、尿β2微球蛋白以及肾衰指数明显低于对照组,尿渗透压、肾小球滤过率明显高于对照组(P<0.05).治疗组进入透析的人数(6人)低于对照组(13人)(x2=3.9,P< 0.05).结论 PGE1可促进AKI缓解,增强疗效.%Objective To observe the effect of alprostadil (PGE1) on patients with acute kidney injury (AKI). Methods The 56 patients, definitely diagnosed as AKI in Department of Nephrology and Rheumatology of Hainan Provincial People's Hospital during Jan 2010 to Jun 2012, were randomly divided into treatment group (28 patients) and control group (28 patients). All the patients in two groups were received the basic therapy, PGE1 at dose of 10μg ivgtt qd was added to those in the treatment group for two weeks. The urine osmotic pressure and levels of urinary NAG enzyme, serum creatinine, blood urea nitrogen, urine beta 2 microglobulin and renal failure index and glomerular filtration rate in the two groups were determined and compared before and after treatment. Results In the treatment group before and treatmernt the levels of Bun were 34.56± 4.61mmol/L,10.33±2.11mmol/L,Cr were 284.17±10.86μmol/L, 125.85±29.01μmol/L, Urinary NAG60 were 4±20.4U/L, 24.09± 5.86U/L, Urine osmotic pressure were 495.85±32.42mmol/L, 795±103.41mmol/L,Urine β2 microglobulin 1 were 26±0.52mg/L、 0.54±0.14mg/L,Renal failure indexl.9±0.82, 0.8±0.31,Glomerular filtration rates were 82±7

  17. The Clinical Observation of Alprostadil Lipid-microsphere Injection in Treatment of Elderly Patients with Stable Angina Pectoris of Coronary Heart Disease%前列地尔脂微球注射液治疗老年冠心病稳定型心绞痛的临床观察

    Institute of Scientific and Technical Information of China (English)

    闫秀莲

    2014-01-01

    Objective:To observe the clinical effect of Lipo-PGE1 injection in treatment of elderly patients with stable angina pectoris of coronary heart disease.Method:120 stable angina patients in department of Cardiology from September 2012 to September 2013 were selected,they were divided into the alprostadil treatment group and the control group according to the random number table method,60 cases in each group.The control group was given conventional treatment,the alprostadil treatment group took the alprostadil Lipo-PGE1 injection of 10 μg into the small pot of intravenous injection on the basis of conventional therapy,1/d.Both of the two groups took 7 days for a course of treatment, a total of 3 courses of treatment.The total effective rate,total effective rate of ECG,blood rheology changes and adverse reactions of the two groups were observed.Result:After 3 courses of treatment,the angina pectoris and ECG total effective rate in alprostadil group were significantly higher than those of control group,the degree of blood rheology indexes of the two groups after treatment were significantly lower than before treatment,and those in the alprostadil group were significantly lower than the control group,the differences were statistically significant(P<0.05),and both of the two groups were no serious adverse reactions.Conclusion:Alprostadil lipid microsphere injection is safe and effective in the treatment of elderly patients with stable angina pectoris of coronary heart disease,clinical reference can be used.%目的:观察前列地尔脂微球注射液辅助治疗老年冠心病稳定型心绞痛的临床效果。方法:选取本院心内科2012年9月-2013年9月收治的120例老年冠心病稳定型心绞痛患者,按照随机数字表法将其分为前列地尔组和对照组各60例。对照组给予常规治疗,前列地尔组在常规治疗的基础上将前列地尔脂微球注射液10μg入小壶静脉滴注,1次/d。两组均以7 d

  18. 依达拉奉与前列地尔脂微球载体靶向制剂联合治疗急性脑梗死的疗效观察%Edaravone with Alprostadil Lipid Microsphere Carrier Targeting Agents in the Treatment of Acute Cerebral Infarction

    Institute of Scientific and Technical Information of China (English)

    赵群

    2012-01-01

      目的探讨依达拉奉与前列地尔脂微球载体靶向制剂联合治疗急性脑梗死的临床疗效.方法选择80例急性脑梗死患者随机分为治疗组(40例)和对照组(40例),治疗组在常规治疗的基础上给予依达拉奉和前列地尔脂微球载体靶向制剂.结果观察两组治疗后临床疗效,治疗组总有效率95.0%显著优于对照组(75.0%).结论依达拉奉与前列地尔脂微球载体靶向制剂联合治疗急性脑梗死安全、有效.%  Objective  To study of Edaravone and alprostadil lipid microsphere carrier targeting agents in the treatment of acute cerebral infarction. Methods 80 cases of acute cerebral infarction were randomly divided into treatment group (40 cases) and control group ( n =40), the treatment group was treated with routine therapy on the basis of Edaravone and alprostadil lipid microsphere carrier targeting preparation. Results In two groups were observed after treatment of clinical efficacy, the treatment group was significantly better than the control group. Conclusion Edaravone with alprostadil lipid microsphere carrier targeting preparation combined with safe, effective treatment of acute cerebral infarction.

  19. 探讨前列地尔联合低分子肝素钙治疗老年肿瘤高凝状态的效果%To Explore the Effect of Alprostadil Combine With Low Molecular Heparin in Treatment of Hypercoagulable State in Elderly Cancer

    Institute of Scientific and Technical Information of China (English)

    孙建明

    2015-01-01

    目的 探讨前列地尔联合低分子肝素钙在老年肿瘤高凝状态中的应用效果.方法 选取患者65例,按随机数字表法分为对照组(低分子肝素及肿瘤综合治疗)32例、观察组(加用前列地尔联合治疗) 33例.结果 治疗后,观察组D-dimer、PLT等指标改善情况优于对照组,且治疗后观察组血流变各项指标变化更明显,P<0.05,差异具有统计学意义.结论 前列地尔联合低分子肝素钙治疗老年肿瘤高凝状态的效果显著.%Objective To investigate the effect of alprostadil combine with low molecular weight heparin calcium in elderly tumor hypercoagulable state.Methods 65 patients were randomly divided into control group (LMWH and comprehensive cancer treatment) had 32 cases, the observation group ( plus alprostadil combination therapy) had 33 cases. Results After treatment, the observation group D-dimer, PLT and other indicators improve blood lfow in patients than the control group and the observation group after treatment becomes more pronounced changes in the indicators,P<0.05,had difference statistically.Conclusion Alprostadil low molecular weight heparin effect senile tumor hypercoagulable state is remarkable.

  20. Alprostadil Combined With Octreotide in the Treatment of Patients With Hyperlipidemia and AP Negative Conversion Rate of Amylase%前列地尔联合奥曲肽治疗对高脂血症性急性胰腺炎患者血淀粉酶阴转率的影响研究

    Institute of Scientific and Technical Information of China (English)

    朱焱

    2016-01-01

    目的:观察前列地尔与奥曲肽用于高脂血症性急性胰腺炎患者治疗中的临床效果。方法选取来我院就诊的80例高脂血症性急性胰腺炎患者进行研究,将其分为治疗组与对照组,各40例,对照组采用奥曲肽进行常规治疗,治疗组使用前列地尔与奥曲肽进行联合治疗,对比两组治疗后的临床效果。结果治疗组的血淀粉酶阴转率与临床效果明优于对照组,差异有统计学意义(P <0.05)。结论对高脂血症性急性胰腺炎患者采用前列地尔与奥曲肽联合治疗,效果显著。%Objective To observe the effect of alprostadil combined with octreotide used in the clinical effect in the treatment of patients with hyperlipidemia hyperlipidemia acute pancreatitis. Methods In our hospital 80 cases of hyperlipidemia hyperlipidemia acute pancreatitis patients were studied and divided into treatment group and control group with 40 cases in each. The control group were treated with octreotide, the treatment group using alprostadil combined with octreotide combined therapy, compared two groups of treatment the clinical effect. Results The treatment group, the blood amylase negative rate and the clinical effect was significantly higher than the control group,P<0.05, there was statistical significance. Conclusion The combined treatment with Alprostadil Combined with octreotide in patients with hyperlipidemic acute pancreatitis, significant effect.

  1. 小剂量多巴胺联合前列地尔治疗慢性肾功能不全的临床疗效分析%Analysis clinical effect of the low-dose dopamine combined with alprostadil for treatment of chronic renal insufficiency

    Institute of Scientific and Technical Information of China (English)

    孙丽萍

    2013-01-01

      目的分析小剂量多巴胺联合前列地尔治疗慢性肾功能不全的疗效。方法将我院2010年3月-2012年12月90例慢性肾功能不全患者随机分为两组各45例,对照组患者给予常规治疗,观察组患者在此基础上加用小剂量多巴胺和前列地尔治疗。结果观察组24h尿蛋白量、内生肌酐清除率、血肌酐、尿素氮及疗效均优于对照组(P<0.05)。结论小剂量多巴胺联合前列地尔治疗慢性肾功能不全的疗效确切,能延缓疾病进展,值得临床推广。%Objective To analyze the effect of low-dose dopamine combined with alprostadil for treatment of chronic renal insufficiency. Methods 90 patients with chronic renal insufficiency in our hospital from March 2010 to December 2012 were randomly divided into observation group and control group. Observation group was given low-dose dopamine combined with alprostadil on the basis of general treatment therapy and control group was given general treatment therapy. Results The 24h urine protein quantity, endogenous creatinine clearancerate, serum creatinine, blood urea nitrogen, and the clinical effect in the observation group were significant better than those in the control group(P<0.05). Conclusions The low-dose dopamine combined with alprostadil for treatment of chronic renal insufficiency is efficacy, decrease in development. It is worthy to be popularized.

  2. 前列地尔治疗高龄糖尿病并慢性肾脏病患者疗效和安全性探讨%To Explore the Efficacy and Safety of Alprostadil in Treatment of Diabetes Mellitus in Patients With Chronic Kidney Disease

    Institute of Scientific and Technical Information of China (English)

    杨斌

    2016-01-01

    Objective Analysis of alprostadil in treatment of elderly patients with diabetes and chronic kidney disease and safety.Methods Selected 62 cases with senile diabetes and chronic kidney disease in our hospital, which were divided into two groups, the control group with conventional therapy, the experimental group with alprostadil, analysis of therapeuticeffects of two groups were compared.Results The experimental group after treatment, 24 hours UAER, Cr improvement and clinical total effective rate was better than the control group (P<0.05). Conclusion The alprostadil treatment of senile diabetes and chronic kidney disease effect, and high safety.%目的:试析前列地尔治疗高龄糖尿病并慢性肾脏病患者疗效及安全性。方法选取我院收治的高龄糖尿病并慢性肾脏病患者62例,分为两组,对照组用常规治疗,实验组用前列地尔治疗,分析两组治疗疗效。结果实验组治疗后Cr、24 h UAER改善程度及临床总有效率优于对照组(P<0.05)。结论采用前列地尔治疗高龄糖尿病并慢性肾脏病的效果显著,且安全性高。

  3. A clinical study on Zhuyu Tongmai capsule combined with Alprostadil injection in treating lower extremity phlebitis%逐瘀通脉胶囊联合前列地尔治疗下肢静脉炎的临床观察

    Institute of Scientific and Technical Information of China (English)

    朱鸣琴

    2013-01-01

      目的:对逐瘀通脉胶囊联合前列地尔治疗下肢静脉炎的临床疗效进行观察和分析。方法:选取符合纳入标准的下肢静脉炎患者56例,按照随机数字法分为中西医结合治疗组和西药治疗组,分别给予相应的治疗措施且对其病情进行观察,最后进行统计学处理。结果:逐瘀通脉胶囊联合前列地尔治疗组优于单纯前列地尔组。结论:中西医结合治疗下肢静脉炎的疗效确切。%  Objective: To observe and analyze Zhuyu Tongmai capsules combined with alprostadil injection in treating lower extremity phlebitis. Methods:56 cases of the lower extremity phlebitis were divided into modern medicine group and integrative medicine group according to the random number method, both of the groups were given certain treatment measures and observed the illness ation, then do statistics processing. Results:The treatment of Zhuyu Tongmai capsules combined with alprostadil injection groups was better than pure alprostadil injection groups. Conclusion:Integrative medicine in treating lower extremity phlebitis has definite effects.

  4. Efficacy analysis of alprostadil combined with betahistine in treating vertebral-basilar artery insufficiency%前列地尔联合倍他司汀治疗椎-基底动脉供血不足的疗效分析

    Institute of Scientific and Technical Information of China (English)

    肖有为; 许彩芹; 庞燕; 刘宇鹏

    2011-01-01

    目的 观察前列地尔联合倍他司汀治疗椎-基底动脉供血不足的临床疗效.方法 将136例椎-基底动脉供血不足患者随机分为前列地尔联合倍他司汀治疗组(68例)和倍他司汀对照组(68例),观察临床疗效及治疗前后椎-基底动脉平均血流速度的改善情况.结果 治疗组治愈率及总有效率高于对照组(P<0.05);治疗组各动脉平均血流速度均明显较对照组改善(P<0.05).结论 前列地尔联合倍他司汀治疗椎-基底动脉供血不足疗效显著.%Objective To observe the clinical efficacy of alprostadil combined with betahistine in treating vertebral-basilar artery insufficiency.Methods 136 patients with vertebral-basilar artery insufficiency were randomly divided into alprostadil combined with betahistine treatment group (68 cases) and betahistine control group (68 cases), clinical efficacy and the improvement of vertebral-basilar artery mean blood flow rate was observed before and after treatment.Results The cure rate and total effective rate of treatment group were higher ( P < 0.05 ); Artery mean blood flow velocity of treatment group were improved significantly than that in control group ( P < 0.05 ).Conclusion It is effective to treat the vertebral-basilar artery insufficiency with alprostadil combined with betahistine.

  5. 血必净联合前列地尔治疗脑梗死急性期的疗效及安全性观察%Effect and safety of Xuebijing combined Alprostadil in the treatment of acute period of cerebral infarction

    Institute of Scientific and Technical Information of China (English)

    程京

    2014-01-01

    目的:观察血必净联合前列地尔治疗脑梗死急性期的疗效与安全性。方法70例脑梗死急性期患者进行分组治疗,观察组给予血必净联合前列地尔,对照组给予前列地尔。观察2组有效率、美国国立卫生院神经功能缺损评分(NIHSS)以及肝、肾功能等指标。结果观察组有效率94.29%,高于对照组的77.14%,差异有统计学意义( P<0.05)。治疗前2组NIHSS 评分差异无统计学意义(P>0.05),治疗后7、14、21 d ,观察组NIHSS 评分均显著低于对照组,差异有统计学意义( P <0.05)。2组肝、肾功能等方面差异均无统计学意义( P>0.05)。结论血必净联合前列地尔治疗脑梗死急性期,具有较好的临床疗效,能够一定程度上恢复患者的神经功能,安全可靠,值得推广。%Objective To observe the clinical effect and safety of Xuebijing combined Alprostadil in the treatment of acute period of cerebral infarction. Methods Seventy patients with acute period of cerebral infarction were divided into 2 groups.Observation group was given Xuebijing combined Alprostadil ,while control group was given Alprostadil only. The effective rate ,NIHSS score and safety index of liver and kidney function of the two groups were compared.Results The effective rate of observation group was higher than control group(P0.05. Conclusion Xuebijing combined Alprostadil for treatment of acute period of cerebral infarction has a high clinical effec-tive rate ,it can promote recovery of nerve function of patients to some extent and it is safe and reliable ,so it is worth of being popularized.

  6. Therapeutic effect of α-lipoic acid combined with mecobalamin and alprostadil on diabetic peripheral neuropathy%α-硫辛酸联合甲钴胺及前列地尔治疗糖尿病周围神经病变的疗效观察

    Institute of Scientific and Technical Information of China (English)

    张菁; 邓晓龙; 王敏哲

    2011-01-01

    目的 评价α-硫辛酸联合甲钴胺及前列地尔治疗糖尿病周围神经病变(DPN)的疗效.方法 将32例患者随机分为两组:治疗组予α-硫辛酸、甲钴胺及前列地尔,对照组予甲钴胺及前列地尔,治疗2周.观察两组临床疗效及神经传导速度(NCV).结果 治疗组总有效率达87.5%,明显高于对照组的50%(P<0.05);两组患者的神经病变主觉症状问卷(TSS)评分明显改善(P<0.05);治疗组NCV较对照组有显著提高(P< 0.01).结论 临床使用α-硫辛酸联合甲钴胺及前列地尔治疗DPN安全有效.%Objective To evaluate the therapeutic effect of α-lipoic acid combined with mecobalamin and alprostadil on diabetic peripheral neuropathy(DPN). Methods The 32 DPN patients receiving a 2 weeks of therapy were randomly divided into two groups: treatment group treated with α-lipoic acid combined with mecobalamin and alprostadil and control group treated with mecobalamin and alprostadil.The therapeutic effect and nerve conduction velocity(NCV)were observed. Results The total efficacious rate was higher in treatment group than in control group (87. 5% vs 50. 0%, P<0. 05). TSS score improvement in treatment group was superior to control group (P<0. 05). NCV acceleration was more in treatment group than in control (P<0.01). Conclusions Treatment with α-lipoic acid combined with mecobalamin and alprostadil in patients with DPN is safe and effective.

  7. 前列地尔注射液联合百令胶囊治疗儿童急性肾衰竭的临床研究%Clinical study on Alprostadil Injection combined with Corbrin Capsules in treatment of children with acute renal failure

    Institute of Scientific and Technical Information of China (English)

    陈少秀; 张秋芳; 何华琼

    2016-01-01

    Objective To observe the clinical effect of Alprostadil Injection combined with Corbrin Capsules in treatment of children with acute renal failure.Methods Children (244 cases) with acute renal failure in Shiyan Taihe Hospital in Hubei from June 2014 to January 2016 were randomly divided into conventional, alprostadil, Corbrin Capsules and combination groups, and each group had 61 cases. The children in the conventional group were given timely treatment to remove the etiology. The children in alprostadil group were iv administered with Alprostadil Injection on the basis of the conventional group, 5μg added into normal saline 100 mL, and the dropping speed was 5 ng/(kg·min), once daily. The children in the Bailing Capsules werepo administered with Corbrin Capsules on the basis of the conventional group, 3 grains/time, three times daily. The treatment method in the combination group was the combination of the medication of alprostadil and Corbrin Capsules groups. The children in four groups were treated for 2 weeks. After treatment, the efficacy was observed, and hs-CRP, IL-6, and the changes ofβ2-MG, mALB, UAER, SOD, LDH5, MDA, Scr, BUN, and Cys-C levels in four groups were compared.Results After treatment, the efficacies in the conventional, alprostadil, Corbrin Capsules, and combination groups were 86.88%, 90.16%, 91.80%, and 98.36%, respectively, and the efficacies in the alprostadil and Corbrin Capsules groups were significantly higher than that in the conventional group (P < 0.05). And the efficacy in the combination group was significantly higher than those in the alprostadil and Corbrin Capsules groups (P < 0.05). After treatment, UAER, mALB, andβ2-MG in four groups were significantly decreased (P < 0.05). And those indexes in the alprostadil, Corbrin Capsules, and combination groups were significantly lower than those in the conventional group (P < 0.05). After treatment, those indexes in the combination group were significantly lower than those in the

  8. The observation of the curative effect of compound α - Ketoacid tablets combined with Alprostadil injection treatment of stage 3 chronic kidney disease%复方α-酮酸联合前列地尔注射液治疗3期慢性肾脏病疗效观察

    Institute of Scientific and Technical Information of China (English)

    孔刚; 骆青; 刘翠珍; 吕学爱

    2015-01-01

    目的:观察复方α-酮酸联合前列地尔注射液治疗3期慢性肾脏病(CKD)的疗效。方法将140例3期慢性肾脏病患者随机分为4组,即阴性对照组、复方α-酮酸对照组、前列地尔对照组、复方α-酮酸联合前列地尔治疗组。阴性对照组采用 CKD 常规方法进行治疗,复方α-酮酸对照组在常规治疗的基础上加入复方α-酮酸5片,每日3次口服,前列地尔对照组在常规治疗的基础上加入前列地尔10μg,入壶,静脉点滴,每日一次,联合治疗组在常规治疗的基础上加入复方α-酮酸5片,每日3次口服,前列地尔10μg 入壶,静脉点滴,每日一次。14天为1个疗程,1个疗程后观察患者血肌酐、尿素氮和内生肌酐清除率(Ccr)的变化。结果4组均可降低患者血肌酐、尿素氮和提升内生肌酐清除率(CCr )和血红蛋白(Hb),具有统计学意义,但联合治疗组指标变化更显著(P <0.05)。结论复方α-酮酸联合前列地尔注射液治疗3期慢性肾脏病具有叠加效应,临床效果显著,值得在临床上推广使用。%Objective:To observe the effect of compound α - Ketoacid tablets combined with Alprostadil injection treat-ment of stage 3 chronic kidney disease(CKD3). Methods:140 patients with stage 3 chronic kidney disease patients were randomly divided into 4 groups,the negative control group,the compound α - Ketoacid tablets control group,the Alpros-tadil injection control group,and the compound α - Ketoacid tablets combined with Alprostadil injection treatment group. The negative control group with conventional treatment methods of CKD,the compound α - Ketoacid tablets control group on the basis of routine treatment and compound α - Ketoacid tablets 5 tablets,orally 3 times a day,the Alprostadil injec-tion control group on the basis of conventional treatment with alprostadil 10μg,into the pot,the intravenous drip,once a day,The combined

  9. 前列地尔对急性脑梗死患者血清β淀粉样蛋白水平及神经功能的影响%Effects of alprostadil on serum levels of β-amyloids and neurological impairment in patients with acute cerebral infarction

    Institute of Scientific and Technical Information of China (English)

    周永; 林森; 赵连东

    2015-01-01

    目的:探讨前列地尔治疗对急性脑梗死患者血清β淀粉样蛋白(1-40)、(1-42)[Aβ(1-40)、Aβ(1-42)]水平及神经功能的影响。方法选择急性脑梗死患者84例,分为前列地尔组及对照组各42例,前列地尔组给予静脉滴注前列地尔10μg/d,每日1次,共治疗14天;对照组不使用前列地尔,其他治疗相同。两组患者分别于治疗前、治疗后14天和28天测定静脉血 Aβ(1-40)、Aβ(1-42)水平并评价神经功能缺损程度。结果治疗前两组间血清 Aβ(1-40)、Aβ(1-42)及 Aβ(1-40)/Aβ(1-42)比值差异无统计学意义(P >0.05)。治疗后14天、28天,前列地尔组 Aβ(1-40)及 Aβ(1-40)/Aβ(1β-42)比值逐步降低(P <0.001),Aβ(1-42)于治疗后14天升高(P <0.05)。对照组 Aβ(1-40)和 Aβ(1-42)水平无显著改变(P >0.05)。两组神经功能缺损情况均较治疗前明显改善,与对照组相比,治疗组改善更明显(P <0.01)。结论前列地尔可以降低急性脑梗死后血清 Aβ(1-40)水平,降低血清 Aβ(1-40)/Aβ(1-42)比值。对急性脑梗死神经功能缺损有更好的改善作用。%Objective To investigate the effects of alprostadil on serum levels of A β1-40 and Aβ1-42 and neurological impair-ment in patients with acute cerebral infarction .Methods Eighty-four patients with acute cerebral infarction were enrolled within 48 h of onset.The enrolled patients were randomly divided into alprostadil and control groups .Alprostadil was infused at a dose of 10 μg, once daily for 14 days while the control group received similar treatment except alprostadil infusion .Blood samples were collected before treatment and 14 and 28 days after treatment to measure changes of serum levels of A β1-40 and Aβ1-42.Meanwhile,the degree of neu-rological impairment was estimated

  10. TanshinoneIIA and Alprostadil treatment acute time brain blocks the clinical curative effect%丹参酮域A 联合前列地尔治疗急性脑梗死的临床研究

    Institute of Scientific and Technical Information of China (English)

    邵志坚; 庄大和; 王俊松

    2014-01-01

    目的探讨丹参酮域A联合前列地尔治疗急性脑梗死的临床疗效。方法 急性脑梗死患者143例,随机分为治疗组(72例)及对照组(71例)。对照组给予丹参酮域A50mg加入到生理盐水250ml静滴,1次/天,连用10天。治疗组在对照组的基础上给前列地尔注射液10滋g加入到生理盐水10ml静脉注射,1次/天,连用10天。观察两组治疗前后临床疗效、神经功能缺损评分(采用美国国立卫生研究院卒中量表NIHSS评定)和日常生活能力评分(BI)的变化并进行对比分析。结果 两组患者治疗后临床疗效、神经功能缺损评分(NIHSS)和日常生活能力评分(BI)的变化差异有显著性(P<0.05),临床疗效治疗组明显优于对照组。结论 丹参酮域A联合前列地尔治疗急性脑梗死临床疗效显著,能有效改善神经功能缺损症状,提高日常生活能力。%Objective Discussing TanshinoneIIA and Alprostadil treatment acute time brain blocks the clinical cura-tive effect. Method 143 cases of acute cerebral infarction patients were randomly divided into treatment group (72 cases) and control group (71 cases). Control group given tanshinoneIIA 50mg join the physiological salt, 250 ml static drops, 1 time/day, stay for 10 days. Treatment group on the basis of the control group of alprostadil injection 10μg,including into physiological salt 10 ml intravenous, 1 time/day, stay for 10 days. Observe two groups before and after treatment clinical curative effect, neural function defect score ( in the United States national institutes of health stroke scale, NIHSS evaluation) and changes in the daily life ability score ( BI) and were analyzed. Result Two groups of patients after treatment clinical curative effect and neural function defect score ( NIHSS) scores and daily life ability score (BI) the change of the difference was statistically significant (P<0. 05), Results of clinical efficacy of the treatment group significantly better than the

  11. The Effect of Combined Alprostadil with Micardis in Treating Early Diabetic Nephropathy%前列地尔联合美卡素治疗早期糖尿病肾病疗效观察

    Institute of Scientific and Technical Information of China (English)

    李青山; 黄灿茂

    2015-01-01

    Objective To discuss the clinical effect of combined Alprostadil with Micardis in treating early diabetic nephropathy.Methods 66 inpatients with early diabetic nephropathy were divided into three groups randomly: PGE1 treatment group (n=22), Micardis treatment group (n=22) and combined treatment group (n=22), to compare respectively the change of blood glucose, urea nitrogen, serum creatinine, urine creatinine, quantitative test of 24 h urinary protein and urinary microalbumin level of three groups after 4 weeks clinical observation and treatment.Results After 4 weeks treatment, quantitative test of 24 h urinary protein, urinary microalbumin and other medical indicators of all three groups were clearly improved than before (P﹤0.01); quantitative test of 24 h urinary protein and urinary microalbumin of combined treatment group were much more improved than the other two groups (P﹤0.01).Conclusion Apply of combined Alprostadil with Micardis in treating early diabetic nephropathy could work out a different mechanism of synergistic effect, reduce urinary protein, and help better slowing down the occurrence and the development of diabetic nephropathy into mid-stage and end-stage renal disease.%目的:探讨前列地尔(PGE1)联合美卡素在治疗早期糖尿病肾病(DN)中的临床疗效。方法收集住院66例早期DN患者,随机分为前列地尔组22例,美卡素组22例,联合组22例,进行4周临床观察治疗,分别比较三组血糖、尿素氮、血肌酐、尿肌酐、24 h尿蛋白定量、尿微量白蛋白水平的变化。结果治疗4周后,各组24 h尿蛋白定量及尿微量白蛋白等指标较治疗前均有明显好转(P﹤0.01);而联合组的24 h尿蛋白定量及尿微量白蛋白较另两组改善更显著(P﹤0.01)。结论前列地尔联合美卡素治疗早期DN,能有效地发挥不同机理的协同作用,减少尿蛋白,更有助于延缓DN向中末期肾病发生和发展。

  12. The Effects of Alprostadil on Serum iNOS and TNF-α of Septic Rats%前列地尔对脓毒症大鼠血清iNOS和TNF-α表达的影响

    Institute of Scientific and Technical Information of China (English)

    杨建平; 翁金森; 林静萍; 林建东

    2012-01-01

      目的研究前列地尔对脓毒症大鼠血清中 iNOS 和 TNF-α表达的影响。方法45只 wistar 大鼠随机等分为前列地尔组、脓毒症组和对照组。脓毒症模型则以盲肠结扎穿孔(CLP)来构建,对照组行除 CLP 外的相同手术。前列地尔组于制模前1h 尾静脉注射注射前列地尔10μg/kg,对照组和脓毒症组则分别静脉注射平衡液5mL/kg,术后每隔8h 同样给药一次。术后12、24h 尾静脉采集血标本检测血清中 iNOS 和 TNF-α水平。结果前列地尔组大鼠血清中 iNOS 和 TNF-α表达水平低于脓毒症组且有显著意义。结论前列地尔可能通过调节 iNOS 和 TNF-α表达量从而起到对脓毒症脏器的保护作用。%  Objective  To study the effects of alprostadil on serum iNOS and TNF-α of septic rats. Methods 45 wistar rats were randomly divided into the alprostadil group, sepsis group and control group. Septic model was induced by cecal ligation and puncture (CLP).The rats of control group were made by the same surgery except CLP. Rats of alprostadil group were injected alprostadil 10μg/kg 1h before surgery. The rats of control group and sepsis group were injected intravenously with balanced salt solution 5mL/kg. And then rats of three groups were made by the same administration every eight hours. Blood samples were collected through tail vein 12 and 24 hours after surgery. And then the serum of iNOS and TNF-α levels were detected. Results The iNOS and TNF-α levels of alprostadil group were significantly lower than those in the sepsis group. Conclusion Alprostadil may through regulating the expression of iNOS and TNF-α expression levels to play a protective effect on organs of septic rats.

  13. Effect of alprostadil deliberate hypotension on heart rate variability in elderly patients%前列地尔控制性降压对老年患者心率变异性的影响

    Institute of Scientific and Technical Information of China (English)

    舒爱华; 陈小波; 占乐云; 王强; 方海滨; 吕恩

    2011-01-01

    bjective To clarify the heart rate variability (HRV) changes in patients subjected to deliberate hypotension with alprostadil.Methods Eighty-six elderly patients scheduled for nasal endoscopic surgery in general anesthesia were divided into alprostadil group (group A) and nitroglycerin group (group N) with 43 cases each by random digits table.Hypotension was induced with alprostadil and nitroglycerin through continuous infusion respectively,and the mean arterial pressure (MAP) was reduced to about 25%-30% of baseline MAP.The MAP,heart rate (HR),total power ( TP ),low frequency (LF),high frequency (HF),and LF/HF were continuously monitored and blood was taken for analysis of lactate (LAC) before deliberate hypotension (T0),at the time of dropping to target blood pressure (T1),at 5 and 30 min after deliberate hypotension (T2 and T3),stopping deliberate hypotersion (T4) and 30 min after recovery from hypotension (T5).Results HR at T1-T4 was faster than that at T0in group N(P < 0.05),and faster than that in group A( P < 0.05 ),HR at T5 was faster than that at T0 in group N( P < 0.05 ),but HR was stable at T1-T5 in group A (P > 0.05 ).There was no significant difference in LAC of group A and group N whether in interior group or between two groups (P> 0.05).TP,LF and HF at T1-T4 were lower than those at T0 in two groups ( P < 0.05 ),HF at T1-T4 was higher in group A than that in group N(P < 0.05 ) ; LF/HF was no change at T1-T4 compared with that at T0 in group A (P > 0.05),but increased in group N (P < 0.05 ) which was higher than that in group A at the same time ( P < 0.05 ) ;TP,LF and HF was recovered at Ts in two groups,and HF at T5 in group A was higher than that in group N( P < 0.05 ) ; LF/HF at T5 in group A maintained the level at T0,but decreased in group N and lower than that at T5 in group N(P < 0.05).Conclusion Alprostadil for deliberate hypotension is more likely to maintain cardiac autonomic nerve balance that is helpful for

  14. 前列地尔注射液与麝香保心丸联合治疗冠心病心绞痛的疗效观察%Observation of the curative effect on Alprostadil Injection combined with Shexiang Baoxin Wan on angina pectoris

    Institute of Scientific and Technical Information of China (English)

    宋国良; 裴兆辉; 漆满英

    2012-01-01

    目的 观察前列地尔注射液与麝香保心丸联合应用对冠心病心绞痛的治疗效果.方法 将120例心绞痛患者采用随机单盲对照法分为三组,对照组给予口服硝酸酯类、阿司匹林、他汀类调脂、β受体拮抗剂和钙离子拮抗剂等常规治疗药物.麝香保心丸组在对照组基础上加用麝香保心丸口服(2丸,每日3次),前列地尔组在麝香保心丸治疗组基础上加用前列地尔注射液(10 μg,静脉滴注,每日1次).治疗10 d后观察三组临床、心电图疗效.结果 前列地尔组临床疗效总有效率(95.0%)高于麝香保心丸组(80.0%)及对照组(57.5%),差异有统计学意义(P < 0.05).前列地尔组心电图疗效总有效率(82.5%)高于麝香保心丸组(60.0%)及对照组(40.0%),差异有统计学意义(P < 0.05).结论 前列地尔联合麝香保心丸治疗心绞痛疗效好.%Objective To observe the therapeutic effect of Alprostadil Injection combined with Shexiang Baoxin Wan on angina pectoris. Methods 120 patients with angina pectoris were randomly divided into 3 groups with random single-blind contrast method. The patients in control group (38 cases) were given conventional treatment including Aspirin, statins tune es -ter, P receptor antagonists and calcium channel blockers. The patients in Shexiang Baoxin Wan group (42 cases) were giv -en Shexiang Baoxin Wan per os (2 pills, three times a day) in addition to the conventional treatment. The patients in Al -prostadil group were given Alprostadil (10 |xg intravenous push, one time a day). The patients in 3 groups were observed for 15 days to check the efficacy of treatment and ECG changes. The clinical effects and ECG curatives were recorded after treatment for 15 days. Results The clinical total effective rate in Alprostadil group (95.0%) was higher than those of Shexiang Baoxin Wan group (80.0%) and control group (57.5%), the difference was significant (P < 0.05). The total effective rate of ECG in

  15. 前列地尔联合糖皮质激素治疗急性视神经炎的临床观察%Clinical observation of alprostadil combined with glucocorticoids on acute optic neuritis

    Institute of Scientific and Technical Information of China (English)

    范可顺; 邵新香; 周雷

    2015-01-01

    AIM:To study the clinical effect of alprostadil combined with glucocorticoids in the treatment of acute optic neuritis( AON) . METHODS: Seventy patients (70 eyes) with AON from January, 2012 to June, 2014 were randomly divided into two groups. 35 patients in observation group were used 10ug alprostadil with 10mL normal saline ( NS ) by intravenous injection, once/d for 7d/one treatment course, and 10mL NS was used by intravenous injection in 35 patients of control group. Besides, the two groups were treated with the combined therapy as follows:20mg methylprednisolone was injected periglomerularly beside the eyeballs, once /3d for 3 times; 800 ~ 1 000mg of methylprednisolone through intravenous drip for 3d, once/d; after 3d, oral administration of prednisone acetate for 1wk, 1mg/( kg · d ); after 1wk, the dose decreased to 5mg/wk until withdraw. Simultaneously, oral administration of ranitidine capsules, calcium carbonate and vitamin D3 tablets were combined in the supportive treament. The differences of curative effect between two groups were comparatively analyzed. RESULTS:In the observation group, 25 eyes (71. 4%) were markedly effective, 7 eyes (20. 0%) were valid and 3 eyes (8. 6%) were invalid, and the total effective rate was 91. 4%. In the control group, 15 eyes ( 42. 9%) were markedly effective, 14 eyes ( 40. 0%) were valid and 6 eyes ( 17. 1%) were invalid, and the total effective rate was 82. 9%. The difference of total effective rate between the two groups was not statistically significant (P=0. 477), but there was a significant difference in markedly effective rate between the two groups (χ2=5. 833, P=0. 016). CONCLUSION:Alprostadil combined with glucocorticoids is effective for AON, and it is worth of advocation.%目的:探讨前列地尔联合糖皮质激素综合治疗急性视神经炎的临床疗效。  方法:将我院2012-01/2014-06急性视神经炎住院患者70例70眼随机分组,观察组35例给予前列地尔10μg入10m

  16. 前列地尔联合尼麦角林治疗后循环缺血性眩晕的临床疗效观察%Clinical Effect of Alprostadil Combined with Nicergoline on Posterior Circulation Ischemic Vertigo

    Institute of Scientific and Technical Information of China (English)

    刘涛

    2015-01-01

    目的:观察前列地尔联合尼麦角林治疗后循环缺血性眩晕( PCIV)的临床疗效。方法选取2013年10月—2014年10月武汉市第十一医院收治的128例PCIV患者,随机分为观察组65例和对照组63例。两组患者入院后给予阿司匹林肠溶片、他汀类药物、钙离子拮抗剂等常规治疗。对照组患者在常规治疗基础上给予尼麦角林治疗,观察组患者在对照组基础上联合前列地尔治疗。比较两组患者治疗第3天、第7天临床疗效,治疗前、治疗第3天、治疗第7天眩晕障碍调查表( DHI)评分,治疗前、治疗第7天左侧椎动脉、右侧椎动脉、基底动脉流速,不良反应发生情况。结果治疗第3天、第7天观察组患者临床疗效均优于对照组( P﹤0.05)。治疗前两组患者DHI评分比较,差异无统计学意义(P﹥0.05);治疗第3天、第7天观察组患者DHI评分均低于对照组(P﹤0.05)。治疗前两组患者左侧、右侧椎动脉及基底动脉流速比较,差异无统计学意义( P﹥0.05);治疗第7天观察组患者左侧、右侧椎动脉及基底动脉流速均高于对照组(P﹤0.05)。两组患者均未出现明显肝功能异常、血肌酐升高等不良反应。结论前列地尔联合尼麦角林治疗PCIV的临床疗效确切,能有效改善患者生活质量及椎动脉系统血流动力学,减轻患者焦虑情绪。%Objective To investigate the clinical effect of alprostadil combined with nicergoline on posterior circulation ischemic vertigo( PCIV). Methods A total of 128 patients with PCIV were selected in the Eleventh Hospital of Wuhan from October 2013 to October 2014,and they were randomly divided into observation group(n=65)and control group(n=63). Patients of both groups were given conventional treatment,including aspirin enteric tablets,statins,calcium channel blockers and so on after admission, patients of control group were given extra nicergoline

  17. Effect of alprostadil combined with Sanqi Panax Notoginseng Injection on proteinuria in early diabetic nephropathy%前列地尔联合血塞通注射液对早期糖尿病肾病尿蛋白的影响

    Institute of Scientific and Technical Information of China (English)

    王春花

    2015-01-01

    ABSTRACT:Objective To observe the effect of alprostadil combined with Sanqi Panax Notoginseng Injection on renal function and proteinuria in early diabetic nephropathy.Methods A total of 85 patients with early diabetic nephropathy were divided randomly into four groups,including 20 patients in control group,20 patients treated with alprostadil 10 μg daily for 14 days,22 patients treated with Sanqi Panax Notoginseng Injection 4 ml daily for 14 days and 23 patients treated with alprostadil 10 μg combined with Sanqi Panax Notoginseng Injection 4 ml daily for 14 days. The control group only got management of blood glucose,blood pressure and blood lipid.Results In the treating group (alprostadil group,Sanqi Panax Notoginseng Injection group and the combination treatment group),the levels of 24-h urinary proteinuria,microalbuminuria,blood and urine β2-MG significantly reduced after treatment (P <0.05 ).In the treating group,the levels of 24-h urinary proteinuria,microalbuminuria and urine β2-MG significantly reduced as compared with the control group (P < 0.01 );Blood β2-MG also significantly reduced in the alprostadil group and Sanqi Panax Notoginseng Injection group than in the control group (P <0.05),and more reduced in the combination treatment group (P < 0.01 ); In the combination treatment group, the levels of 24-h urinary proteinuria, microalbuminuria,blood and urine β2-MG were significantly decreased as compared with alprostadil and Sanqi Panax Notoginseng Injection group (P < 0.05 ).Conclusion Both alprostadil and Sanqi Panax Notoginseng Injection may decrease proteinuria in patients with early diabetic nephropathy,while combination treatment may be more prominent but without significant effect on the urea nitrogen and creatinine.%目的:探讨短期静脉应用前列地尔联合血塞通注射液对早期糖尿病肾病患者肾功能及尿蛋白的影响。方法选取血糖、血压稳定的早期糖尿病肾病患者85例,随机分为对照组20

  18. 前列地尔联合水化治疗对老年患者经皮冠状动脉介入治疗术后对比剂肾病的预防作用%Preventive Effect of Alprostadil Combining Hydration Therapy on Contrast-induced Nephropathy After Percutaneous Coronary Intervention in Elder Patients

    Institute of Scientific and Technical Information of China (English)

    雷靖祎; 常海霞; 廖菽丹; 马锋

    2015-01-01

    Objective: To investigate the preventive effect of alprostadil (prostaglandin E1) combining hydration therapy on contrast induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in elder patients. Methods: A total of 175 patients with coronary artery disease (CAD) elder than 75 years received PCI in our hospital from 2011-03 to 2014-03 were retrospectively studied, those including 122/175 (69.71 %) with male gender. The patients were at the mean age of (74.7 ± 3.9) years and randomly allocated into 2 groups: Control group, based on routine treatment, the patients received regular hydration of intravenous normal saline 1 ml/(kg•h) at 6 hours prior and 12 hours after PCI,n=84 and Alprostadil+hydration group, based on routine treatment and regular hydration, the patients received intravenous alprostadil 10μg in 100ml normal saline twice a day at 1 day prior PCI and the 3rd day after PCI,n=91. The serum levels of creatinine (SCr) were examined prior PCI and 3 days continuously after PCI, creatinine clearance rates (Ccr) were calculated and the CIN occurrence rates were compared between 2 groups. Results: At the 3rd day after PCI, the mean SCr level in Alprostadil+hydration group (92.08 ± 21.65) μmol/L was lower than Control group (99.43 ± 22.77) μmol/L,P<0.05, the mean Ccr level in Alprostadil+hydration group (63.78 ± 20.58) ml/min was higher than Control group (57.09 ± 22.31) ml/min,P<0.05. The occurrence rate of CIN after PCI was higher in Control group (13.1%, 11/84 patients) than Alprostadil+hydration group (3.3%, 3/91 patients),P<0.05. Conclusion: Alprostadil combining hydration therapy may obviously protect renal function and reduce the incidence rate of CIN in elder CAD patients after PCI treatment.%目的:探讨前列地尔(前列腺素E1)联合水化治疗对老年冠心病患者行经皮冠状动脉介入治疗(PCI)术后对比剂肾病(CIN)的预防作用。方法:选择2011-03至2014-03我院收治的175

  19. Clinical evaluation of Yiqifumai combined with Alprostadil in the treatment of cardiac insufficiency with unstable angina pectoris%益气复脉联合前列地尔治疗老年人心功能不全伴不稳定心绞痛的临床观察

    Institute of Scientific and Technical Information of China (English)

    赵春杰; 曹明英; 姚朱华

    2014-01-01

    Objective To assess the therapeutic effects of Yiqifumai combined with Alprostadil injection on patients with chronic cardiac insufficiency and angina pectoris.Methods One hundred and fifty patients with heart dysfunction (NYHA [Ⅱ-Ⅲ) and angina pectoris were randomly divided into three groups,the control group (n=50),the Yiqifumai group (n=50),and the Yiqifumai plus Alprostadil group (n=50).Parameters including clinical effectiveness,electrocardiograph (ECG),heart function and hemodynamics were evaluated.Results The overall clinical effectiveness rate in the Yiqifumai plus Alprostadil group (94 %) was higher than those in the Yiqifumai group (78 %) and the control group (54%) (P<0.05 for both).The overall effectiveness rate in ECG changes was higher in the Yiqifumai plus Alprostadil group (84%) than in the Yiqifunai group (58%) and the control group (42%) (P<0.05 for both).While no significant difference in the left ventricular ejection fraction (LVEF) was found among the three groups before treatment,evident improvement in LVEF was observed in the Yiqifunai group and the Yiqifumai plus Alprostadil group 14 days after treatment,compared with pre-treatment data [(49±9)% vs.(40±10)% and (59±9)% vs.(41±10) %,respectively; P<0.05 for both].However,there was no significant difference between the two groups (P>0.05).There was no improvement in LVEF in the control group after treatment (P >0.05).No difference in hemodynamic parameters,including cardiac output,cardiac index and left ventricular stroke work index,was found among the three groups before treatment (P>0.05),but they showed improvement in the Yiqifunai group and the Yiqifumai plus Alprostadil group after treatment (P<0.05 for both),with greater improvement in the latter group.The improvement was not significant in the control group before and after treatment (P>0.05).Conclusions Yiqifumai combined with Alprostadil in the treatment of cardiac insufficiency with

  20. To Observe the Curative Effect of the Combination of Captopril Tablets and Alprostadil Injection in Treating Diabetic Nephropathy%卡托普利片、前列地尔注射液联合应用治疗糖尿病肾病的疗效观察

    Institute of Scientific and Technical Information of China (English)

    袁峰

    2015-01-01

    目的:探讨卡托普利片联合前列地尔注射液治疗糖尿病肾病临床应用效果。方法对照组在常规治疗基础上加用卡托普利片,研究组在常规治疗基础上加用卡托普利片、前列地尔注射液联合治疗,两组糖尿病肾病患者均持续治疗2周后,记录其临床疗效及不良反应发生情况,将所得资料经专业统计学分析后获得结论。结果两组糖尿病肾病患者治疗前各项肾功能指标对比,P>0.05;两组BUN、UAER、24 h尿蛋白定量、Scr均较之前降低,但研究组改善效果优于对照组, P<0.05;研究组不良反应发生率为17.07%略高于对照组12.20%,P>0.05。结论对糖尿病肾病患者给予卡托普利、前列地尔注射液可提高其疗效,有利于保障患者生活质量及生命安全。%Objective To investigate the captopril tablets combined alprostadil injection clinical effect in treating diabetic nephropathy. Methods Control group in the on the basis of routine treatment with captopril tablets, study group on base of routine treatment plus captopril tablet, alprostadil injection combined with treatment, two groups of patients with diabetic nephropathy (DN) continued to two weeks of treatment, the recorded incidence of the clinical efifcacy and adverse reactions, the income data after statistical analysis professional conclusion. Results Before the renal function indexes were compared with the treatment of two groups of patients with diabetic nephropathy (DN), P>0.05, bun, UAER, 24 h urine protein, SCR were compared to the previous decreased signiifcantly, but the study group was signiifcantly better than that of the control group (P0.05. Conclusion In patients with diabetic nephropathy given captopril, alprostadil injection can signiifcantly improve the therapeutic effects, is conducive to protect the quality of life of patients and life safety.

  1. The clinical observation of the efficacy of mecobalami, alprostadil, and extract of ginkgo biloba leaves combination therapy in elderly diabetic peripheral neuropathy%弥可保、凯时和金纳多联合治疗老年糖尿病周围神经病变的临床观察

    Institute of Scientific and Technical Information of China (English)

    王炜; 王晓湘; 张汝; 李改丽; 王建

    2012-01-01

    目的 了解弥可保、凯时和金纳多联合治疗在改善糖尿病患者周围神经疼痛及感觉异常方面的作用,为临床治疗糖尿病周围神经病变提供参考.方法 以老年Ⅱ型糖尿病患者伴周围神经病变为研究对象,给予弥可保、凯时和金纳多联合治疗,动态观察患者的局部神经疼痛、感觉异常和神经传导速度的改善情况.结果 共纳入54例临床诊断为Ⅱ型糖尿病伴周围神经病变的患者.在给予联合治疗4周后,54例患者中分别有24例(44.4%)和25例(46.3%)患者的局部自发痛或(和)感觉异常缓解程度达到了临床显效和有效的标准,而仅5例(9.3%)患者的局部不适无改善.结论 弥可保、凯时和金纳多联合治疗对改善老年糖尿病周围神经病变疗效显著.%Objective To investigate the efficacy of mecobalami, alprostadil, and extract of ginkgo biloba leaves combination therapy in reducing pain and paresthesia of diabetic patients and provide a reference for the clinical treatment of diabetic peripheral neuropathy. Methods The elderly type 2 diabetic patients with peripheral neuropathy were given mecobalami, alprostadil, and extract of ginkgo biloba leaves treatment, and the improvement of local nerve pain, paresthesia and nerve conduction velocity were dynamically observed. Results A total of 54 elderly type 2 diabetic patients with peripheral neuropathy were included in this study. After giving 4 weeks of combination therapy, there were 24 (44. 4%) and 25 (46. 3%) patients respectively, whose local spontaneous pain or paresthesia remission degree reached to markedly effective standard and effective standard; and only 5 patients had no improvement on local discomfort. Conclusion The combination therapy of mecobalami, alprostadil, and extract of ginkgo biloba leaves could significantly improve the remission of diabetic peripheral neuropathy.

  2. 大剂量前列地尔治疗重度黄疸型病毒性肝炎的临床疗效%The clinical efficacy of large dose of alprostadil in the treatment of severe icteric viral hepatitis

    Institute of Scientific and Technical Information of China (English)

    张亚利

    2016-01-01

    Objective:To analyze the clinical efficacy of large dose of alprostadil in the treatment of severe icteric viral hepatitis. Methods:107 patients with severe icteric viral hepatitis were selected.They were divided into the control group with 47 cases and the study group with 60 cases.The control group was given glutathione,diammonium glycyrrhizinate and Yinzhihuang conventional drug treatment,while the research group was treated with high dose of alprostadil drug on the basis of the control group.The liver function indexes and adverse reactions of the two groups were compared.Results:The liver function index of the study group was significantly better than that of the control group,and the difference was statistically significant(P<0.05).Conclusion:Patients treated by glutathione,diammonium glycyrrhizinate and Yinzhihuang combined with alprostadil can improve liver function index, with no significant adverse reactions.%目的:分析大剂量前列地尔治疗重度黄疸型病毒性肝炎的临床疗效。方法:收治重度黄疸型病毒性肝炎患者107例,分设为对照组47例与研究组60例,对照组予以还原型谷胱甘肽、甘草酸二胺以及茵栀黄常规药物医治,研究组于此基础上增用大剂量前列地尔药物医治,比对两组肝功能指标以及不良反应情况。结果:研究组肝功能指标优于对照组,差异具有统计学意义(P<0.05)。结论:患者行还原型谷胱甘肽、甘草酸制剂以及茵栀黄联合前列地尔药物医治可改善肝功能指标,无明显不良反应。

  3. Therapeutic effect of alprostadil combined with sulodexide in treatment of stage-Ⅳ diabetic nephropathy%前列地尔联合舒洛地特治疗Ⅳ期糖尿病肾病的疗效观察

    Institute of Scientific and Technical Information of China (English)

    张海红; 谭晓军

    2015-01-01

    目的:观察前列地尔联合舒洛地特治疗Ⅳ期糖尿病肾病的疗效。方法收集2014年1月至11月本科室住院的Ⅳ期糖尿病肾病患者86例,随机数字法分为治疗组(n=45)与对照组(n=41)。两组患者均进行严格糖尿病饮食控制,口服舒洛地特250 LSU,2次/d;14 d后治疗组此基础上加用前列地尔20μg加入生理盐水100 ml中静脉滴注,2次/d,持续10 d后结束治疗。治疗前后两组患者的收缩压、舒张压、糖化血红蛋白、血清肌酐、尿微量白蛋白、尿蛋白定量、尿白蛋白排泄率等指标进行组内和组间比较。结果治疗前两组患者的收缩压、舒张压、糖化血红蛋白、血清肌酐、尿微量白蛋白、尿蛋白定量、尿白蛋白排泄率差异均无统计学意义(均P>0.05)。与治疗前比较,治疗后两组患者的尿微量白蛋白、尿蛋白定量、尿白蛋白排泄率均降低(均P0.05). After treatment,the both groups showed reduction in microalbuminuria,urinary protein quantity and UAER, as compared with pretreatment(all P<0.05);and compared with the control group,the treatment group show more dramatical reduction in these indexes (all P<0.05). Conclusion Combination treatment with alprostadil and sulodexide for diabetic nephropathy can be more effective in improving the patient outcomes.

  4. 前列地尔联合益气活血化痰通络汤治疗下肢动脉硬化闭塞症的临床观察%Clinical observation of alprostadil combined with Yiqi Huoxue Huatan Tongluo Decoction in treating arteriosclerosis obliterans

    Institute of Scientific and Technical Information of China (English)

    龚伟强; 徐小平

    2015-01-01

    目的:观察前列地尔联合益气活血化痰通络汤治疗下肢动脉硬化闭塞症的临床疗效。方法将60例下肢动脉硬化闭塞症门诊及住院患者按照随机数字表法随机分为治疗组与对照组,每组各30例,将口服肠溶阿司匹林的实验组设为对照组,静脉输注前列地尔,治疗组则是在对照组的基础上加用化痰通络汤,疗程为4周。观察2组患者观察患者的临床症状、血管功能[踝肱指数( ankle-brachial index,ABI)]、低密度脂蛋白胆固醇( low density lipoprotein-cholesterol,LDL-C)、血清总胆固醇( total cholesterol, TC),血液流变学指标包括全血粘度、纤维原蛋白、肝肾功能及不良反应。结果治疗组总有效率为93.33%优于对照组的73.33%( P<0.05),治疗组踝肱指数( ABI)改善优于对照组,治疗组TC、LDL-C、高切全血粘度、低切全血粘度、纤维原蛋白改善均优于对照组(均P<0.05)。结论活血化痰通络方联合前列地尔治疗下肢动脉硬化闭塞症疗效优于单纯前列地尔治疗。%Objective To observe the clinical effect of alprostadil combined with Yiqi Huoxue Huatan Tongluo Decoction in treating arteriosclerosis obliterans.Methods 60 cases of lower extremity arteriosclerosis occlusion disease outpatient and hospitalized patients were randomly divided into treatment group and control group according to the random number table method, each group were 30, the oral administration of enteric coated aspirin experimental group is set to control group intravenous injection of alprostadil treatment for 4 weeks, the treatment group was treated with Huatan Tongluo Decoction on the basis of the control group.The clinical symptoms, blood vessel function (ABI),low density lipoprotein-cholesterol (LDL-C), total cholesterol( TC) were observed in the two groups of patients, and blood rheology indexes included whole blood viscosity, fibrinogen

  5. 前列地尔干乳剂联合甲钴胺胶囊治疗糖尿病周围神经病变的临床观察%Clinical Observation of Alprostadil Dry Emulsion Combined with Mecobalamin Capsules in the Treatment of Diabetes Peripheral Neuropathy

    Institute of Scientific and Technical Information of China (English)

    刘红梅

    2011-01-01

    目的:观察前列地尔干乳剂联合甲钴胺胶囊治疗糖尿病周围神经病变的疗效.方法:选择82例糖尿病周围神经病变患者,随机分为试验组(前列地尔+甲钴胺)41例,对照组(甲钴胺)41例,均用门冬胰岛素30特充控制血糖,试验组给予前列地尔干乳剂10μg·d-1+甲钴胺胶囊0.5mg,tid;对照组给予甲钴胺胶囊0.5mg,tid,2组疗程均为3周,观察其对神经传导速度的影响.结果:试验组总有效率为88%,对照组总有效率为54%,2组疗效比较差异有显著性(P<0.01).试验组对神经传导速度的改善明显优于对照组,2组疗效比较差异有显著性(P<0.01).2组均未见明显不良反应.结论:前列地尔干乳剂联合甲钴胺胶囊治疗糖尿病神经病变疗效优于单独使用甲钴胺.%OBJECTIVE: To observe the therapeutic efficacy of Alprostadil dry emulsion combined with Mecobalamin capsules in the treatment of diabetes peripheral neuropathy. METHODS: 82 patients with diabetes peripheral neuropathy were randomly assigned to observation group (alprostadil and mecobalamin, 41 case) and control group (mecobalamin, 41 case). Insulin aspart 30 injection was used to control plasma glucose in 2 groups. Both groups received Mecobalamin capsules 0.5 mg three times a day and observation group were additionally treated with Alprostadil dry emulsion 10 μg·d-1 for three weeks. The therapeutic efficacy and nerve conduction velocity (SNCV, MNCV) of 2 groups were observed. RESULTS: Total effective rate was 88% for observation group and 54% for control group. There was significant difference (P<0.01). The improvement of nerve conduction velocity in observation group was better than control group, there was significant difference between 2 groups (P<0.01). No serious adverse drug reactions were found in 2 groups. CONCLUSION: Alprostadil dry emulsion combined with Mecobalamin capsules is better than mecobalamin alone in the treatment of diabetes peripheral neuropathy.

  6. 前列地尔干乳剂对糖尿病肾病动静脉内瘘血管流量的影响%Application of Alprostadil Dry Emulsion in Diabetic Nephropathic Arteriovenous Fistulation

    Institute of Scientific and Technical Information of China (English)

    罗敬河; 刘春慧; 王湘川; 刘宏敏

    2015-01-01

    【目的】探讨注射用前列地尔干乳剂对糖尿病肾病造瘘血管血流量的影响。【方法】选择本院收治的糖尿病肾病终末期肾衰行血液透析的患者46例,随机分为A组和B组,均行桡动脉‐头静脉端端吻合术。A组患者术后予常规换药处理;B组术后给予注射用前列地尔干乳剂10μg静脉注射,共10 d。采用彩色血管多普勒超声每隔3 d检查两组患者吻合口血流量,观察比较其变化。【结果】①治疗10d后彩色多普勒超声检查A组血流量为31957 mL/min;B组血流量为42572 mL/min ,B组内瘘血流量血明显高于A组,且两组相比较差异有显著性( P <0.05)。②A组有12例术后出现内瘘处血流减弱,血管震颤减弱、血管杂音降低,发生率为52.17%(12/23),经保守治疗同时加强前臂功能锻炼1周后好转;B组有2例术后d3出现血管震颤及血管杂音减弱,发生率为8.69%(2/23),明显低于A组,且两组相比较差异有显著性( P<0.05)。2例患者加强功能锻炼2 d后好转;有1例术后次日出现术肢肿胀,瞩其抬高患肢,1周后肿胀逐渐消失。两组均未发现切口感染及术区渗漏液体情况。【结论】注射用前列地尔干乳剂有预防糖尿病肾病动静脉内瘘术后狭窄或闭塞,增加血流量、提高手术成功率的作用。%[Objective] To explore the application of alprostadil dry emulsion in patients with diabetic nephro‐pathic arteriovenous fistulation .[Methods] A total of 46 diabetics with chronic renal failure were divided into groups A and B .Both groups underwent radial artery‐cephalic vein standard fistulation .Group A received conven‐tional treatment after operation while group B group had an intravenous injection of alprostadil 10 μg for 10 days . And the anastomotic flow was observed once by color vascular Doppler ultrasound every 4 days .[Results] Color Doppler

  7. 前列地尔序贯疗法治疗老年临床糖尿病肾病期患者的疗效观察%Clinical effect of sequential therapy with alprostadil and beraprost in elderly patients with clinical diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    王珊珊; 常宝成; 单春艳; 孔岩; 卢军; 郑妙艳; 杨菊红; 任惠珠; 王颖

    2014-01-01

    目的 观察前列地尔注射液与贝前列素钠片序贯疗法对于老年临床糖尿病肾病(DN)期患者的临床疗效、安全性及影响. 方法 将老年临床期DN患者90例随机分为3组,对照组30例,常规治疗4周;前列地尔组30例,常规+前列地尔注射液治疗2周后,继续常规治疗2周;序贯治疗组30例,常规+前列地尔注射液治疗2周,常规+贝前列素钠片治疗2周.比较治疗前后24 h尿微量白蛋白(UMA)、总蛋白、肾血流、尿6酮-前列素F1α(6 keto-PGF1α)及血栓素B2的变化情况.结果 治疗4周后,前列地尔组和序贯治疗组UMA和总蛋白水平均较治疗前明显下降,两组UMA分别下降9.7%比25.6%,总蛋白分别下降16.0%比35.0%,序贯治疗组下降更明显(均P<0.05).两组主肾动脉(MRA)阻力指数(RI)、段动脉(SRA) RI和叶间动脉(IRA) RI在治疗后均明显下降,序贯治疗组下降更明显(MRA RI:6.8%比8.2%,SRA RI:5.8%比9.7%,IRA RI:6.3%比9.1%),差异均有统计学意义(均P<0.05).两组6-keto-PGF1α均上升,分别为(261.4±43.9)ng/24 h比(288.7±39.7)ng/24 h、(251.9±47.6)ng/24 h比(313.7±50.2)ng/24 h;两组尿血栓素B2均下降,分别为(172.4±33.5)ng/24 h比(152.1±31.6)ng/24 h、(177.3±28.8)ng/24 h比(130.6±34.7)ng/24 h,而序贯治疗组上述指标上升的改变更加明显(均P<0.05).对照组治疗前后变化差异无统计学意义. 结论 前列地尔注射液与贝前列素钠片序贯疗法可能通过改善老年临床期DN患者肾血流以及血栓素A2和前列腺素I2的平衡,降低尿蛋白,且具有较好的安全性.%Objective To observe the curative effect and safety of the sequential therapy with alprostadil injection and beraprost sodium tablets in elderly type 2 diabetic patients on the stage of clinical diabetic nephropathy.Methods 90 elderly T2DM patients on clinical diabetic nephropathy stage were randomly divided into 3 groups:control group(conventional therapy for 4 weeks,n=30

  8. 苦碟子注射液联合前列地尔治疗后循环缺血性眩晕的临床观察%Clinical Observation of Kudiezi Injection Combined with Alprostadil in the Treatment of Posterior Circula-tion Ischemic Vertigo

    Institute of Scientific and Technical Information of China (English)

    任钦; 戎立辉

    2015-01-01

    OBJECTIVE:To observe the clinical efficacy and safety of Kudiezi injection combined with alprostadil in the treat-ment of posterior circulation ischemic vertigo. METHODS:Totally 180 patients with posterior circulation ischemia were randomly divided into group A,group B and group C. All patients were given aspirin,atorvastatin,nutrition nerve,antihypertensive,hypo-glycemic and other conventional treatment. On this basis,group A was given Alprostadil injection 10 μg,adding into 0.9% Sodium chloride injection 100 ml,iv,once a day;Kudiezi injection 30 ml,adding into 0.9% Sodium chloride injection 250 ml,iv,once a day. Group B was given Alprostadil injection(the same usage as group A);group C was given Kudiezi injection(the same usage as group A). The course was 14 d. The clinic data was observed,including clinical efficacy;blood flow velocity in left vertebral ar-tery(LVA),blood flow velocity in right vertebral artery(RVA),blood flow velocity of basilar artery(BA),changes of peak laten-cy(PL)and incubation period latency(IPL)before and after treatment;and the incidence of adverse reactions. RESULTS:The to-tal effective rate in group A was significantly higher than group B and C,with significant difference(P0.05). There were no obvious adverse reactions during treatment. CONCLUSIONS:Kudiezi injection combined with alprostadil has better effica-cy than only Kudiezi injection or alprostadil in the treatment of posterior circulation ischemic vertigo,with good safety.%目的:观察苦碟子注射液联合前列地尔治疗后循环缺血性眩晕的临床疗效和安全性。方法:180例后循环缺血患者随机均分为A、B、C组。所有患者均给予拜阿司匹林、阿托伐他汀、营养神经、降压、降糖等常规治疗。在此基础上,A组患者给予前列地尔注射液10μg,加入0.9%氯化钠注射液100 ml中,静脉滴注,每日1次+苦碟子注射液30 ml,加入0.9%氯化钠注射液250 ml中,静脉滴注,每日1次;B组

  9. Observation of the clinical effect of alprostadil combined with granisetron in the treatment of dizziness after cerebellar infarction%前列地尔联合格拉司琼治疗小脑梗死后眩晕的疗效观察

    Institute of Scientific and Technical Information of China (English)

    曾彪; 阙清松; 孙军德

    2016-01-01

    Objective To investigate the clinical treatment effect of alprostadil combined with granisetron in the treat‐ment of dizziness after cerebellar infarction ,so as to provide reference basis for the clinical study .Methods Forty patients with cerebellar infarction from 2011 to 2014 in our hospital were chosen .They were randomly divided into the treatment group (al‐prostadil combined with granisetron group )of 20 cases and control group(simply alprostadil group)of 20 cases .The clinical o‐verall treatment effect ,Barthel index and Berg balance scale score of the two groups were observed and compared .Results The total efficiency rates of two groups were compared ,the rate of treatment group was higher than that of control group ,the difference was significant(P<0.05) .The differences of the Barthel index and Berg balance scale score of two groups before the treatment were not significant .After treatment ,the above indicators of the two groups after the treatment were significantly in‐creased ,the differences were significant(P<0.05) .After treatment ,the above indicators of treatment group after the treatment were significantly higher than those of control group ,the differences were significant(P<0.05) .Conclusion The symptoms of vertigo of alprostadil combined with granisetron in the treatment of dizziness after cerebellar infarction can be significantly im‐proved ,and the combination therapy can improve clinical effect .%目的:探讨前列地尔联合格拉司琼治疗小脑梗死后眩晕的临床效果。方法选取2011—2014年我院收治的小脑梗死后眩晕患者40例为研究对象,随机分成治疗组和对照组各20例,分别给予前列地尔联合格拉司琼治疗和单纯前列地尔治疗。观察2组临床治疗效果、Barthel指数评分和Berg平衡量表评分。结果临床总有效率组间比较,治疗组高于对照组,差异有统计学意义(P<0.05)。治疗前2组Barthel指数评分和Berg平衡量表

  10. 肾康注射液联合前列地尔治疗糖尿病肾病的临床效果系统评价%Efficacy of Shenkang injection combined with alprostadil in treatment of diabetic nephropathy:A systematic review

    Institute of Scientific and Technical Information of China (English)

    祁佳; 唐跃年; 张宇锋; 夏清青; 江卫龙

    2015-01-01

    Objective To systematically evaluate the clinical efficacy and safety of Shenkang injection combined with alprostadil in treatment of diabetic nephropathy .Methods Meta-analysis was used .The literatures of randomized clinical trials ( RCTs) on Shenkang injection combined with alprostadil for diabetic nephropathy in EMBASE , PUBMED, MED-LINE, AMED, CINAHL, Cochrane Library , China National Knowledge Infrastructure Database , Chongqing VIP Chinese Science and Technology Periodical Database , Chinese Biomedical Literature Database and Wanfang Database from the in-ception of each database up to 25 January 2015 were electronically searched .The Cochrane risk of bias tool was used to as-sess the risk of bias .We assessed the quality of included studies using the Jadad rating scale .The Cochrane Collaboration's RevMan5.3 software was used for meta-analysis.All the patients had diabetic nephropathy .Patients in the treatment group were treated with Shenkang injection combined with alprostadil on the basis of the conventional treatment .Patients in the control group was treated with the conventional treatment or the use of other drugs based on the conventional treatment or Shenkang injection alone based on the conventional treatment or alprostadil alone based on the conventional treatment .Re-sults Eleven studies were included and made a meta-analysis.When we compared the treatment group with the control group, the odds ratio(OR) of total efficiency rate was 3.00, 95% confidence interval (CI) was 1.57 to 5.57, and the difference was statistically significant (P=0.00 09);24-hour urinary albumin mean difference (MD) was -0.11, 95%CI[-0.18 to -0.04], and the difference was statistically significant (P=0.002);24-hour urinary micro albumin MD was -122.13, 95%CI[-185.24 to -59.01], and the difference was statistically significant (P=0.000 1);serum cre-atinine MD was -28.07, 95%CI[-35.91 to -20.24], and the difference was statistically significant (P<0.000 01);blood urea nitrogen

  11. Observation of curative effect on Lipid Microsphere Alprostadil in acute cerebral infarction combined type 2 diabetes%脂微球前列地尔治疗急性脑梗死合并2型糖尿病的效果观察

    Institute of Scientific and Technical Information of China (English)

    李莉; 田发发

    2013-01-01

    Objective To observe the effect of Lipid Microsphere Alprostadil in treating acute cerebral infarction combined type 2 diabetes.Methods 60 patients with ACI combined type 2 diabetes in Xiangya Hospital of Central South University from August 2011 to July 2012 were randomly divided into two groups.The treatment group was given Lipid Microsphere Alprostadil combined with routine treatment and the control group was merely given routine treatment for 14 days.National institutes of health stroke scale (NIHSS), Barthel Index (BI), hemorheology indexes, effective ratio were measured before and after treatment respectively.Results MHSS, BI in the treatment group reached to (4.50±3.11), (3.18±2.29) points and (59.78±19.6), (70.16±20.12) points after 7 and 14 days respectively, which had statistically significant differences compared with those before treatment and the control group (P < 0.05).Hemorheology indexes were (4.6±0.4) mPa·s, (1.91±0.32) mPa·s, (0.53±0.03), (2.1±0.5), (5.3±2.0 ) g/L in the treatment group after 14 days treatment, the data all had statistically significant differences compared with before treatment and control group after treatment (P < 0.05).Overall effective rate in the treatment group was 93.3%, which was higher than control group (76.7%), with a significant difference (P < 0.05).Conclusion Lipid Microsphere Alprostadil plus routine therapy can effectively improve the nerve function of patients with acute cerebral infarction combined type 2 diabetes and decrease the blood viscosity as well.This kind of drug is of high reliability and security.%目的 观察脂微球前列地尔治疗急性脑梗死合并2型糖尿病的临床疗效.方法 选择中南大学湘雅医院2011年8月~2012年7月收治的脑梗死合并2型糖尿病患者60例,随机分为两组,应用脂微球前列地尔加常规治疗为治疗组,常规药物治疗为对照组.比较治疗前后两组患者神经功能缺损评分(NIHSS)、Barthel指数(BI)评分、

  12. Effect of alprostadil combined wih glycyrrhizin in treatment of severe chronic cholestatic hepatitis B and its affect on serum biochemical indexes%前列地尔联合复方甘草酸苷治疗重度慢性乙型肝炎合并淤胆的疗效及对血清生化指标的影响

    Institute of Scientific and Technical Information of China (English)

    张海燕; 范晖

    2014-01-01

    目的:探讨前列地尔联合复方甘草酸苷治疗重度慢性乙型肝炎合并淤胆的临床疗效。方法将92例重度慢性乙型肝炎合并淤胆患者采用数字表法随机分为两组,两组均给予复方甘草酸苷注射液,另外观察组在此基础上加用前列地尔,比较两组临床疗效及血清生化指标变化。结果观察组总有效率为89.13%,显著高于对照组(76.09%)(χ2=7.83,P<0.05);观察组治疗后总胆红素(TBIL)、直接胆红素(DBIL)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转肽酶(γ-GT)和碱性磷酸酶(AKP)指标分别为(68.78±7.82)μmol/L、(54.64±6.68)μmol/L、(64.57±8.97)IU/L、(59.62±7.34)IU/L和(60.23±8.22)IU/L,均显著低于治疗前[(265.63±11.78)μmol/L、(138.49±11.29)μmol/L、(557.62±21.23)IU/L、(157.72±10.31)IU/L 和(170.38±11.20)IU/L](t=11.23、10.42、10.63、9.88、10.68,P<0.05)和对照组[(153.68±8.62)μmol/L、(137.44±9.31)μmol/L(、152.02±12.33)IU/L(、114.82±9.21)IU/L和(106.83±9.01)IU/L](t=8.38、8.01、7.92、8.30、7.20,P<0.05)。结论前列地尔联合复方甘草酸苷治疗重度慢性乙型肝炎合并淤胆具有显著疗效。%ObjectiveTo investigate the effect of alprostadil combined wih glycyrrhizin in treatment of severe chronic cholestatic hepatitis B.Methods92 patients with severe chronic cholestatic hepatitis B combined were divided into two groups by using a random number table metod. Two groups were given glycyrrhizin injection while the observation group were treated with alprostadil in addton. The clinical efifcacy and serum biochemical parameters changes were compared between the two groups.ResultsThe observation group's total effective rate was 89.13%, signiifcantly higher than the control group's 76.09% (χ2=7.83,P<0.05);The observation group's indicators of TBIL, DBIL, ALT, γ-GT and AKP after treatment were (68

  13. 凯时对急性脑梗死患者血清丙二醛、超氧化物歧化酶、过氧化氢酶水平的影响%Effect of Alprostadil injection on serum MDA, SOD and CAT in patients witha cute cerebral infarction

    Institute of Scientific and Technical Information of China (English)

    颜玮茹; 廖春梅

    2015-01-01

    目的:观察前列地尔注射液对急性脑梗死患者血清过氧化氢酶( CAT)、丙二醛( MDA)、超氧化物歧化酶( SOD)的影响,探讨其神经保护作用机制。方法将120例急性脑梗死患者随机分为实验组和对照组,每组60例,同时选取健康体检者60例作为健康组。实验组给予前列地尔注射液静滴,对照组给予丹参注射液静滴,均1次/d,连用10 d。在治疗前及治疗3,7,14 d测定血清中MDA、SOD和CAT水平,并对患者进行欧洲卒中评分( ESS)及日常生活能力Barthel指数( BI)疗效评定。结果实验组和对照组治疗前MDA水平高于健康组(P<0.01),SOD、CAT水平低于健康组(P均<0.01)。对照组治疗后MDA水平无明显变化(P>0.05),实验组MDA治疗后明显低于治疗前(P<0.05)。实验组治疗后血清SOD、CAT活力逐渐上升,均明显高于对照组(P均<0.05)。实验组治疗后第7天、第14天ESS和BI评分均优于对照组(P均<0.05)。结论前列地尔注射液通过降低血清MDA含量,提高CAT和SOD活性,从而改善神经细胞功能。%Objective It is to observe the effect of Alprostadil injection on serum malondialdehyde(MDA),superoxide dis-mutase(SOD) and catalase(CAT) in patients with acute cerebral infarction, and discuss the nerve protection mechanism. Methods 120 cases with acute cerebral infarction were randomly divided into experimental group and control group, 60 cases in each group, and 60 cases of healthy persons were selected as healthy group.The experimental group was given Alprostadil intravenous drip infusion and the control group was given Danshen injection by intravenous drip infusion once per day, and both groups were treated for 10 days.The serum levels of MDA, SOD and CAT were measured before treatment and after treat-ment for 3 days, 7 days and 14 days.Therapeutic efficacy was evaluated by the European Stroke Scale( ESS

  14. Effect of concomitant Low-frequency neural muscular electric stimulation and alprostadil on the lower limb functions of acute ischemic infarction:an observational study%低频神经肌肉电刺激联合前列地尔改善急性缺血性脑卒中患者下肢运动功能的临床观察

    Institute of Scientific and Technical Information of China (English)

    张士森

    2014-01-01

    Objective To observe the effect of concomitant low-frequency neural muscular electric stimulation (NMES)and alprostadil on the motion and balance in paralysis patients with acute ischemic infarction (AIS ).Methods 82 cases with AIS admitted in Ningjin Country People's Hospital,from August 2008 to August 2013 were divided into three groups.Conventional treatment group (n =26)were received conventional rehabilitation,NMES control group (n=30)were received conventional rehabilitation+NEMS(4 times a day,every 15 min)and observation group were received conventional rehabilitation+NEMS(4 times a day,every 15 min)+alprostadil (2 mL+10 mL normal saline intravenously slowly,1 times a day),all patients were treated for three weeks.Ankle dorsi-flexors tension were evaluated by comprehensive spasm scale (CSS).The ankle dorsiflexion and plantar flexor of top isometric voluntary contraction (TIVC)were tested by surface electromyography(sEMG).Quantitative detection of“integrator”EMG and the cooperative shrinkage rate of muscles were detected to evaluate patients'balance level and walking ability.Results Each index score of patients in three groups before treatment had no difference.3 weeks after treatment,the ankle plantar flexion muscle spasm in patients of observation group were aggravating,and CSS had increased highest,there were significant differences with other two groups(P<0.05).After treatment, the ankle back of MIVC pretibial muscle were increased in all three groups,which were respectively 10 ±6 nm,6 ±4 nm,5 ±4 nm.When ankle dorsiflexion,co-contraction rate were significantly lower,respectively at (9 ±0.5)%,(28 ±0.27)%,(27 ±0.19)%.3 weeks treatment,patients in observation group walk to restore balance and walking force time was 3~4 d ahead than two control groups.Conclusion Low frequency electric stimulation combined alprostadil can improve the movement function in AIS hemiplegia patients.%目的:观察前列地尔联

  15. 刺五加注射液联合前列地尔治疗4期糖尿病肾病%Clinical Study on the Effect of Acanthopanex Injection Combined with Liposomal Alprostadil in the Treatment of Stage-Ⅳ Diabetic Nephropathy

    Institute of Scientific and Technical Information of China (English)

    盖云; 张彤

    2011-01-01

    Objective-To study the effect of Acanthopanex Injection combined with Hposomal alprostadil(Lipo-PG El) in the treatment of stage-Ⅳ diabetic nephropathy. Methods: A Prospective comparative study method was utilized in this clinical trial. 70 diagnosed cases were divided into groups, study group (35 cases) and control group (35cases). On the base controlling of blood glucose and pressure, the control group were injected liposomal alprostadi, while the the study group were injected Acanthopanex Injection combined with liposomal alprostadi. With a course of 2 weeks, 24 hours urinary protein, serum creatinine and the levels of hemorheology indexes were analyzed for evaluation before and after treatment. Results: After the treatment, the effect on TCM syndrome of the study and control group were 82. 86% and 48. 57% , respectively(P0. 05) ,but there were significant difference of the two groups with intra-group comparison (P<0. 05). Conclusions: Acanthopanex Injection combined with liposomal alprostadi on the base treatment can de-creace urine protein excretion and the level of serum creatinine, and this method may be a potential treatment strategy on the process of stage-Ⅳ diabetic nephropathy progressing into end-stage renal disease.%目的:观察刺五加注射液联合前列地尔治疗4期糖尿病肾病的临床疗效.方法:对70例4期糖尿病肾病病例分为研究组(35例)与对照组(35例).对照组给予常规疗法控制血糖、血压,同时采用前列地尔静脉滴注.研究组在对照组用药基础上加用刺五加注射液静脉滴注,2周后观察2组临床疗效、24 h尿蛋白定量、血清肌酐、血液流变学等指标的变化情况.结果:治疗后研究组与对照组中医症侯疗效分别为82.86%和48.57% (P<0.05),西医临床疗效分别为57.14%和29.63%(P<0.05).研究组治疗后24 h尿蛋白量、血肌酐明显降低(P<0.05).2组治疗前患者血液流变学无显著差异;治疗后研究组指标优于

  16. Effectiveness of Combined Treatment with Alprostadil Injection and Danhong Injection on Posterior Circulation Ischemic Vertigo%前列地尔联合丹红注射液治疗后循环缺血性眩晕的效果研究

    Institute of Scientific and Technical Information of China (English)

    单翠红; 王思箭

    2013-01-01

    Objective To investigate and assess the the therapeutic effect of combined treatment with Alprostadil injection and Danhong Injection on posterior circulation ischemic vertigo. Methods 136 Patients who had been treated in our hospital suffered from posterior circulation ischemic vertigo from January 2012 to June 2012 were randomly sampled and divided into two groups,the experiment group were treated with Alprostadil injection and Danhong Injection and the controlled group was treated with Xuesetong injection,the efficacy was observed after 14 days treatment. Results 46 cases were cured,10 markedly effective,7 effective and 5 ineffective in the experiment group,and the corresponding figures were 31,7,10 and 20 in the controlled group,total effective rates in experiment group and controlled group were 92.65%and 70.59%,respectively ,showing significant difference between two groups(P<0.05). The mean time of initiation of effect in experiment group and controlled group show significant difference,(4.3±1.2) d and (7.4±1.5)d,separately. Conclusion The effectiveness of Alprostadil injection combine Danhong Injection in the treatment of posterior circulation ischemic vertigo has the benefits of reacting fast and showing better therapy effect,thus worthy popularization in clinical application.%  目的 观察前列地尔联合丹红注射液对后循环缺血性眩晕的治疗效果.方法 选取2012年1月至2012年6月就诊于我院的后循环缺血性眩晕患者136 例,分为两组,实验组采用前列地尔联合丹红注射液治疗后循环缺血性眩晕,对照组采用血塞通治疗,14d后评效.结果 实验组痊愈46例,显效10例,有效7例,无效5例,总有效率92.65%.对照组患者痊愈31例,显效7例,有效10例,无效20例,总有效率70

  17. Evaluate of the Equivalence and Safety of Two Dosage Form of Alprostadil Injection in Patients with Diabetic Lower Extremity Arterial Occlusive Dis-ease by a Clinical Multi-Centre Trial%两种前列地尔注射液治疗糖尿病下肢动脉闭塞症的等效性和安全性比较研究

    Institute of Scientific and Technical Information of China (English)

    张星光; 虞冠锋; 冉兴无; 刘福平; 吕肖锋; 朱旅云; 刘俊江; 吕伯南; 刘超; 刘长建; 王立明

    2015-01-01

    目的:观察2种前列地尔注射液在治疗糖尿病下肢动脉闭塞症(糖尿病足)的等效性和安全性。方法:采用随机双盲、阳性药平行对照、多中心临床研究。试验组使用前列地尔脂微球注射液,对照组使用前列地尔注射液。疗程均为14 d。结果:随机入组235例受试者。对照组入选117人,试验组118人。主要疗效指标中踝肱比值,全分析数据集(full analysis set,FAS)人群组内比较:两组治疗14 d后踝肱比值均较基线时有所提高,且有统计学意义。组间比较:治疗14 d后对照组提高0.09;试验组提高0.10,两组间无统计学意义,符合方案数据集(per-protocol set, PPS)人群结果趋势和FAS一致。两组治疗14 d后静息痛均较基线时有所下降,且有统计学意义,组间比较无统计学差异,PPS人群结果趋势和FAS一致。最大无痛行走距离在两组间无统计学意义,PPS 结果和FAS一致。全部不良事件发生率对照组为19.33%;试验组为17.65%。相关不良事件对照组10.08%;试验组为8.4%;差别无统计学意义。结论:2种前列地尔注射液在治疗慢性下肢动脉闭塞性疾病的过程中,表现出相同的疗效和安全性。%Objective: To compare the equivalence and safety between reference preparation and test preparation of alprostadil injection in patients with chronic lower extremity arterial occlusive disease (LEAOD). Methods: It was a random, blind, multicentre and controlled clinical pharmaceutical trial. All subjects were divided into two groups and each of group. The test and reference preparations of alprostadil injections by different companies were given via the same administration route. Results: Eight hospitals in China and 235 volunteers were involved in the study, and 117 patients received the reference preparation and 118 received the test preparation. The ankle brachial index of both groups increased significantly

  18. [Effect of alprostadil on serum level of miRNA-155 
in uremic patients].

    Science.gov (United States)

    Zhang, Wei; Shi, Linjing; Zhang, Hao; Wang, Chen; Gao, Shan; Ma, Yarong; Li, Wei; Liu, Jian; Wang, Jinwei; Liu, Jishi

    2015-07-01

    目的:观察尿毒症透析患者外周血血清microRNA-155(miR-155)的表达水平及前列地尔(alprostadil,A)对其的影响,探讨miR-155在尿毒症透析患者炎症状态中的临床意义。方法:按研究标准纳入慢性肾脏病尿毒症患者81例,其中腹膜透析组(PD组)20例,腹膜透析+前列地尔治疗组(PD+A组)20例,维持性血液透析组(HD组)21例,维持性血液透析+前列地尔治疗组(HD+A组)20例,另设健康人群对照组(NC组)16例。采集各观察对象外周血并提取血清,采用实时荧光定量PCR技术检测血清中miR-155的表达水平,ELISA检测血清IL-6水平。收集各观察对象的一般临床资料并检测血脂、血红蛋白、白蛋白、超敏C-反应蛋白、血清铁蛋白等血液生化指标。结果:4组透析患者血清miR-155及IL-6水平均显著高于NC组(P<0.05);PD+A组miR-155水平较PD组或HD组显著下调(P<0.05),PD+A组及HD+A组血清IL-6水平均低于PD组或HD组(P<0.05)。相关分析显示:血清miR-155水平与炎症因子IL-6水平呈显著正相关(P<0.01);同时,血清miR-155水平与超敏C-反应蛋白水平呈正相关,而与HDL及白蛋白水平呈负相关(P<0.01);血清白蛋白与miR-155呈独立负相关,超敏C-反应蛋白与miR-155呈独立正相关。结论:尿毒症患者外周血清miR-155和IL-6表达水平明显上调;前列地尔可能通过抑制IL-6表达改善尿毒症透析患者炎症状态;血清miR-155有可能成为尿毒症透析患者炎症状态早期诊断及干预的新靶点。.

  19. Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review

    OpenAIRE

    Anaissie J; Hellstrom WJG

    2016-01-01

    James Anaissie, Wayne JG Hellstrom Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA Abstract: Erectile dysfunction (ED) is a common and debilitating disorder seen in over 50% of men older than 70 years. Oral phosphodiesterase type 5 (PDE5) inhibitors are the mainstay of treatment for ED, but cannot be used by a significant subset of patients due to systemic side effects and drug–drug interactions. Second-line therapy may include intracaverno...

  20. Drug: D02705 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02705 Drug Alprostadil alfadex (JP16); Tandetron (TN) (C36H60O30)x. C20H34O5 D0270...219 Miscellaneous 2190 Miscellaneous D02705 Alprostadil alfadex (JP16) 26 Epidermides 269 Miscellaneous 2699... Others D02705 Alprostadil alfadex (JP16) Anatomical Therapeutic Chemical (ATC) c... Prostaglandins C01EA01 Alprostadil D02705 Alprostadil alfadex (JP16) G GENITO URINARY SYSTEM AND SEX HORMON...E01 Alprostadil D02705 Alprostadil alfadex (JP16) USP drug classification [BR:br08302] Hormonal Agents, Stim

  1. Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia–reperfusion injury in rats

    OpenAIRE

    Erer D; Özer A; Demirtaş H; Gönül İI; Kara H; Arpacı H; Çomu FM; Oktar GL; Arslan M; Küçük A

    2016-01-01

    Dilek Erer,1,* Abdullah Özer,1,* Hüseyin Demirtaş,1 İpek Işık Gönül,2 Halil Kara,3 Hande Arpacı,4 Faruk Metin Çomu,5 Gürsel Levent Oktar,1 Mustafa Arslan,6 Ayşegül Küçük7 1Department of Cardiovascular Surgery, 2Department of Pathology, Gazi University Medical Faculty, 3Department of Pharmacology, Yıldırım Beyazıt University Medical Faculty, 4Department of Oral and Maxillofacial Surgery, Ankara University Faculty of Dentistry, Besevler, An...

  2. The Effects of False Physiological Feeback, on Sexual Arousal in Sexually Functional and Dysfunctional Men

    Science.gov (United States)

    2004-03-31

    constriction device Figure 8. Intraurethral applicator for MUSE ( alprostadil ) drug administration Figure 9. Inflatable penile implant Figure 10...phentolamine, alprostadil , and prostaglandin E1 (PGE1). These treatments are effective for most cases of erectile dysfunction, regardless of etiology. However...sildenafil citrate, alprostadil , and similar drugs or over the counter remedies were reminded not to take these drugs prior to the assessment. This

  3. 前列地尔对慢性右心衰竭的治疗作用观察%Therapeutic effects of alprostadil on chronic right heart failure

    Institute of Scientific and Technical Information of China (English)

    王爱东

    2015-01-01

    目的:探讨前列地尔对慢性右心衰竭(CRHF)的治疗效果及其作用机制.方法:选取本院收治的CRHF患者120例,随机分为观察组与对照组各60例,两组入院均给予CRHF常规治疗,包括小剂量强心剂,应用利尿剂,改善患者通气,应用祛痰、支气管舒张剂及持续低流量吸氧等治疗,观察组在常规治疗的基础上加用前列地尔静脉滴注,20 μg+生理盐水100 mL,每天一次,两周为一疗程;观察两组治疗前及治疗一疗程后B型利钠肽(BNP)、右心室射血分数(RVEF)、肺动脉收缩压(PASP)变化,并对治疗前后两组血液流变学各项指标进行比较.结果:两组治疗前BNP、RVEF、PASP比较,差异无统计学意义(P>0.05);治疗后两组BNP、PASP较治疗前明显下降,RVEF均较治疗前明显上升,差异具有统计学意义(P<0.05);观察组治疗后三项指标改善明显优于对照组,组间比较差异有统计学意义(P<0.05);观察组治疗后肺动脉压(MPAP)、血浆比黏度、全血比黏度、血细胞比容、纤维蛋白原明显低于对照组,差异具有统计学意义(P<0.05).结论:在常规治疗的基础上加用前列地尔治疗,可有效提高CRHF患者RVEF,降低BNP、PASP及血液黏稠度,进而改善患者心脏功能,疗效明显.

  4. The Effect of False Physiological Feedback on Sexual Arousal in Sexually Functional and Dysfunctional Men

    Science.gov (United States)

    2004-01-01

    constriction device Figure 8. Intraurethral applicator for MUSE ( alprostadil ) drug administration Figure 9. Inflatable penile implant Figure 10. Rigiscan device... alprostadil , and prostaglandin E1 (PGE1). These treatments are effective for most cases of erectile dysfunction, regardless of etiology. However, individuals...citrate, alprostadil , and similar drugs or over the counter remedies were reminded not to take these drugs prior to the assessment. This information

  5. The Effect of Feedback on Penile Tumescence in Sexually Functional Men

    Science.gov (United States)

    2003-01-06

    MUSE ( alprostadil ) drug administration Figure 6. Inflatable penile implant Figure 7. Rigiscan device Figure 8. Sbrocco and Barlow’s (1996) model...of treatment are papaverine hydrochloride, phentolamine, and alprostadil . These treatments are effective for most cases of erectile dysfunction...dilate the tonically- closed arterial vessels in the penis. Used by itself, phentolamine is also not very effective. Alprostadil is the third most

  6. Effect of alprostadil injection on lung injury in patients with paraquat poisoning%前列地尔注射液对百草枯中毒患者肺损伤的影响

    Institute of Scientific and Technical Information of China (English)

    吕望; 陈新国; 金焕治; 张雪良

    2012-01-01

    AIM: To investigate the association between the CalpainlO gene polymorphism and the risk of PTDM in Chinese renal allograft recipients. METHODS; Three single nucleotide polymorphisms (CAPN10 gene SNP-19, SNP-43, SNP-63) were genotyped in the cohort, which consisted of 97 renal allograft recipients with PTDM (PTDM group) and 301 renal allograft recipients without PTDM ( control group). The genotypes of polymorphisms were performed by allele specific polymerase chain reaction ( ASPCR ) , PCR-restriction fragment length polymorphism (PCR-RFLP). Logistic regression test was used to identify risk factors for PTDM development and calculate the odds ratio, RESULTS: The 11 and 12 genotypes of SNP-19 and the GG genotypes of SNP-43 were more common in patients with PTDM than those without PTDM (F<0. 05). After adjustments for age, sex, body weight and BMI, the effect of genotype remained significant (11 vs 22, OR = 1.502, 95%CI: 1.016-2.347, P = 0.048; 12 vs 22, OR=1. 764, 95%CI: 1.055 -2.947, P =0. 030) in SNP-19 and the patients carrying gen otype GG had higher risk comparison with carriers with genotype AA or GA(OR = 2. 190, 95% CI: 1.047 -3.473, P = 0. 044) in SNP-43. But SNP-63 was not association with PTDM. CONCLUSION; The 1-allele in SNP-19 and GG genotype in SNP-43 of CAPN10 gene are the independent risk factors of PTDM in Chinese renal allograft recipients.%目的:观察前列地尔注射液对百草枯中毒患者炎症介质和肺损伤的影响,为临床治疗提供参考.方法:30例急性百草枯中毒患者随机分为常规治疗组(对照组)和常规治疗+前列地尔注射液组(试验组),每组15例.前列地尔注射液用法:10 μg加入100 mL生理盐水(NS)静脉滴注,1次/d,连用7d.分别于入院当天及入院后7d测定患者血浆IL-6、IL-8、基质金属蛋白酶-9(MMP-9)浓度,行动脉血气分析和胸部X线检查,并随访生存情况.结果:与对照组比较,入院后7d试验组患者IL-6、IL-8、MMP-9浓度降低,急性肺损伤(ALI)及全身炎症反应综合症发生率降低(P<0.05);两组患者病死率差异无统计学意义(P>0.05).结论:前列地尔注射液可减轻百草枯中毒患者炎症反应和肺损伤.

  7. Acute macular edema following intracorporeal prostaglandin injection for erectile dysfunction

    Directory of Open Access Journals (Sweden)

    Asahi MG

    2015-07-01

    Full Text Available Masumi G Asahi, Calvin Chou, Ron P Gallemore Retina Macula Institute, Torrance, CA, USA Purpose: We aimed to describe the first case of macular edema following intracorporeal injection of alprostadil, a prostaglandin E1. Methods: This was a retrospective case report followed with optical coherence tomography, fundus photos, and fluorescein angiography images. Results: A patient developed bilateral cystoid macular edema following intracorporeal injection of alprostadil, a prostaglandin E1 for treatment of erectile dysfunction. The edema resolved following treatment with nonsteroidal anti-inflammatory drugs (NSAIDs and corticosteroids, with subsequent recovery in visual acuity. Discussion: Systemic prostaglandin administration can cause macular edema and vision loss, indicating that elevated systemic prostaglandin levels may affect visual function. This has potential implications for other systemic disorders and treatments that could affect macular function. Keywords: alprostadil, inflammation

  8. 前列地尔及依帕司他治疗早期2型糖尿病肾病蛋白尿的疗效观察

    Institute of Scientific and Technical Information of China (English)

    阮希成; 蔡奕琪; 肖建宏; 张家永; 金希波

    2012-01-01

      Objective To evaluate the Effect of Alprostadil and Epalrestat on uric protein in patients at early stage of type 2 diabetic nephropathy. Methods 80 patients who have been filmLy diagnosed as early stage of type 2 diabetic nephropathy were chosen and randomLy divided into four groups, namely, Alprostadil group, Epalrestat group, Alprostadil and Epalrestat group,constrast group. After 12 weeks treatments, index such as uric protein were check. Results Alprostadil may lower the uric protein from the patients of early diabetic nephropathy in short term, the combination of Alprostadil and Epalrestat may evidently lower the uric protein from the patients of early diabetic nephropathy. Conclusion The combinated administration of Alprostadil and Epalrestat could obtain better effects in the patients of early diabetic nephropathy.%  目的观察前列地尔、依帕司他治疗早期2型糖尿病肾病的临床效果。方法选取确诊为2型糖尿病早期糖尿病肾病患者,随机分为对照组、前列地尔组、依帕司他组及前列地尔+依帕司他联合组,疗程12周。观察患者治疗前后尿蛋白、血糖、肾功能、血浆白蛋白的变化情况。结果治疗后前列地尔组蛋白尿有明显下降,前列地尔联合依帕司他组蛋白尿下降效果更明显。结论依帕司他联合前列地尔可保护肾功能,控制蛋白尿,值得临床推广使用。

  9. 突发性耳聋的椎-基底动脉DSA表现及经椎动脉内灌注前列地尔治疗的初步研究%Digital Subtraction Angiography Abnormalities in 30 Adults with Sudden Sensorineural Hearing Loss and Evaluation of Alprostadil Injection Into the Vertebral Artery

    Institute of Scientific and Technical Information of China (English)

    刘源; 张勤修; 邓晓筑; 周立; 谢慧; 何春水; 廖华强; 刘洋; 张丽峰; 曾伟

    2010-01-01

    目的 分析突发性耳聋(sudden sensorineural hearing loss,SSNHL)患者椎-基底动脉系统DSA的表现特点及经椎动脉灌注前列地尔的疗效.资料与方法 对30例SSNHL患者分别在两侧椎动脉行DSA检查,分析椎动脉、基底动脉、小脑前下动脉(AICA)、内听动脉的影像学表现,然后经导管在椎动脉灌注前列地尔(平均剂量5μg,灌注时间5 min).术后1周复查听力,观察听力改善情况.结果 30例均成功进行上述检查、治疗,无相关并发症出现.30例中,2例出现一侧椎动脉闭塞,5例椎动脉硬化.分别有23.3%(7/30)的右侧AICA和30.0%(9/30)的左侧AICA呈现缺失或细小改变,63.3%(19/30)的右侧内听动脉和73.3%(22/30)的左侧内听动脉呈现缺失或细小改变.术后纯音听阈测试显示听阈水平(500 Hz、1000 Hz、2000 Hz、4000Hz听阈的平均值)平均升高28.2 dBHL,其中痊愈2例,显效8例,有效15例,无效5例,总有效率83.3%.结论 SSNHL与内听动脉、AICA细小、缺失导致的内耳缺血有关,灌注扩张血管的药物能够改善症状,提高听力.

  10. The Application of Fluorescence Optical Imaging in Systemic Sclerosis

    Directory of Open Access Journals (Sweden)

    Alexander Pfeil

    2015-01-01

    Full Text Available Objective. The aim of this study was to visualize soft tissue inflammation using FOI on patients with Systemic Sclerosis (SSc characterized by SSc-related Raynaud’s phenomenon and to detect the therapeutic response to treatment with iloprost or alprostadil. Methods. Twenty-one patients with SSc and Raynaud’s phenomenon and twenty-six healthy controls were prospectively included. The SSc patients were intravenously treated with iloprost or alprostadil over seven days. FOI was performed at baseline and after seven days using an intravenous application of indocyanine green (ICG. The hands were divided into nineteen segments per hand. All segments were quantitatively evaluated to determine changes in ICG. Results. The sensitivity and specificity of FOI in the detection of ICG enhancement in patients with SSc were 95% versus 96%. At baseline, 31.5% hand segments showed ICG enhancement. After seven days of either iloprost or alprostadil therapy a significant reduction in the ICG was observed which ranged from 40.9% to 24.7%. Conclusion. The study demonstrates that the FOI technique is able to visualize soft-tissue inflammation with both high sensitivity and specificity. The anti-inflammatory therapeutic effects of iloprost were slightly stronger than alprostadil. FOI offers promising benefits in the diagnosis and therapy of patients with SSc-associated Raynaud’s phenomenon.

  11. In vitro hemorheological effects of parenteral agents used in peripheral arterial disease

    Science.gov (United States)

    Biro, Katalin; Sandor, Barbara; Toth, Andras; Koltai, Katalin; Papp, Judit; Rabai, Miklos; Toth, Kalman; Kesmarky, Gabor

    2014-05-01

    Peripheral arterial disease (PAD) is a frequent manifestation of systemic atherosclerosis. In PAD hemorheological parameters were defined as risk factors in a number of studies and several therapeutic agents were tried in these conditions. Our study aims to investigate and compare the in vitro hemorheological effects of various drugs generally used in the parenteral treatment of intermittent claudication and critical limb ischemia. Blood samples of healthy male volunteers were incubated with iloprost, alprostadil, pentoxifylline, sulodexide or pentosan polysulfate at calculated therapeutic serum concentration. Hematocrit (Hct) was determined by microhematocrit centrifuge. Plasma and apparent whole blood viscosities (WBV) were evaluated by capillary viscometer. Red blood cell aggregation was measured by LORCA (laserassisted optical rotational cell analyzer) aggregometer, and LORCA ektacytometer was used for measuring erythrocyte deformability at 37°C. Iloprost, alprostadil, and pentoxifylline incubation did not have any significant effect on plasma and apparent WBV. Elongation index increased in samples incubated with alprostadil at low shear stresses 0.95 and 0.53 Pa (p alprostadil may improve a microrheological parameter. Hemorheological alterations could be important in PAD patients with hampered vasodilator capacity.

  12. Effect of sildenafil in cavernous arteries of patients with erectile dysfunction

    Directory of Open Access Journals (Sweden)

    Claro Joaquim A

    2003-01-01

    Full Text Available INTRODUCTION: Sildenafil citrate is a type 5 phosphodiesterase inhibitor, which has demonstrated excellent results in the treatment of erectile dysfunction. The effect of sildenafil citrate in the cavernous arteries of patients with erectile dysfunction has not been established yet. The objective of this study was to assess the effect of sildenafil citrate in the cavernous arteries of patients with erectile dysfunction, following an intracavernous injection of alprostadil. MATERIALS AND METHODS: 29 male patients, with mean age of 53.8 years (32 to 75 years, were prospectively evaluated. The mean time with complaint of erectile dysfunction was 50.5 months (6 to 168 months. Each patient was his own control. Patients underwent a measurement of peak systolic velocity before and after use of sildenafil citrate associated with 5 micrograms of alprostadil, through ultrasonic velocitometry Knoll/MIDUS® system. In the interval between measurements, approximately 15 days, patients used 3 tablets of sildenafil at home with their partners. RESULTS: Using only 5 mcg of alprostadil, average peak systolic velocity was 23.9 cm/s, and when associated to 50 mg of sildenafil it was 24.8 cm/s. Despite the increase in the flow rate caused by sildenafil, the difference was not statistically significant, Zcalculated = - 0.695 NS (Wilcoxon test. Twenty one of the 29 patients (72.4% showed global improvement in sexual performance with the use of sildenafil citrate at home. There was not a statistically significant correlation between the global response to sildenafil citrate and the increase in the peak systolic velocity. CONCLUSION: We concluded that, even though the use of 50 mg of sildenafil citrate associated with 5 mcg of alprostadil provides an increase in the peak systolic velocity of the cavernous arteries, there was no statistic difference in relation to alprostadil alone. There was no correlation between the global response to sildenafil and the increase in

  13. Treatment of infertility in men with spinal cord injury

    DEFF Research Database (Denmark)

    Brackett, N.L.; Lynne, C.M.; El Dib, Hussein Ibrahim El Desouki Hussein

    2010-01-01

    Most men with spinal cord injury (SCI) are infertile. Erectile dysfunction, ejaculatory dysfunction and semen abnormalities contribute to the problem. Treatments for erectile dysfunction include phosphodiesterase type 5 inhibitors, intracavernous injections of alprostadil, penile prostheses...... of intrauterine insemination increases as the total motile sperm count inseminated increases. In vitro fertilization and intracytoplasmic sperm injection are options in cases of extremely low total motile sperm count. Reproductive outcomes for SCI male factor infertility are similar to outcomes for general male...... factor infertility...

  14. Intra-Arterial Prostaglandin E1 Infusion in Patients with Rest Pain: Short-Term Results

    Directory of Open Access Journals (Sweden)

    A. Chatziioannou

    2012-01-01

    Full Text Available Purpose. To present our results after short-term (1 month intra-arterial infusion therapy of PGE1-alprostadil via a port system implanted in the ipsilateral external iliac artery (EIA in patients with severe rest pain. Methods. Ten patients with severe rest pain were included. All patients showed extensive peripheral vascular disease below the knee. The tip of the catheter was introduced via a retrograde puncture in the ipsilateral external iliac artery (EIA. The patients received intraarterial infusion of PGE1, 20 mgr alprostadil daily, via the port catheter for 1 month. Results. Clinical success was evaluated according to subjective grading of pain (group A significant decrease, group B moderate decrease and group C no response. A significant decrease of rest pain was observed in 8 (group A, 80% patients, a moderate decrease in 2 (Group B, 20%, whereas no patients demonstrated any significant response. Both patients of group B had Buergers' disease and continue to smoke during therapy. No peripheral thrombosis or clinical deterioration was noticed. Conclusion. Intraarterial infusion of PGE1 alprostadil on a daily basis, using a port catheter into the ipsilateral EIA, in selected patients with severe rest pain, seems to be very effective, without any serious complications.

  15. STRUCTURE OF PULMONARY HYPERTENSION IN PATIENTS AWAITING HEART TRANSPLANTATION

    Directory of Open Access Journals (Sweden)

    A. A. Piontek

    2009-01-01

    Full Text Available The selection of recipients for the orthotopic heart transplantation is of great importance. In 2006–2009 we examined 25 tests on reversibility of pulmonary hypertension, i.e. in 14 patients with dilated cardiomyopathy (DCM (11 males and 3 females aged 41,1 ± 9,3 and in 11 patients with coronary artery disease (CAD (all males aged 50 ± 4.9. Initial pulmonary vascular resistance (PVR was 3,61 ± 1,02 and 3,59 ± 0,98 respectively. Alprostadil was infused to all the patients. Pulmonary hypertension was irreversible in 4 (28,5% DCM patients and in 2 (18% CAD patients. Initial PVR in those patients was 6,27 ± 3,2 and 5,7 ± 2,4 respectively. The average alprostadil dose necessary for the reverse of pulmonary hypertension was 0,054 ± 0,027 μg/kg/min in DCM patients, and 0,047 ± 0,022 μg/kg/min in CAD patients. Thus, the application of alprostadil for the pharmacological correction of pulmonary vascular resistance is most effective in patients with moderate pulmonary hypertension according to Rich classification. 

  16. Research on Treatment of Diabetic Nephropathy%糖尿病肾病临床治疗效果研究

    Institute of Scientific and Technical Information of China (English)

    王加军

    2011-01-01

    目的:探讨前列地尔联合缬沙坦治疗糖尿病肾病的临床效果.方法:将2007年1月至2010年12月期间收治的84例糖尿病肾病患者,随机分为三组,前列地尔组在综合治疗的基础上给予前列地尔静滴治疗;缬沙坦组在综合治疗的基础上给予缬沙坦口服治疗;观察组在综合治疗基础上给予前列地尔静滴加缬沙坦口服治疗;观察治疗前后三组患者的24h尿微量白蛋白、血压等指标的改善情况.结果:三组患者治疗后24h尿微量白蛋白均下降(P<0.01),血糖水平控制较理想,均达到或接近理想水平,血压54.8%达到正常水平,29.8%接近正常,15.5%未达标.另外联合治疗组的疗效优于前列地尔组和缬沙坦组,结果具有统计学意义.结论:前列地尔和缬沙坦具有降低蛋白尿、保护肾脏功能的作用,将两者联合应用可提高疗效,延缓病情发展,是治疗糖尿病肾病的一种有效的方法.%Objective: To study alprostadil combined with valsartan in treatment of diabetic nephropathy. Method: Randomly divided 84 diabetic nephropathy patients into three groups during January 2007 to December 2010, alprostadil group was given alprostadil infusion therapy on the basis of the comprehensive treatment; valsartan group in the consolidated valsartan treatment on the basis of oral treatment; the observation group was given combined therapy with alprostadil on the basis of intravenous plus oral treatment of Valsartan; Observed three groups of patients before and after treatment 24h urinary albumin, blood pressure and other indicators of improvement. Result: After treatment, three groups of patients were decreased 24h urinary albumin ( P <0.01 ), better control of blood glucose levels were at or close to the ideal level of blood pressure to normal levels of 54.8%, 29.8% nearly normal, 15.5% were not reached. Another combination therapy was more effective than alprostadil group and valsartan group, the results were

  17. 前列地尔联合缬沙坦治疗糖尿病肾病的临床分析

    Institute of Scientific and Technical Information of China (English)

    黄平

    2014-01-01

    Objective: To evaluate the alprostadil combined effects of valsartan treatment of diabetic nephropathy. Methods: A total of 88 cases of diabetic nephropathy patients were divided into two groups, a control group of 41 patients received only drug alprostadil treatment, observation group, 47 cases accepted alprostadil valsartan drug treatment, comparing two treatment of patients, and urinary protein levels before and after treatment. Results: The study showed that the treatment groups were observed treatment efficiency, there are significant differences compared to the 24h urinary protein and the control group was statisticaly significant (P <0.05). Conclusion: The patients with diabetic nephropathy using alprostadil valsartan drug therapy, can significantly improve the quality of life of patients, the effect is significant.%目的:评价前列地尔联合缬沙坦治疗糖尿病肾病的效果。方法回顾分析我院收治的88例糖尿病肾病患者,均分为两组,对照组41例仅接受前列地尔用药治疗,观察组47例接受前列地尔联合缬沙坦用药治疗,比较两组患者的治疗效果以及治疗前后的尿蛋白水平。结果研究表明,治疗后观察组患者的治疗有效率、24h尿蛋白定量与对照组相比有明显差异,有统计学意义(P<0.05)。结论糖尿病肾病患者采用前列地尔联合缬沙坦用药治疗,有效降低蛋白尿,显著改善患者生活质量。

  18. Current diagnosis and therapy of non-occlusive mesenteric ischemia; Aktuelle Diagnostik und Therapie der nicht okklusiven mesenterialen Ischaemie

    Energy Technology Data Exchange (ETDEWEB)

    Ernst, S.; Fuerst, G. [Inst. fuer Diagnostische Radiologie, Heinrich-Heine-Univ. Duesseldorf (Germany); Luther, B.; Boehner, H.; Wilke, R. [Klinik fuer Gefaesschirurgie und Nierentransplantation, Heinrich-Heine-Univ. Duesseldorf (Germany); Zimmermann, N.; Feindt, P. [Klinik fuer Thorax- und Kardiovaskulaere Chirurgie, Heinrich-Heine-Univ. Duesseldorf (Germany)

    2003-04-01

    Purpose: Non-occlusive mesenteric ischemia (NOMI) is a life threatening disease. Therapy and prognosis depend upon the length of time elapsed between primary clinical manifestation and the time of definitive diagnosis and treatment. Materials and Methods: NOMI was diagnosed by intraarterial selective angiography in four patients. After a bolus administration of 20 g Alprostadil (Prostavasin trademark) into the superior mesenteric artery, intraarterial perfusion was continued with 60 {mu}g Alprostadil/day via the catheter for three days. Results: The mesenteric ischemia resolved in all patients. One patient recovered completely. Three patients recovered from mesenteric ischemia, but died subsequently due to complications of their primary diseases. Conclusion: When NOMI without perforation or necrosis of the bowel wall is suspected clinically, immediate intraarterial angiography is the diagnostic method of choice. If NOMI is confirmed, the appropriate treatment is the intraarterial application of potent vasodilators for several days. The diagnostic work-up in suspected NOMI and the impact of different radiological examinations are explained. The literature is reviewed. (orig.) [German] Einleitung: Die nicht okklusive mesenteriale Ischaemie (NOMI) ist eine lebensbedrohliche Erkrankung. Therapie und Prognose haengen von der Zeitspanne zwischen Auftreten der ersten Beschwerden und Diagnosesicherung ab. Material und Methode: 4 Patienten mit einer NOMI wurden mittels intraarterieller Gabe eines Bolus von 20 {mu}g Alprostadil (Prostavasin trademark) in die A. mesenterica superior und fortgesetzter intraarterieller Infusion von 60 {mu}g Alprostadil pro Tag ueber 3 Tage behandelt. Ergebnisse: Alle 4 Patienten zeigten eine Rueckbildung der mesenterialen Ischaemie. Ein Patient konnte beschwerdefrei entlassen werden. Bei drei Patienten bildete sich die Darmischaemie vollstaendig zurueck, sie verstarben aber im weiteren Verlauf an Komplikationen der Grunderkrankung

  19. Nanocapsular forms of preparations in preclinical studies

    Directory of Open Access Journals (Sweden)

    Ekaterina Grinevich

    2010-07-01

    Full Text Available The paper examines preclinical study of nanocapsule deliverysystem, particularly the influence of nanocapsule with a vasodilatorin the process of programmed myocardial cells death. Isosorbidedinitrate was loaded in nanocapsules. To investigate the effectnanocapsule isosorbide dinitrate on the process of apoptosis incardiomyocytes, a series of experimental works wereperformed. For this purpose, a model of coronary insufficiency in 4groups of animals were elaborated. The experimental works onlaboratory animals were conducted in accordance withrequirements of the European Convention for the protection ofvertebrate animals. The first preclinical trials showed the presenceof specific activity of obtained drugs. The basis of nanocapsularsystem was phosphatidylinositol, and the active loading substanceswere alprostadil, interferon alpha.

  20. 前列地尔治疗高血压伴肾损害66例疗效观察

    Institute of Scientific and Technical Information of China (English)

    张爱萍

    2002-01-01

    @@ 前列地尔(alprostadil)具有扩张血管、抑制血小板凝聚、保护多脏器血管内皮细胞及改善微循环障碍等多种药理作用[1],临床多应用于治疗心、脑血管及呼吸系统疾病.本研究旨在探讨其对高血压伴肾损害的临床疗效.

  1. Pharmacotherapy of erectile dysfunction: Current standards

    Directory of Open Access Journals (Sweden)

    Kew-Kim Chew

    2006-01-01

    Full Text Available Pharmacotherapy is currently the therapeutic option of choice for erectile dysfunction. Comprising mainly intracavernosal injection therapy using alprostadil or alprostadil combined with phentolamine and/or papaverine and oral phosphodiesterase-5 inhibitors, it is safe and effective if appropriately prescribed and administered. The medications in current use produce satisfactory erectile responses by enhancing cavernosal vasodilatation mainly through their ability to promote relaxation of the smooth muscle cells in the corpora cavernosa involving the synthesis and activity of nitric oxide via the cyclic guanosine monophosphate and cyclic adenosine monophosphate biochemical pathways. The main side-effects and complications of intracavernosal injections are postinjection pain, prolonged erections, priapism and penile fibrosis. There may be a variety of side-effects with phosphodiesterase-5 inhibition but these are usually inconsequential. Recent serious ill health and the need for ongoing long-acting nitrate therapy or frequent use of short-acting nitrates for angina are absolute contraindications to the use of phosphodiesterase-5 inhibitors. Caution has to be exercised in prescribing phosphodiesterase-5 inhibitors for patients with impaired renal or hepatic functions or receiving multi-drug therapy for any systemic disease. All patients presenting with erectile dysfunction should be investigated and treated for cardiovascular risk factors. They should also be counseled regarding lifestyle factors particularly healthy balanced diet, regular physical exercise and inappropriate social habits.

  2. Identification of Drugs that Regulate Dermal Stem Cells and Enhance Skin Repair

    Science.gov (United States)

    Naska, Sibel; Yuzwa, Scott A.; Johnston, Adam P.W.; Paul, Smitha; Smith, Kristen M.; Paris, Maryline; Sefton, Michael V.; Datti, Alessandro; Miller, Freda D.; Kaplan, David R.

    2015-01-01

    Summary Here, we asked whether we could identify pharmacological agents that enhance endogenous stem cell function to promote skin repair, focusing on skin-derived precursors (SKPs), a dermal precursor cell population. Libraries of compounds already used in humans were screened for their ability to enhance the self-renewal of human and rodent SKPs. We identified and validated five such compounds, and showed that two of them, alprostadil and trimebutine maleate, enhanced the repair of full thickness skin wounds in middle-aged mice. Moreover, SKPs isolated from drug-treated skin displayed long-term increases in self-renewal when cultured in basal growth medium without drugs. Both alprostadil and trimebutine maleate likely mediated increases in SKP self-renewal by moderate hyperactivation of the MEK-ERK pathway. These findings identify candidates for potential clinical use in human skin repair, and provide support for the idea that pharmacological activation of endogenous tissue precursors represents a viable therapeutic strategy. PMID:26724904

  3. Identification of Drugs that Regulate Dermal Stem Cells and Enhance Skin Repair

    Directory of Open Access Journals (Sweden)

    Sibel Naska

    2016-01-01

    Full Text Available Here, we asked whether we could identify pharmacological agents that enhance endogenous stem cell function to promote skin repair, focusing on skin-derived precursors (SKPs, a dermal precursor cell population. Libraries of compounds already used in humans were screened for their ability to enhance the self-renewal of human and rodent SKPs. We identified and validated five such compounds, and showed that two of them, alprostadil and trimebutine maleate, enhanced the repair of full thickness skin wounds in middle-aged mice. Moreover, SKPs isolated from drug-treated skin displayed long-term increases in self-renewal when cultured in basal growth medium without drugs. Both alprostadil and trimebutine maleate likely mediated increases in SKP self-renewal by moderate hyperactivation of the MEK-ERK pathway. These findings identify candidates for potential clinical use in human skin repair, and provide support for the idea that pharmacological activation of endogenous tissue precursors represents a viable therapeutic strategy.

  4. Bilateral external and internal pudendal veins embolization treatment for venogenic erectile dysfunction

    Directory of Open Access Journals (Sweden)

    Daniel Lee, BBA, BS

    2017-03-01

    Full Text Available Erectile dysfunction (ED or impotence is estimated to affect around 20-30 million men in the United States (Rhoden et al, 2002. Vascular etiology is purported to be the most prevalent cause of ED in the elderly population, with venogenic ED being the most common subtype (Shafik et al, 2007; Rebonato et al, 2014. A patient, who developed severe venogenic ED, was referred to interventional radiology after ineffective pharmaceutical treatments. Selective embolization of bilateral external and internal pudendal veins was performed through accessing the deep dorsal vein of penis. Subsequent venogram verified successful embolization with stasis within the outflow of the deep dorsal vein of penis. Close to 6 weeks after the procedure, the patient purports to be able to achieve approximately 65% of full penile erection and complete penile erection with penile stimulation and 0.25 mL injection of alprostadil after 25 minutes.

  5. Advances in the treatment of erectile dysfunction: what’s new and upcoming? [version 1; referees: 2 approved

    Directory of Open Access Journals (Sweden)

    Chintan K. Patel

    2016-03-01

    Full Text Available Erectile dysfunction adversely affects up to 20% of all men and is the most commonly treated sexual disorder. The public health implications of this condition are significant and represent a challenge for our healthcare system. The physiological pathways responsible for erections have been extensively studied, and much advancement has been made since the introduction of phosphodiesterase 5 inhibitors. Newer agents, such as dopaminergic and melanocortin receptor agonists, which target central erectogenic pathways, are under investigation. Newer formulations and delivery methods of existing medications such as alprostadil will also be introduced in the near future. Furthermore, low-intensity shockwave lithotripsy and stem cell regenerative techniques are innovative approaches to the treatment of erectile dysfunction.

  6. Advances in the treatment of erectile dysfunction: what’s new and upcoming?

    Science.gov (United States)

    Patel, Chintan K.; Bennett, Nelson

    2016-01-01

    Erectile dysfunction adversely affects up to 20% of all men and is the most commonly treated sexual disorder. The public health implications of this condition are significant and represent a challenge for our healthcare system. The physiological pathways responsible for erections have been extensively studied, and much advancement has been made since the introduction of phosphodiesterase 5 inhibitors. Newer agents, such as dopaminergic and melanocortin receptor agonists, which target central erectogenic pathways, are under investigation. Newer formulations and delivery methods of existing medications such as alprostadil will also be introduced in the near future. Furthermore, low-intensity shockwave lithotripsy and stem cell regenerative techniques are innovative approaches to the treatment of erectile dysfunction. PMID:27516878

  7. A New Approach for the Patient with Erectile Dysfunction

    Directory of Open Access Journals (Sweden)

    Ian Eardley

    2015-05-01

    Full Text Available This satellite symposium was held in two sessions. The first session was offered in a traditional format where invited experts reviewed and discussed the latest concepts and developments on the management of erectile dysfunction (ED. During the second session, experts discussed clinical cases from their real-life practice in an interactive format, to facilitate discussions with the audience, and to provide participants with the most relevant aspects of ED. The symposium objectives were to review and discuss the current status of the management of ED and treatment needs for patients with ED, and to explore the latest evidence on the use of topical alprostadil cream (Vitaros®, Virirec®, Vytaros®1 – who benefits the most?

  8. Effect of sequential therapy of prostaglandins on renal function indexes in blood and urine specimens in patients with diabetic nephropathy

    Institute of Scientific and Technical Information of China (English)

    Guo-Zhao Zhang; Zhi-Yuan Lu; Zhen Ren; Wei Wang

    2016-01-01

    Objective:To study the effect of sequential therapy of prostaglandins on renal function indexes in blood and urine specimens in patients with diabetic nephropathy.Methods: A total of 96 cases of patients with diabetic nephropathy (IV) were selected as the subjects of the study and randomly divided into control group (group A), alprostadil group (group B), beraprost sodium group (group C) and sequential therapy group (group D), renal color Doppler ultrasound was carried out, and trace albumin, total protein, 6-keto-prostaglandin F1α (6-keto-PGF1α) and thromboxane B2(TXB2) levels in 24 h urine specimens as well as creatinine (Cr), blood urea nitrogen (BUN), 6-keto-PGF1α, TXB2, cystatin C (CysC), retinol-binding protein (RBP) levels in blood specimens were determined.Results:Renal blood flow of group B, C and D were higher than that of group A and renal blood flow of group D was higher than those of group B and C; 24 h urine trace albumin, total protein and TXB2 levels as well as serum BUN, Cr, CysC and RBP levels of group B, C and D were significantly lower than those before treatment, and serum and urine 6-keto-PGF1α levels of group B, C and D were significantly higher than those before treatment; 24 h urine trace albumin, total protein and TXB2 levels as well as serum BUN, Cr, CysC and RBP levels of group D group were significantly lower than those of group B and group C, and serum and urine 6-keto-PGF1α levels of group D after treatment were significantly higher than those of group B and group C.Conclusion:Sequential therapy of alprostadil can protect renal function in patients with diabetic nephropathy, reduce proteinuria, improve glomerular filtration function and microcirculation disturbance, and inhibit platelet activation.

  9. Leg ulcer and osteomyelitis due to methicillin-susceptible Staphylococcus aureus infection after fracture repair treatment: a case highlighting the potential role of prostaglandin E₁ vasodilator.

    Science.gov (United States)

    Bentivegna, Erminia; Citarrella, Emanuele; Vivaldi, Roberto; De Luca, Dario; Maira, Giovanna Grazia; Casuccio, Alessandra; Di Carlo, Paola

    2015-03-01

    Prostaglandins appear to reduce biofilm formation and chronicization of infections, and stimulate a rapid and effective clearance of infecting micro-organisms. We report a case of recovery from methicillin-susceptible Staphylococcus aureus (MSSA) osteomyelitis after multidisciplinary management with antibiotics, anti-thrombotics and prostaglandin E1 (PGE1) vasodilator, in a patient with tibial plateau fracture repaired with internal fixation devices. A 47-year-old HIV-negative male with chronic ulcer on the proximal third of the left leg was admitted to the Orthopaedic Unit of the Orestano Clinic in Palermo, Italy, for suspected osteomyelitis. A biopsy of the skin ulcer and blood cultures were performed and resulted positive for MSSA. Labelled leukocyte scintigraphy confirmed osteomyelitis. No clinical improvement was observed after combined antibiotic treatment with rifampicin plus trimethoprim-sulfamethoxazole. The patient underwent a 4-day therapeutic cycle: PGE1 (alprostadil 60 mg/day IV) combined with nadroparin calcium plus gentamicin, followed by treatment with aminaftone plus sulodexide plus levofloxacin. At discharge, the patient's painful symptoms had completely resolved and the ulcer had cicatrized; recovery from osteomyelitis was confirmed by scintigraphy. This treatment protocol including PGE1 may result in a significant improvement in quality of life and functional status of patients with a reduction in direct and indirect costs and economic benefit for the National Health Service.

  10. EFFECTS OF PROSTAGLANDIN E1 ON THE PROGRESSION OF ARISTOLOCHIC ACID NEPHROPATHY

    Institute of Scientific and Technical Information of China (English)

    Dong Sun; Jiang-min Feng; Yan-ling Zhao; Tao Jin; Li-ning Wang

    2005-01-01

    Objective To investigate the effects of prostaglandin El (PGE1) on the progression of aristolochic acid nephropathy AAN).Methods Twenty-four patients diagnosed as AAN with serum creatinine (Scr) between 1.5 mg/dL and 4 mg/dL during September 2001 to August 2003 were randomly divided into 2 groups. All patients had ingested long dan xie gan wan containing aristolochic acid (0.219 mg/g) for at least 3 months. Twelve patients were injected with Alprostadil (10 μg/d for 10days in one month, summing up to 6 months). Except for PGE1, the other therapy was same in both groups. Renal function was assessed using reciprocal serum creatinine levels (1/Scr).Results The level of Scr and serum hemoglobin (Hgb) was similar in both groups prior to therapy. During follow-up,1/Scr levels in PGE1 group were significantly higher than control group (P < 0.01), and Hgb levels in PGE1 group were significantly increased compared with control (P < 0.05).Conclusion PGE1 can slow the progression of renal failure and increase Hgb level of AAN patient.

  11. Association Between IL-18 and Carotid Intima-Media Thickness in Patients with Type II Diabetic Nephropathy

    Science.gov (United States)

    Zhang, Yuanyuan; Feng, Haomiao; Wei, Zhiyong

    2017-01-01

    Background We specifically designed this study to determine the relationship between levels of IL-8 and carotid intima-media thickness (cIMT) in patients with type 2 diabetes mellitus (T2DM). Material/Methods A total of 149 diabetic patients at different stages of diabetic nephropathy and 72 matched controls were recruited in this study. A wide range of parameters were measured: IL-18 (by ELISA), urinary albumin excretion rates (UAER), and carotid intima-media thickness (cIMT, by pulse wave velocity [PWV]). All the diabetic patients were treated by alprostadil. Results ELISA indicated that the level of IL-18 in the patient group was significantly higher compared with that in the control group. The level of IL-18 apparently increased in the higher cIMT group in T2DM patients. Serum IL-18 levels were positively correlated with cIMT in patients with T2DM, the level of IL-18 was negatively correlated with cIMT, and IL-18 levels were positively correlated to age. Moreover, IMT was positively correlated with hemoglobin A1C (HbA1C) and IL-18 levels were significantly associated with cIMT (all P<0.05). Conclusions IL-18 levels were positively correlated with atherosclerotic burden in patients with T2DM and it may be considered as a significant therapeutic target. PMID:28125566

  12. Erectile dysfunction post-radical prostatectomy – a challenge for both patient and physician

    Science.gov (United States)

    Bratu, O; Oprea, I; Marcu, D; Spinu, D; Niculae, A; Geavlete, B; Mischianu, D

    2017-01-01

    Post-radical prostatectomy erectile dysfunction (post RP ED) is a major postoperative complication with a great impact on the quality of life of the patients. Until present, no proper algorithm or guideline based on the clinical trials has been established for the management of post RP ED. According to literature, it is better to initiate a penile rehabilitation program as soon as possible after surgery than doing nothing, in order to prevent and limit the postoperative local hypoxygenation and fibrosis. The results of numerous clinical trials regarding the effectiveness of the phosphodiesterase 5 inhibitors therapy on post RP ED have made them the gold standard treatment. Encouraging results have been achieved in studies with vacuum erectile devices, intraurethral suppositories with alprostadil and intracavernosal injections, but due to their side effects, especially in the cases of intracavernosal injections and intraurethral suppositories, their clinical use was limited therefore making them a second line option for the post RP ED treatment. What should not be forgotten is that penile implant prosthesis has proven very effective, numerous studies confirming high rates of satisfaction for both patients and partners. PMID:28255370

  13. Management of erectile dysfunction post-radical prostatectomy

    Directory of Open Access Journals (Sweden)

    Saleh A

    2015-02-01

    Full Text Available Alan Saleh, Hamid Abboudi, MB Ghazal-Aswad, Erik K Mayer, Justin A Vale Division of Surgery and Cancer, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK Abstract: Radical prostatectomy is a commonly performed procedure for the treatment of localized prostate cancer. One of the long-term complications is erectile dysfunction. There is little consensus on the optimal management; however, it is agreed that treatment must be prompt to prevent fibrosis and increase oxygenation of penile tissue. It is vital that patient expectations are discussed, a realistic time frame of treatment provided, and treatment started as close to the prostatectomy as possible. Current treatment regimens rely on phosphodiesterase 5 inhibitors as a first-line therapy, with vacuum erection devices and intraurethral suppositories of alprostadil as possible treatment combination options. With nonresponders to these therapies, intracavernosal injections are resorted to. As a final measure, patients undergo the highly invasive penile prosthesis implantation. There is no uniform, objective treatment program for erectile dysfunction post-radical prostatectomy. Management plans are based on poorly conducted and often underpowered studies in combination with physician and patient preferences. They involve the aforementioned drugs and treatment methods in different sequences and doses. Prospective treatments include dietary supplements and gene therapy, which have shown promise with there proposed mechanisms of improving erectile function but are yet to be applied successfully in human patients. Keywords: erectile dysfunction, phosphodiesterase 5 inhibitors, vacuum erection devices, intraurethral suppositories, intracavernosal injections

  14. Idiopathic Low-Flow Priapism in Prepuberty: A Case Report and a Review of Literature

    Directory of Open Access Journals (Sweden)

    Ihab A. Hekal

    2008-01-01

    Full Text Available Introduction. The incidence of priapism in adults is higher than in children. Although approximately 50% of all episodes of priapism are thought to be idiopathic, there are a number of known specific causes of this disorder. In adults intracavernous therapy with papaverine, phentolamine, alprostadil or combinations of these agents is the most common cause of ischemic priapism. In children the most common etiology is sickle cell anemia for low-flow priapism or post-traumatic high-flow priapism. We present a 13-year-old boy, not sexually active presented to our outpatient clinic suffering from long standing (3.5 hours sustained painful erection. To the best of our knowledge the idiopathic low-flow priapism in pre-pubertal boy was not reported before in literature. Our case is the first case to be reported in pre-pubertal age. Conclusion. In pre-pubertal boys idiopathic recurrent priapism is a rare condition. In the literature, several empirical therapies are described. Recently, it is postulated that a low dose of a PDE5 inhibitor. The early conservative management is the best treatment option to safe the corporeal smooth muscles from irreversible damage.

  15. Efficacy of catheterization of left atrium for postoperative management in pediatric patients undergoing congenital heart disease complicated with moderate to severe pulmonary hypertension%术中置入左心房导管用于合并中重度肺动脉高压患儿先天性心脏病修复术后管理的效果

    Institute of Scientific and Technical Information of China (English)

    李中云; 陆健君

    2013-01-01

    Objective To evaluate the efficacy of catheterization of left atrium for postoperative management in pediatric patients undergoing congenital heart disease complicated with moderate to severe pulmonary hypertension.Methods Sixty ASA Ⅲ or Ⅳ pediatric patients of both sexes,aged 9 months-14 yr,scheduled for elective congenital heart disease complicated with moderate-to-severe pulmonary hypertension under cardiopulmonary bypass,were randomly divided into 2 groups (n =30 each):central venous catheterzation group (C group)and catheterization of left atrium group (L group).After induction of anesthesia,triple-lumen central venous catheters were inserted in both groups.In group L,the right internal jugular vein was cannulated with a single lumen venous catheter passed through the left atrium for monitoring postoperative left atrial pressure (LAP) and administration of vasoactive drug and LAP was maintained at 8-12 mm Hg after operation.Duration of mechanical ventilation and duration of stay in intensive care unit were recorded.The amount of dopamine,dobutamine,nitroprusside,milrinone,and alprostadil consumed within 48 h after operation was also recorded.Results Compared with C group,the amount of dopamine,dobutamine,nitroprusside,milrinone,and alprostadil consumed was significantly reduced and duration of mechanical ventilation and duration of stay in intensive care unit were significantly shortened in group L.Conclusion Catheterization of left atrium is used for monitoring postoperative LAP,which can provide a basis for reasonable clinical prescription and optimize the efficacy of postoperative management in pediatric patients undergoing congenital heart disease complicated with moderate to severe pulmonary hypertension.%目的 评价术中置入左心房导管用于合并中重度肺动脉高压患儿先天性心脏病修复术后管理的效果.方法 择期CPB下行心脏修复术的先天性心脏病合并中重度肺动脉高压患儿60例,性别不限,年龄9

  16. An Observational Study to Evaluate the Prevalence of Erectile Dysfunction (ED) and Prescribing Pattern of Drugs in Patients with ED Visiting an Andrology Specialty Clinic, Mumbai: 2012-14

    Science.gov (United States)

    Kulkarni, Vijay R.; Bhagat, Sagar B.; Beldar, Amit S.; Patel, Sadiq B.

    2015-01-01

    Introduction: Erectile dysfunction (ED) is a common occurrence and its incidence is expected to increase significantly along with the increase in various lifestyle diseases. The drug utilization for ED is very low. Also, studies describing the prescription pattern in ED are lacking. Materials and Methods: We conducted a retrospective cross-sectional observational study, including a drug utilization analysis, of 606 prescriptions as per the standard guidelines (WHO and STROBE). Results: Out of 606, 249 (41%) were from the age group of 30-39 years. Addictions were present in 388 (64%). Out of 606, 186 had urological, 154 had cardiovascular and 102 had psychological co-morbid disorders. Out of 348, 201 were prescribed Tadalafil (low dose) on a once daily basis. Out of 172, 121 were prescribed Sildenafil (high dose) on an ‘as and when required’ basis. Nutritional/ herbal supplements were prescribed in 126/606. The ratio of ‘Prescribed Daily Dose’ to ‘Defined Daily Dose’ of Tadalafil, Sildenafil, and Dapoxetine were 1.1, 1.3 and 1.5 respectively. Conclusion: Measures for de-addiction play an important role in the overall management of ED. The most common co-morbid disorders were urological, like BPH, LUTS, etc, followed by cardiovascular, psychological and diabetes. Overall, rational pharmacotherapy was observed. Tadalafil was the most commonly prescribed drug for ED. The main factor in the selection of a particular PDE5 inhibitor was its pharmacokinetics and cost. Udenafil, being the costliest, was the least prescribed. Dapoxetine was used in a significant number of individuals primarily for PE with ED. The combination of Papaverine, Chlorpromazine ± Alprostadil was used as intracavernosal injection in patients not responding to oral drugs. PMID:26393163

  17. Venous leakage treatment revisited: pelvic venoablation using aethoxysclerol under air block technique and Valsalva maneuver

    Directory of Open Access Journals (Sweden)

    Ralf Herwig

    2015-03-01

    Full Text Available Objective: We evaluated the effectiveness of pelvic vein embolization with aethoxysclerol in aero-block technique for the treatment of impotence due to venous leakage in men using sildenafil for intercourse. The aim of the procedure was to reduce the use of sildenafil. Methods: A total of 96 patients with veno-occlusive dysfunction, severe enough for the need of PDE5 inhibitors for vaginal penetration, underwent pelvic venoablation with aethoxysclerol. The mean patient age was 53.5 years. Venous leaks were identified by Color Doppler Ultrasound after intracavernous alprostadil injection. Under local anesthesia a 20-gauge needle was inserted into the deep dorsal penile vein. The pelvic venogram was obtained through deep dorsal venography. Aethoxysclerol 3% as sclerosing agent was injected after air-block under Valsalva manoeuver. Success was defined as the ability to achieve vaginal insertion without the aid of any drugs, vasoactive injections, penile prosthesis, or vacuum device. Additionally, a pre- and post- therapy IIEF score and a digital overnight spontaneous erections protocol (OSEP with the NEVA™-system was performed. Results: At 3 month follow-up 77 out of 96 patients (80.21% reported to have erections sufficient for vaginal insertion without the use of any drug or additional device. Four (4.17% patients did not report any improvement. Follow up with color Doppler ultrasound revealed a new or persistent venous leakage in 8 (8.33% of the patients. No serious complications occurred. Conclusions: Our new pelvic venoablation technique using aethoxysclerol in air-block technique was effective, minimally invasive, and cost-effective. All patients were able to perform sexual intercourse without the previously used dosage of PDE5 inhibitor. This new method may help in patients with contra-indications against PDE5 inhibitors, in patients who cannot afford the frequent usage of expensive oral medication or those who do not fully respond to PDE5

  18. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease)

    Science.gov (United States)

    Narváez, Javier; García-Gómez, Carmen; Álvarez, Lorenzo; Santo, Pilar; Aparicio, María; Pascual, María; López de Recalde, Mercè; Borrell, Helena; Nolla, Joan M.

    2016-01-01

    Abstract The cornerstone of therapy in thromboangiitis obliterans (TAO) is complete abstinence from tobacco. In addition to discontinuation of cigarette smoking, very few pharmacological and surgical options of controversial efficacy are available to date. New therapeutic options with greater efficacy are clearly needed to properly manage these patients. In this preliminary study, we assessed the effectiveness and safety of bosentan in a case series of 8 adults with TAO and severe ischemic ulceronecrotic lesions who were treated with bosentan after inadequate response to platelet inhibitors, vasodilators, and intravenous alprostadil. Additionally, we reviewed 18 well-documented patients with refractory TAO treated with bosentan, which was previously reported (PubMed 1965–2015). These 26 patients formed the basis of our present analysis. All were current smokers. The median duration of bosentan treatment (SD) was 4.5 ± 4 months (range 3–16). Eleven patients (42%) were unable to completely abstain from smoking during their follow-up. With bosentan treatment, no new ischemic lesions were observed in the target extremities. A complete therapeutic response was achieved in 80% of patients, whereas a partial response was observed in 12%. Two patients (8%) ultimately required amputation despite treatment. After discontinuation of bosentan, patients were followed for a median of 20 ± 14 months (range 3–60). Two patients whose trophic lesions had healed relapsed. When comparing patients who gave up smoking with those who were unable to completely abstain from smoking during follow-up, no significant differences were found in efficacy outcomes. Four patients (15%) developed adverse events, requiring bosentan discontinuation in 1 case. These preliminary data suggest that bosentan may be considered a therapeutic option for treatment of cases of severe TAO refractory to conventional treatment, and merit further evaluation in larger controlled, randomized clinical

  19. Differential roles of prostaglandin E-type receptors in activation of hypoxia-inducible factor 1 by prostaglandin E1 in vascular-derived cells under non-hypoxic conditions

    Directory of Open Access Journals (Sweden)

    Kengo Suzuki

    2013-11-01

    Full Text Available Prostaglandin E1 (PGE1, known pharmaceutically as alprostadil, has vasodilatory properties and is used widely in various clinical settings. In addition to acute vasodilatory properties, PGE1 may exert beneficial effects by altering protein expression of vascular cells. PGE1 is reported to be a potent stimulator of angiogenesis via upregulation of VEGF expression, which is under the control of the transcription factor hypoxia-inducible factor 1 (HIF-1. However, the molecular mechanisms behind the phenomenon are largely unknown. In the present study, we investigated the mechanism by which PGE1 induces HIF-1 activation and VEGF gene expression in human aortic smooth muscle cells (HASMCs and human umbilical vein endothelial cells (HUVECs, both vascular-derived cells. HUVECs and HASMCs were treated with PGE1 at clinically relevant concentrations under 20% O2 conditions and HIF-1 protein expression was investigated. Expression of HIF- 1α protein and the HIF-1-downstream genes were low under 20% O2 conditions and increased in response to PGE1 treatment in both HUVECs and HASMCs in a dose- and time-dependent manner under 20% O2 conditions as comparable to exposure to 1% O2 conditions. Studies using EP-receptor-specific agonists and antagonists revealed that EP1 and EP3 are critical to PGE1-induced HIF-1 activation. In vitro vascular permeability assays using HUVECs indicated that PGE1 increased vascular permeability in HUVECs. Thus, we demonstrate that PGE1 induces HIF- 1α protein expression and HIF-1 activation under non-hypoxic conditions and also provide evidence that the activity of multiple signal transduction pathways downstream of EP1 and EP3 receptors is required for HIF-1 activation.

  20. Treatment for pulmonary artery hypertension in liver tranaplantation%肝移植过程中肺动脉高压的处理

    Institute of Scientific and Technical Information of China (English)

    罗远国; 胡春林; 李洪

    2008-01-01

    selective for the liver transplantation. METHODS: Undergoing general anesthesia, mean arterial blood pressure, central venous pressure, pulmonary arterial pressure and pulmonary arterial wedge pressure were continuously monitored by Swan-Ganz catheter method and reversible Fick's law continuous monitoring. Available respiration administration, low dose of glyceryltrinitrate (0.1-5.0 u g/kg/min) and Alprostadil (1.0-2.0 u g) were administered to diminish elevated pulmonary arterial pressure and pulmonary arterial wedge pressure during the period after unclamping portal vein in liver transplantation. MAIN OUTCOME MEASURES: Changes of mean arterial blood pressure and pulmonary arterial pressure. RESULTS: The mean arterial blood pressure deceased at the time of unclamping portal vein in all 13 patients, pulmonary arterial pressure and pulmonary arterial wedge pressure both increased significantly at 5 and 15 minutes within neo-hepatic stage, which were more obvious than those during anhepatic stage in 13 patients(P<0.05).The pulmonary arterial pressure and pulmonary arterial wedge pressure revived to the level before unclamping inferior vein by treatment with glyceryltrinitrate and Alprostadil within 30 minutes. CONCLUSION: Reasonable application of glyceryltrinitrate and Alprostadil can obviously release pulmonary arterial pressure during neo-hepatic stage in liver transplantation.

  1. Using a Cobalt Amine United Front, For the Treatment of Diabetic Periph-eral Neuropathy Clinical Observations and Curative Effect Analysis%运用甲钴胺联合前列地尔治疗糖尿病周围神经病变的临床观察与疗效分析

    Institute of Scientific and Technical Information of China (English)

    王毓

    2015-01-01

    Objective To observe diabetic peripheral neuropathy (diabetic peripheral neuropathy, DPN) clinical treatment methods to explore the use of Mecobalamin alprostadil therapy of diabetic peripheral neuropathy. Methods 60 patients ad-mitted to our hospital with diabetic peripheral neuropathy patients, based on length of stay were randomly divided into con-trol and experimental groups of 30 patients in the control group using only mecobalamin treatment. The experimental group Mecobalamin alprostadil treatment, the difference between the two groups after treatment. Results After treatment, patients in the experimental group effective rate was 92.3%, the effective rate was 71.3% in the control group, the experimental group was significantly higher, the difference was statistically significant(P<0.05), using Mecobalamin alprostadil treatment of diabetes peripheral neuropathy has a significant effect, high safety factor, significantly reduced adverse reactions, which can effectively improve and enhance the quality of life in patients with diabetic peripheral neuropathy. Conclusion Through clinical research, the use of a united front to cobalt amine in the process of the treatment of diabetic peripheral neuropathy, after two drugs used in combination, the two drugs synergy in the body to achieve the improvement and restore the function of diabetic peripheral neuropathy. Compared with single application of a form of drug treatment, remarkable curative effect, high safety coefficient, less adverse reaction, for the clinical treatment of diabetic peripheral neuropathy disease provided the powerful basis.%目的:通过观察糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)的临床治疗方法,探讨运用甲钴胺联合前列地尔治疗糖尿病周围神经病变的疗效。方法选择该院收治的60例糖尿病周围神经病变患者,根据住院时间随机分为对照组和实验组,每组30例,对照组仅使用甲钴胺进行治疗。实验组

  2. 双介入治疗糖尿病足的临床研究%Study on Double Interventional Treatment for Diabetic Foot

    Institute of Scientific and Technical Information of China (English)

    王东盛; 王成纲; 陆英; 刘明; 刘海洋

    2011-01-01

    Objective:To investigate the clinical efficacy of percutaneous transluminal angioplasty(PTA)and percutaneous intra-arterial femoral port-catheter system(PCS) for treatment for diabetic foot. Methods:60 patients with diabetic foot were treated by PTA and rusing alprostadil injection and salvia miltiorrhiza injection via PCS.The patients were treated in 4 weeks. Ankle brachial indexs(ABI) were examined before and after treaments. Results:The effective percentage of treatment were 96.7%.There were significant difference of the ABI between before and after treaments. Conclusion:The technique of PTA and PCS implatation for interventional treatment for diabetic foot is available.%目的:探讨经皮腔内成形术(PTA)联合经皮动脉穿刺导管药盒系统(PCS)治疗糖尿病足的临床疗效.方法:60例糖尿病足患者,行PTA术治疗后,再于皮下植入动脉药盒系统,并经动脉连接导管系统行前列地尔注射液、丹参注射液灌注治疗.14天为l疗程,共治疗2个疗程.治疗前后测定踝臂指数(ABI).结果:全部糖尿病足患者,治愈38例,有效20例,无效2例,总有效率96.7%.治疗前ABI为0.32±0.11,治疗后ABI为0.76±0.14,(治疗前后比较P=0.000).结论:PTA联合PCS灌注药物对糖尿病足有明显治疗作用,疗效满意,能有效改善下肢血液循环.

  3. Effect of Shenkang injection in combined with nursing intervention on the renal function in patients with chronic renal failure

    Institute of Scientific and Technical Information of China (English)

    Ya-Nan Sun

    2016-01-01

    Objective:To explore the effect of Shenkang injection in combined with nursing intervention on the renal function in patients with chronic renal failure (CRF).Methods: A total of 90 patients with CRF who were admitted in our hospital from May, 2015 to May, 2016 were included in the study and randomized into the study group and the control group. The patients in the two groups were given routine pressure reducing, water-electrolyte and acid-base balance correcting, and corresponding nursing intervention. On the above basis, the patients in the control group were given ligustrazine injection (200 mg) + 5% glucose (250 mL), ivdrip, 1 time/d, and alprostadil (20 μg) + 0.9%NaCl (100 mL), ivdrip slowly, 1 time/d. On the basis of the treatments in the control group, the patients in the study group were given additional Shenkang injection (100 mL)+5% glucose (250 mL), iv drip, 1 time/d. The patients in the two groups were treated for 4 weeks, and the efficacy was evaluated after the treatment. The morning fasting elbow venous blood before and after treatment was extracted. The serum Scr, BUN, Ccr, TC, TG, HDL-C, Apo-A, and Apo-B before and after treatment were detected. 24 h urine before and after treatment was collected, and 24 h urine protein volume (24 h pro) was calculated.Results: Scr, BUN, and 24 h pro after treatment in the two groups were significantly reduced, while Ccr was significantly elevated when compared with before treatment, and those in the study group were significantly superior to those in the control group. TC, TG, and Apo-B after treatment in the two groups were significantly reduced, while HDL-C and Apo-A were significantly elevated when compared with before treatment, and those in the study group were significantly superior to those in the control group.Conclusions:Shenkang injection in combined with nursing intervention in the treatment of CRF can effectively regulate the lipid metabolism disorder, delay the progression, and protect the renal

  4. Ioversol injection induced cortical blindness%碘佛醇注射液致皮质盲

    Institute of Scientific and Technical Information of China (English)

    王涌臻; 王艳华; 那世杰; 戴峰; 黄国金; 胡迪

    2015-01-01

    1例54岁男性慢性乙型肝炎、肝硬化伴上消化道出血患者行经皮肝穿刺食管胃底曲张静脉栓塞术及部分脾动脉栓塞术,术中静脉注射碘佛醇160 ml.术后约6.5h,患者出现双目失明.磁共振成像(M RI)检查示大脑、小脑多发新鲜梗死灶,CT检查未见异常.给予吸氧以及地塞米松、七叶皂苷钠、甘露醇、前列地尔、长春西汀、川芎嗪、单唾液酸四己糖神经节苷脂钠治疗.失明后58 h,患者视力恢复至术前水平.2周后复查MRI,脑梗死灶范围变小、信号降低.14个月后复查,患者未再出现消化道出血,视力正常.%A 54-year-old male patient with chronic hepatitis B and liver cirrhosis with upper gastrointestinal hemorrhage was treated with the percutaneous transhepatic embolization of gastroesophageal varices and partial splenic embolization.He received an intravenous ioversol injection 160 ml.About 6.5 hours after intervention, the patient became blind in both eyes.Magnetic resonance imaging (MRI) showed widely fresh brain infarction, but nothing abnormal was found in brain computed tomography.He was given oxygen and dexamethasone, sodium aescinate, mannitol, alprostadil, vinpocetine, ligustrazine,monosialotetrahexosyl ganglioside sodium.Fifty-eight hours after blindness, the eyesight was completely resumed.Two weeks later, MRI showed that the range of cerebral infarcts became smaller, signal intensity was reduced.Fourteen months later, the gastrointestinal hemorrhage did not occur and the eyesight was normal.

  5. Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study

    Directory of Open Access Journals (Sweden)

    Paulis G

    2015-07-01

    Full Text Available Gianni Paulis,1,7 Giorgio Cavallini,2 Davide Barletta,3 Paolo Turchi,4 Antonio Vitarelli,5 Andrea Fabiani6 1Regina Apostolorum Hospital, Andrology Center, Rome, Italy; 2Andrological Section, Gynepro Medical Team, Bologna, Italy; 3Department of Urology, Andrology Center, San Matteo Hospital, Pavia, Italy; 4Azienda ASL 4 Prato – Andrology Service, Prato, Italy; 5Department of Urology, University of Bari, Bari, Italy; 6Department of Surgery, Section of Urology and Andrology, ASUR Marche 9, Macerata, Italy; 7Castelfidardo Medical Team, Peyronie's Disease Care Center, Rome, Italy Abstract: The average age of men affected by Peyronie's disease (PD is approximately 50–55 years, but cases have been reported even in adolescence. Several studies have already investigated the presence of PD in young men, and these studies reported a PD prevalence that varies between 1.5% and 10.8%. Having noticed a greater number of young patients in our centers in recent years, we decided to carry out a retrospective study to evaluate the prevalence of PD in patients aged <40 years, as well as to investigate any possible difference in evolution based on the age of PD patients. We selected a sample of patients (n=271 with a similar time of onset of disease. We then stratified all 271 patients into two groups: group A (age <40 years [n=46] and group B (age ≥40 years [n=225]. All 271 patients were evaluated for the following variables: penile plaque volume, degree of penile curvature, penile pain, and erectile function. Plaque volume was measured in cm3 by dynamic penile color Doppler sonography after administration of intracavernosal alprostadil 10 mcg. The number of younger patients was 46, accounting for 16.9% of the whole sample. Our study showed more frequent appearance and greater progression of penile curvature in younger patients. The average angle of penile curvature and average score of penile pain intensity in the younger men were significantly higher than

  6. PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction

    Directory of Open Access Journals (Sweden)

    Luis Labairu-Huerta

    2015-09-01

    Full Text Available Objectives: To compare the effectiveness in the treatment of erectile dysfunction when using PDE-5 inhibitors (PDE5i, alprostadil (PG-E1 and testosterone (TES in monotherapy or combination therapy. Material and Methods: Observational multicentre retrospective study of men diagnosed and treated for ED between January 2008 and January 2014. Age, social and employment situation, pathological medical history, risk factors, usual treatments, IIEF-5 at the first consultation and at first and each 6 months follow-ups, physical examination, calculated total and free testosterone and received treatment were analysed. Descriptive statistics, one-way ANOVA analysis, Chi2 for qualitative data, t-test, Fisher's exact test and Pearson's correlation coefficient were used; p < 0.05 is considered significant. Results: Average age was 58.61 years, SD5.02, average follow- up time 48.21 months, SD 6.21, range 6-174 months. Out of the patients 76.12% were married, 9.81% divorced/separated, 10.04% single, 4.03% widowed; 85.14% of the total in stable partnership but 66.16% were not accompanied by their partners. In total 844 patients received monotherapy (597 PDE5i; 62 PG-E1; 36 TES; 27 penile prosthesis; 121 psychotherapy/alternative therapies and 357 combination therapy (167 PDE5i+TES; 124 PDE5i+PGE1; 66 PG-E1+TES. There was a homogeneous distribution between risk factors and medical history groups. Satisfactory response according to IIEF-5 was achieved for 72.33% of patients on PDE5i monotherapy, 46.65% of patients on PDE5i+PG-E1 combination therapy and 83.41% of patients on PDE5i+TES. Conclusions: The best therapeutic success for ED in this series was achieved through a combination of testosterone+PDE-5 inhibitors without increasing morbidity and maintaining the response over time. Larger studies with longer follow-up will corroborate these findings.

  7. Post-prostatectomy erectile dysfunction: contemporary approaches from a US perspective

    Directory of Open Access Journals (Sweden)

    Hamilton Z

    2014-05-01

    treatment selection, patient satisfaction and improved erectile function can be achieved. We advise that patients use a vacuum erection device daily in the early postoperative period in combination with an oral PDE5I. For patients who do not respond to a vacuum erection device or PDE5I, consideration should be given to intraurethral alprostadil, intracorporal injections, or a penile prosthesis. Keywords: vacuum erection device, phosphodiesterase inhibitor, intracorporal injection, penile prosthesis

  8. Clinical study of Salvia miltiorrhiza injection in patients with systemic sclerosis%注射用丹参治疗局限型系统性硬化病的临床疗效及其作用机制

    Institute of Scientific and Technical Information of China (English)

    高戈; 王欣; 田静; 杜金峰; 谢希; 高洁生

    2012-01-01

    目的 探讨注射用丹参静脉滴注治疗系统性硬化病的临床疗效和作用机制.方法 46例系统性硬化病患者分成2组:治疗组予丹参冻干粉针0.8 g,iv,gtt,qod,口服青霉胺0.375 g,qd,沙利度胺100 mg,qd,积雪苷72 mg,qd,泼尼松10 mg,qd;对照组予前列地尔100 μg,iv,gtt,qod,其他治疗同治疗组,连续治疗3 mo,比较2组患者治疗前后皮肤损害的Rodnan修定评分、Furst's内脏评分、全血黏度、血浆黏度、相对黏度、聚集指数、过氧化脂质(LPO)、超氧化物岐化酶(SOD)的变化以判断疗效及作用机制.结果 治疗组皮肤损害的R0dnan修定评分、Furst's内脏评分(3.5±2.2、4.8±6.4)显著低于对照组(6.8±6.3、6.7±3.8) (P<0.01,0.05).治疗组血液流变学指标显著改善,优于对照组(P< 0.01,0.05);LPO明显降低,SOD明显上升与对照组比较有显著差异(P<0.01).结论 丹参冻干粉针能显著改善皮肤损害和减轻内脏受累,其作用机制可能与血液流变学的显著改善、LPO降低、SOD上升有关.%AIM To study the curative effects and probable mechanisms of Salvia miltiorrhiza injection in patients with systemic sclerosis. METHODS A total of 46 systemic sclerosis patients were randomized into two groups. All patients were orally administered with bellacilline 0.375 g-d-1, thalidomide 100 mg^d-1, madecasso-side 72 mg-d-1 and prednisone 10 mg-d-1. The patients in the treatment group and the control group were respectively treated with Salvia miltiorrhiza injection (0.8 g, iv, gtt, qod) and alprostadil (100 μg, iv, gtt, qod) for 3 months. Modified Rodnan skin score and Furst's internal organs score were determined, and whole blood viscosity, blood plasma viscosity, relative viscosity, aggregation index, LPO and SOD were tested. RESULTS Modified Rodnan skin score and Furst' s internal organs score in the treatment group (3.5 ± 2.2,4.8 ± 6.4) were lower than those in the control group (6.8 ± 6.3, 6.7 ± 3.8) (P < 0.01, 0

  9. Clinical Analysis of Longxuejie Capsule in the Treatment of Diabetic Foot Ulcer%龙血竭胶囊治疗糖尿病足溃疡的临床分析

    Institute of Scientific and Technical Information of China (English)

    吴斌; 黄婷婷; 杨纪才; 向大兰

    2013-01-01

    Objective To observe the clinical ef ect of Resina Draconis topical and oral treatment of diabeticfoot ulcer. Methods 72 cases of diabetic foot patients,randomly divided into two groups.Systemic treatment with short acting insulin were subcutaneous injections before meals,long-term neutrul insulin injection once dailysubcutaneous injection of glucose control,Epalrestat,Alprostadil,statins,aspirin and debridement,anti infection therapy,treatment group was added with Resina Draconis capsules oral and Resina Draconis capsule contentamount of topical in the af ected area.Evaluation of patients with clinical changes before and after treatment. Results Before treatment,two groups of patients withsimilar clinical symptoms were observed 8 weeks after thetreatment,clinical symptoms of two patients wereimproved,the total ef ective rate of treatment group 86.5%,control group,the total ef iciency of 62.9%,P<0.05.The curative ef ect of treatment group was bet er than the control group. Conclusion Resina Draconis topical and oral treatment of diabetic foot ulcers can promote woundhealing.%目的:观察龙血竭外敷及口服治疗糖尿病足溃疡的临床疗效。方法选择糖尿病足患者72例,随机分为两组。全身治疗均用短效胰岛素分别三餐前皮下注射,长效胰岛素注射液1次/d皮下注射控制血糖,用依帕司他、前列地尔、他汀、阿司匹林及清创、抗感染等治疗基础上,治疗组加用龙血竭胶囊口服及用龙血竭胶囊内容物适量外敷于患处。治疗前后评估患者临床变化。结果治疗前两组患者临床症状相似,治疗观察8w后两组患者临床症状均有所改善,治疗组总有效率86.5%,对照组总有效率62.9%,P<0.05。治疗组疗效明显优于对照组。结论龙血竭外敷及口服治疗糖尿病足溃疡具有促进疮面愈合的作用。

  10. 甲钴胺不同给药方式治疗糖尿病神经病变患者的临床研究%Clinical Research on Mecobalamine with Various Administrations in Diabetic Neuropathy Patients

    Institute of Scientific and Technical Information of China (English)

    刘晓宇; 吴大方; 李洁; 周岩

    2012-01-01

    Objective: To research the curative effect of mecobalamine on type 2 diabetes with diabetic neuropathy by intramuscular injection, intravenous drip or vertebral canal injection. Method: Total 108 samples of type 2 diabetes with diabetic neuropathy were divided into 3 groups with various mecobalamine administrations. 0. 5 mg Mecobalamine was intramuscularly injected in group A once a day, lmg ecobalamine was intravenously dripped in group B once every 2 days and 2mg Mecobalamine was intraspinally injected in group C once every 4 days. Every group was combined with alprostadil 100μg therapy and the duration was 20 days. Motor nerve conduction velocity and sensory nerve conduction velocity were respectively measured before and after treatment, and the curative effects were examined. Result: The total effective rate of the three groups was 78% , 89% and 97% , respectively with significant difference ( P < 0.05 ). There was no statistical difference in median and peroneal nerve conduction velocity among the groups before the treatment. After the administration, the nerve conduction velocity in the three groups was all increased, and compared with group A, group B and C had faster velocity ( P < 0.01 ). Conclusion: Mecobalamine with various administrations can significantly improve the curative effect on type 2 diabetes with diabetic neuropathy, and intravenous drip and intraspinal injection are better than intramuscular injection with intraspinal injection the best.%目的:观察甲钴胺肌注、静滴与椎管内注射3种不同给药方式治疗2型糖尿病神经病变的疗效.方法:108例2型糖尿病合并痛性神经病变患者,根据甲钴胺不同给药方式分为A组(36例)、B组(36例)与C组(36例).A组甲钴胺0.5 mg肌注,qd;B组甲钴胺1.0 mg静滴,每2天1次;C组甲钴胺2.0 mg椎管内注射,每4天1次.每组均加前列地尔注射液100 μg辅助治疗,疗程均为20 d.治疗前后分别测定运动神经传导速度和感觉神经传导速

  11. AB028. Current status of pharmacotherapy for erectile dysfunction

    Science.gov (United States)

    Adaikan, P Ganesan

    2016-01-01

    The advent of phosphodiesterase type 5 (PDE5) inhibition as oral therapy has significantly revolutionized both clinical and basic research in the area of erectile dysfunction (ED). Much of this progress is due to a better understanding in the last three decades of the various pathophysiological and cellular mechanisms contributing to ED. Apart from the three available PDE5 inhibitors viz., sildenafil, tadalafil and vardenafil globally at the turn of this century, four other PDE inhibitors have joined the armament in recent time; these include avanafil, lodenafil, mirodenafil and udenafil. All seven PDE inhibitors are effective therapies for the treatment of ED in men. There is no significant difference among them with respect to efficacy, safety profile and tolerability. As such, good safety profiles have widened the horizon in patient choice, selectivity and efficacy. With the ease of oral administration and better patient compliance, other measures of the past, including intracavernosal injections and non-pharmacological treatments have been relegated to second-line therapy for most patients with ED. But, PDE inhibitors as first-line oral therapies are effective in about 75% of male patients diagnosed with ED. Intracavernous injection (IC) therapy with PGE1 (alprostadil) for about 10% patient-usage in general is a well-known effective and well tolerated treatment for men with ED. It is also recommended as a second line therapy for ED along with urethral and topical PGE1. Transurethral PGE1 is less effective compared to IC PGE1. Also the transurethral dosage options are 125 to 1,000 µg, while the IC dosage options are 5 to 40 µg. The topical PGE1 (300 µg in 100 mg of the cream) is also less effective compared to IC PGE1. Topical cream is not approved in many countries as yet. Other existing vasoactive agents such as papaverine, and alpha adrenergic blockers and their combinations and the ever increasing number of other agents in the pipeline including nitric

  12. Observation on therapeutic effects of acupuncture plus Chinese herbs for sudden deafness%针药并用治疗突发性耳聋疗效观察

    Institute of Scientific and Technical Information of China (English)

    王环仁; 孟凡锐; 迟晓伟; 丁见

    2015-01-01

    group was treated with the acupoints selected by syndrome differentiation in reference to the textbook of Acupuncture and Moxibustion Science. The WM group was treated by intravenous infusion of Alprostadil injection, Adenosine Disodium Triphosphate and Coenzyme A and muscular injection of Vitamin B12 and Vitamin B1. The decibel values of hearing loss before and after treatment were respectively recorded and analyzed comparatively. Results:In the intra-group comparison after treatment among the three groups, the decibel values of hearing loss all declined, with statistically significant differences (allP Conclusion:The therapeutic effect was better for sudden deafness by wind-expelling method of acupuncture and Chinese herbs than by acupuncture alone or by Western medication.

  13. Single center's experience of ABO-incompatible liver transplantation in 20 cases%ABO血型不合肝移植20例单中心经验

    Institute of Scientific and Technical Information of China (English)

    张玮晔; 邓永林; 侯建存; 朱志军; 沈中阳

    2012-01-01

    ,liver cancer recurrence in 2 cases and cerebral hemorrhage in 1 case.There were 2 cases of acute rejection,3 cases of biliary complications and 3 cases of portal vein thrombosis developing postoperatively. Eleven patients had increased serum creatinine after operation,preoperative high creatinine existed in 6 cases and it maintained posttransplant high level for more than 7 days,the serum creatinine level in other 7 patients was back to normal level in 7 days. Conclusions A combination splenectomy before the portal vein reperfusion,the protocol of basiliximab,tacrolimus (TAC)/mycophenolate mofetil (MMF)/steroids immunosuppression treatment,postoperative peripheral vascular dilatation treatment by Alprostadil,help achieve favorable outcome in selected patients who underwent ABO-incompatible liver transplant.

  14. 30例完全性肺静脉异位引流患儿术后早期并发症分析及处理对策%The early postoperation complications and treatments in 30 children with total anomalous pulmonary venous connection

    Institute of Scientific and Technical Information of China (English)

    付红敏; 刘成军; 谭利平

    2012-01-01

    目的 了解完全性肺静脉异位引流(total anomalous pulmonary venous connection,TAPVC)术后早期发生的并发症,总结处理对策.方法 收集行TAPVC根治术后转入PICU监护的患儿30例,术后常规心电、血压、血氧饱和度监护,呼吸机辅助呼吸,并经镇静、止血、正性肌力药物治疗、利尿、扩血管、抗感染及对症等综合处理.有低心排血量表现时再加用肾上腺素或异丙肾上腺素.出现缓慢性心律失常时,予临时起搏器治疗.患儿术前即有重度肺动脉高压或术后判断有反应性肺动脉高压时予前列地尔或西地那非.结果 30例患儿术后并发肺炎13例(43.3%),心律失常8例(26.7%),低心排血量综合征7例(23.3%),呼吸衰竭6例(20.0%),肺动脉高压4例(13.3%),肺水肿及肺不张各3例(10.0%),肺出血1例(3.3%).术后早期死亡2例.ICU住院时间l~21 d[(5.95±4.94)d].结论 TAPVC术后早期呼吸系统的并发症发生率最高,因此,防治肺部感染、维护肺功能应作为术后早期监测和处理的重点,同时注意纠正心律失常,防治低心排血量和肺动脉高压危象,以提高TAPVC患儿术后的成活率与监护质量.%Objective To summarize the early postoperation complications and treatments in children with total anomalous pulmonary venous connection (TAPVC).Methods Thirty TAPVC children who were treated with corrective operation and transferred into PICU were collected.Patients were monitored routinely for electrocardiogram,blood pressure and SpO2.The routine treatment measures included mechanical ventilation,sedation,hemostasis,positive inotropic agents,diuresis,vasodilator,antibiotics and symptomatic treatment.Adrenaline or isoproterenol was used when low cardiac output syndrome appeared and temporary pacemaker was employed in the case of bradycardia.Alprostadil and sildenafil were added instantly after corrective operation when severe preoperative pulmonary hypertension or reactive

  15. Analysis on the therapeutic effective rate of hyperbaric oxygen in the treatment of full-frequency loss in the patients with sudden deafness%高压氧综合治疗全频听力损失突发性耳聋患者的临床疗效分析

    Institute of Scientific and Technical Information of China (English)

    杨晶; 武连华; 刘雪华; 梁芳; 孙波; 高春锦; 王国忠

    2013-01-01

    Objective To observe the dynamic characteristics of hearing recovery in full-frequency hearing loss in the patients with sudden deafness following HBO therapy.Methods Eighty-two cases of fullfrequency hearing loss confirmed by ENT specialists were randomly divided into the control group (40 cases)and the HBO therapy group (42 cases).The patients in the control group were given routine treatment,i.e.10mg of dexamethasone intravenous infusion for first 3 days,then,5 mg of dexamethasone for another 3 days.Besides,the patients were administered 10 μg alprostadil intravenous infusion,once a day for 14 consecutive days; 100 mg of Vitamin B1,500 μg of B12 muscular injection,once day for 30 consecutive days.The patients in the HBO therapy group were given HBO therapy + routine treatment,once a day,10 sessions a treatment course.Following 2 or 4 consecutive treatment courses,pure tone audiometry was performed.Results After 2 courses of HBO therapy,low-frequency average hearing level [(38.16 ± 5.88) dB] increased for the patients in the HBO therapy group,when compared with that of the patients in the control group[(24.68 ± 3.87) dB],with statistical significance (P < 0.01).On the other hand,high-frequency average hearing level [(12.33 ± 2.98) dB] increased to some extent for the patients in the HBO therapy group,when compared with that of the patients in the control group [(10.49 ± 2.34) dB],without statistical significance(P > 0.05).For most patients,low-frequency hearing level improved more markedly and recovered more quickly.Total effective rate (80.9%) for the HBO group increased,when compared with that of the control group (62.5%),but without statistical significance (P > 0.05).When compared with low-frequency hearing level,high-frequency hearing level recovered more slowly.At the end of the 4 courses,pure tone monitoring indicated that improvement was seen mainly in high-frequency hearing level.For the patients in the HBO therapy group

  16. ABO血型不合肝移植治疗急危重症肝病患者的临床疗效分析%Analysis of the curative effect of ABO-incompatible liver transplantation in the treatment in patients with acute severe liver disease

    Institute of Scientific and Technical Information of China (English)

    沈中阳; 邓永林; 郑虹; 潘澄; 张雅敏; 蒋文涛; 张建军; 高伟; 淮明生

    2014-01-01

    Objective To analyze and evaluate the clinical effect of ABO-incompatible liver transplantation in the treatment of acute severe liver disease.Methods A retrospective clinical study was conducted.The clinical data of 4 136 patients undergoing orthotopic liver transplantation in Organ Transplantation Center of Tianjin First Center Hospital from September 1999 to December 2013 were analyzed.The criteria of patients enrolled were as following:model for end-stage liver disease (MELD) score ≥ 20,the donor's and recipient's blood types were different,age 18-70 years,and undergone primary non-bypass orthotopic liver transplantation.According to the rate of compliance with the principles of blood transfusion,the cases were divided into two groups:ABO-compatible group (ABO-C group,n =41),ABO-incompatible group (ABO-I group,n =22).The patients in ABO-I group received basiliximab + methylprednisolone for immune induction therapy during operation,basiliximab + tacrolimus + mycophenolate + cortisol as quadruple immunosuppressive regimen after operation.They also received subcutaneous injection of low molecular heparin for anticoagulant therapy after operation,and oral warfarin or aspirin and clopidogrel bisulfate instead after 7 days.They also received routine alprostadil after operation.The remaining treatment was the same as that of ABO-C group.The clinical data,postoperative complications,rejection and survival rates of two groups were statistically analyzed.Results There were no significant differences in gender,age,MELD score,complicated with tumor,quality of donor liver,length of cold preservation of donor liver,duration of operation,and blood loss during operation between ABO-C and ABO-I groups.Number of splenectomy during operation was significantly higher in ABO-I group than that in ABO-C group (5 cases vs.1 case,x2=4.687,P=0.030).The 3-month,6-month,1-year,3-year and 5-year survival rates of ABO-C group were 89.5%,78.3%,72.5%,69.1% and 61.8

  17. 肌酸激酶及CT血管造影检查评估肠系膜上动脉栓塞的短期预后%Creatine kinase and computed tomography angiography to evaluate short-term prognosis of patients with superior mesenteric artery embolism

    Institute of Scientific and Technical Information of China (English)

    吕和平; 倪海真; 黄景勇; 陈祥建; 虞冠锋

    2016-01-01

    demonstrated hypodense shadow,with non-contrast of distal branches of artery,including 1 with intestinal ischemia,1 with partial intestinal necrosis and 11 with long segmental intestinal necrosis.Main stem embolism of SMA in 8 patients demonstrated hypodense shadow,with contrast of distal branches of SMA,including 3 with intestinal ischemia,4 with partial intestinal necrosis and 1 with long segmental intestinal necrosis.Main stem embolism of SMA in 2 patients demonstrated hypodense shadow,with non-contrast of distal branches of SMA,showing partial intestinal necrosis.Non-main stem embolism of SMA in 3 patients demonstrated hypodense shadow,with contrast of distal branches of SMA,including 2 with intestinal ischemia and 1 with partial intestinal necrosis.②Indirect signs:5 patients had bowel wall thickening,including 3 with intestinal ischemia and 2 with long segmental intestinal necrosis.Seventeen patients had bowel dilatation combined with effusion and air accumulation,with gas fluid level in local intestinal canal,including 2 with intestinal ischemia,5 with partial intestinal necrosis and 10 with long segmental intestinal necrosis.Two patients had pneumatosis intestinalis,with bubble shadow of bowel wall,showing long segmental intestinal necrosis.(4)Therapy and prognosis:of 6 patients with intestinal ischemia,1 underwent embolectomy of SMA and 5 underwent low-molecular-weight heparin anticoagulation and vasodilator alprostadil therapy.Eight patients with partial intestinal necrosis received resection of necrotic intestine.Of 12 patients with long segmental intestinal necrosis,5 with postoperative short bowel syndrome received resection of necrotic intestine combined with postoperative parenteral hyperalimentation.The above-mentioned patients were improved and discharged from hospital after symptomatic treatment and surgery.Twelve patients with long segmental intestinal necrosis,7 with total small bowel necrosis and partial colonic necrosis underwent only exploratory